<!DOCTYPE html>
<html lang="en">

  <head>
    <meta charset="utf-8">
    </meta>
    <title>Metadata reference</title>
  </head>

  <body>
    <h1>Metadata reference</h1>
    <div id="tocContainer">
      <ul>
        <li><a href="#package">Package ID</a></li>
        <li><a href="#trackedEntityTypes">Tracked Entity Types</a></li>
        <li><a href="#trackedEntityAttributes">Tracked Entity Attributes</a></li>
        <li><a href="#programs">Programs</a></li>
        <li><a href="#programRules">Program Rules</a></li>
        <li><a href="#programIndicators">Program Indicators</a></li>
        <li><a href="#dataElements">Data Elements</a></li>
        <li><a href="#dataElementGroups">Data Element Groups</a></li>
        <li><a href="#categoryCombos">Category Combos</a></li>
        <li><a href="#categories">Categories</a></li>
        <li><a href="#categoryOptions">Category Options</a></li>
        <li><a href="#categoryOptionCombos">Category Option Combos</a></li>
        <li><a href="#optionSets">Option Sets</a></li>
        <li><a href="#options">Options</a></li>
        <li><a href="#userGroups">User Groups</a></li>
      </ul>
    </div>
    <h2>Package info</h2>
    <table>
      <tr>
        <th>Property</th>
        <td>Value</td>
      </tr>
      <tr>
        <th>Code</th>
        <td>TB</td>
      </tr>
      <tr>
        <th>Type</th>
        <td>DRS</td>
      </tr>
      <tr>
        <th>Version</th>
        <td>TRACKER</td>
      </tr>
      <tr>
        <th>DHIS2 version</th>
        <td>V0.9.0</td>
      </tr>
      <tr>
        <th>Created</th>
        <td>DHIS2.31</td>
      </tr>
      <tr>
        <th>Identifier</th>
        <td>TB_DRS_TRACKER_V0.9.0_DHIS2.31_2020-03-18T18:30</td>
      </tr>
    </table>
    <h2 id="trackedEntityTypes">Tracked entity types</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Person</td>
        <td>2020-03-18</td>
        <td>MCPQUTHX1Ze</td>
      </tr>
    </table>
    <h3>Tracked Entity Type - Tracked Entity Type Attributes</h3>
    <table>
      <tr>
        <th>Tracked Entity Type</th>
        <th>Tracked Entity Type Attribute</th>
      </tr>
    </table>
    <h2 id="trackedEntityAttributes">Tracked entity attributes</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Code</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Address</td>
        <td></td>
        <td>undefined</td>
        <td>2020-03-18</td>
        <td>VCtm2pySeEV</td>
      </tr>
      <tr>
        <td>Administrative Area of Residence</td>
        <td></td>
        <td>undefined</td>
        <td>2020-03-18</td>
        <td>ljHL8NnSEAD</td>
      </tr>
      <tr>
        <td>Cluster ID</td>
        <td></td>
        <td>undefined</td>
        <td>2020-03-18</td>
        <td>aOrGt5JE0gV</td>
      </tr>
      <tr>
        <td>Country of origin</td>
        <td></td>
        <td>Patient's country of origin</td>
        <td>2020-03-18</td>
        <td>PBdqXh8Nvuj</td>
      </tr>
      <tr>
        <td>Date of birth (age)</td>
        <td></td>
        <td>undefined</td>
        <td>2020-03-18</td>
        <td>mAWcalQYYyk</td>
      </tr>
      <tr>
        <td>Date of birth is estimated</td>
        <td></td>
        <td>undefined</td>
        <td>2020-03-18</td>
        <td>Z1rLc1rVHK8</td>
      </tr>
      <tr>
        <td>First Name</td>
        <td></td>
        <td>undefined</td>
        <td>2020-03-18</td>
        <td>TfdH5KvFmMy</td>
      </tr>
      <tr>
        <td>Health Facility Code</td>
        <td></td>
        <td>undefined</td>
        <td>2020-03-04</td>
        <td>sWn0CERcUYj</td>
      </tr>
      <tr>
        <td>Last Name</td>
        <td></td>
        <td>undefined</td>
        <td>2020-03-18</td>
        <td>aW66s2QSosT</td>
      </tr>
      <tr>
        <td>Location of Residence</td>
        <td></td>
        <td>The location (coordinates) of the place of residence.</td>
        <td>2020-03-18</td>
        <td>f038nOc9uRF</td>
      </tr>
      <tr>
        <td>Patient DRS ID</td>
        <td></td>
        <td>undefined</td>
        <td>2020-03-18</td>
        <td>BdvE9shT6GX</td>
      </tr>
      <tr>
        <td>Patient DRS Serial Number</td>
        <td></td>
        <td>undefined</td>
        <td>2020-02-03</td>
        <td>Qj7EXFIXcyc</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td></td>
        <td>Gender of Person</td>
        <td>2020-03-18</td>
        <td>CklPZdOd6H1</td>
      </tr>
      <tr>
        <td>TB Registration Number</td>
        <td></td>
        <td>undefined</td>
        <td>2020-03-18</td>
        <td>ntelZthDPpR</td>
      </tr>
    </table>
    <h2 id="programs">Programs</h2>
    <h3>Anti-Tuberculosis Drugs Resistance Survey (DRS)</h3>
    <table>
      <tr>
        <th>Property</th>
        <td>Value</td>
      </tr>
      <tr>
        <th>Name</th>
        <td>Anti-Tuberculosis Drugs Resistance Survey (DRS)</td>
      </tr>
      <tr>
        <th>Tracked Entity Type:</th>
        <td>Person</td>
      </tr>
      <tr>
        <th>Last updated:</th>
        <td>2020-02-06</td>
      </tr>
      <tr>
        <th>UID:</th>
        <td>KYzHf1Ta6C4</td>
      </tr>
    </table>
    <h4>Program Stages</h4>
    <table>
      <tr>
        <th>Program Stage</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>CIF</td>
        <td>2020-03-18</td>
        <td>oHeGGP8b2jT</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>2020-03-18</td>
        <td>ucGVfFax931</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>2020-03-18</td>
        <td>GcwlzpdiI9M</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>2020-03-18</td>
        <td>ZVfK21voZUN</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>2020-03-18</td>
        <td>GkWDp4w0oLP</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>2020-03-18</td>
        <td>Y6qhyXKY6k5</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>2020-03-18</td>
        <td>mKxKBtIDl6q</td>
      </tr>
    </table>
    <h4>Program Stage - Program Stage Section - Data Element</h4>
    <table>
      <tr>
        <th>Program Stage</th>
        <th>Program Stage Section</th>
        <th>Data Element</th>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Screening Test Results for HIV</td>
        <td>TB DRS CIF: HIV Test Date</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Screening Test Results for HIV</td>
        <td>TB DRS CIF: HIV Test Result</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CIF: Bacteriological Confirmation - Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CIF: Bacteriological Confirmation - Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CIF: Specimen 1 Microscopy Test Result</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CIF: Specimen 2 Microscopy Test Result</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CIF: Date of Xpert MTB/RIF Initial Screening Test</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CIF: Xpert MTB/RIF Initial Screening Result</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Control Question</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Injections for TB</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - length of sickness - weeks</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Names of Drugs</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Other Symptoms of Lung Disease</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Prior Symptoms</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Sputum Examinations</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Tuberculosis Drugs</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Based on Medical Records</td>
        <td>TB DRS CIF: Treatment History - Prior TB Registration</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Based on Medical Records</td>
        <td>TB DRS CIF: Treatment History - Previous TB Registration Number</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CIF: Treatment History - Treatment Over 1 Month</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CIF: Treatment History - Outcome</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CIF: Treatment History - CIF Officer Name</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CIF: Treatment History - Outcome Other</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>Sample Shipment</td>
        <td>TB DRS CS: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>Sample Shipment</td>
        <td>TB DRS CS: Date of Samples Arrival at NRL</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>Sample Shipment</td>
        <td>TB DRS CS: Date Samples Shipped to NRL</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Sample 1 Collection Date</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Sample 1 DRS ID</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Sample 1 Additive</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Sample 2 Collection Date</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Sample 2 DRS ID</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Sample 2 Additive</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Sample 3 Collection Date</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Sample 3 DRS ID</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Sample 3 Additive</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Specify Other (Sample 1)</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Specify Other (Sample 2)</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Specify Other (Sample 3)</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Specify Other (Sample 4)</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Sample 4 Collection Date</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Sample 4 DRS ID</td>
      </tr>
      <tr>
        <td>Collection and Shipment of DRS Samples to NRL</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Sample 4 Additive</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sample Rejected or Lost</td>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Date of Sputum Smear Microscopy Examination</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Initial DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Initial DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Specimen Type used for LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Date of LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Date of LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Fluoroquinolones</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Amikacin/Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Culture in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Culture in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Initial DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Initial DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sample Rejected or Lost</td>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Subsequent DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Subsequent DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Storage Only</td>
        <td>TB DRS LAB: Storage Only</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Sample 1 DRS ID</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Date of Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid) </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: LPA (FQ/2LI) - Was MTBc detected by LPA?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: LPA (RIF/INH) - Was MTBc detected by LPA?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Comments and Remarks</td>
        <td>TB DRS LAB: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Specimen Type used for LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Sample 2 DRS ID</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sample Rejected or Lost</td>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Date of Sputum Smear Microscopy Examination</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Culture in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Culture in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Initial DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Initial DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Initial DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Initial DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Subsequent DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Subsequent DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: LPA (FQ/2LI) - Was MTBc detected by LPA?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: LPA (RIF/INH) - Was MTBc detected by LPA?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Date of LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Date of LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Specimen Type used for LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Specimen Type used for LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Amikacin/Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Fluoroquinolones</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid) </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Date of Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Storage Only</td>
        <td>TB DRS LAB: Storage Only</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Comments and Remarks</td>
        <td>TB DRS LAB: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sample Rejected or Lost</td>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Sample 3 DRS ID</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: Sample Rejected or Lost</td>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: Sample Rejected or Lost</td>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Date of Sputum Smear Microscopy Examination</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Culture in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Culture in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Initial DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Initial DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Initial DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Initial DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Subsequent DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Subsequent DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: LPA (FQ/2LI) - Was MTBc detected by LPA?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: LPA (RIF/INH) - Was MTBc detected by LPA?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Date of LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Date of LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Specimen Type used for LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Specimen Type used for LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Amikacin/Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Fluoroquinolones</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid) </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Date of Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Storage Only</td>
        <td>TB DRS LAB: Storage Only</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Comments and Remarks</td>
        <td>TB DRS LAB: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Sample 4 DRS ID</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: Sample Rejected or Lost</td>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: Sample Rejected or Lost</td>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Date of Sputum Smear Microscopy Examination</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Culture in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Culture in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Initial DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Initial DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Initial DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Initial DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Subsequent DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Subsequent DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (LM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (SM)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: LPA (FQ/2LI) - Was MTBc detected by LPA?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: LPA (RIF/INH) - Was MTBc detected by LPA?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Date of LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Date of LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Specimen Type used for LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Specimen Type used for LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Amikacin/Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Fluoroquinolones</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid) </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Date of Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Amikacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bedaquiline</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Capreomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Clofazimine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cycloserine</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Delamanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethambutol</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethionamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Gatifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Streptomycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Isoniazid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Kanamycin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Levofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Linezolid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Moxifloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ofloxacin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Pretomanid</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Pyrazinamide</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Storage Only</td>
        <td>TB DRS LAB: Storage Only</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Rifampicin</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Comments and Remarks</td>
        <td>TB DRS LAB: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Streptomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: Date Samples Shipped to Supranational Laboratory (SRL)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: Samples Shipped to SRL</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: Date of Samples Arrival at SRL</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: DRS ID</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL - Reasons for not Shipping Samples to SRL</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Culture in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Culture in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Initial DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Initial DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Date of LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Date of LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Date of Sputum Smear Microscopy Examination</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Amikacin/Capreomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Ethambutol</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Fluoroquinolones</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Kanamycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Isoniazid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Rifampicin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (LM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (SM)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Initial DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Initial DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Amikacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Bedaquiline</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Capreomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Clofazimine</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Delamanid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ethambutol</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ethionamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Kanamycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Levofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Linezolid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Ofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Rifampicin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Initial DST (LM) Streptomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Amikacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Bedaquiline</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Capreomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Clofazimine</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Delamanid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ethambutol</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ethionamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Kanamycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Levofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Linezolid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Ofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Rifampicin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Initial DST (SM) Streptomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: LPA (FQ/2LI) - Was MTBc detected by LPA?</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: LPA (RIF/INH) - Was MTBc detected by LPA?</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Sample/s Rejected or Lost</td>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td></td>
        <td>TB DRS LAB: Sample 2 - Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td></td>
        <td>TB DRS LAB: Sample 3 - Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td></td>
        <td>TB DRS LAB: Sample 4 - Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Sample/s Rejected or Lost</td>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB DRS LAB: Specimen Type used for LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Rifampicin / Isoniazid)</td>
        <td>TB DRS LAB: Specimen Type used for LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Storage Only</td>
        <td>TB DRS LAB: Storage Only</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Subsequent DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Subsequent DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Amikacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Bedaquiline</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Capreomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Clofazimine</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Delamanid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ethambutol</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ethionamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Kanamycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Levofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Linezolid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Rifampicin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (LM) Streptomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Amikacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Bedaquiline</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Capreomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Clofazimine</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Delamanid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ethambutol</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ethionamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Kanamycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Levofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Linezolid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Rifampicin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB DRS LAB: Subsequent DST (SM) Streptomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid) </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Amikacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Bedaquiline</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Capreomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Clofazimine</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Cycloserine</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Delamanid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ethambutol</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ethionamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Gatifloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Amikacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bedaquiline</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Capreomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Clofazimine</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cycloserine</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Delamanid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethambutol</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethionamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Gatifloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Isoniazid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Kanamycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Levofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Linezolid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Moxifloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pretomanid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pyrazinamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Rifampicin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Streptomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Isoniazid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Kanamycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Levofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Linezolid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Moxifloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Ofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Pretomanid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Pyrazinamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Rifampicin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Streptomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Amikacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Bedaquiline</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Capreomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Clofazimine</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Cycloserine</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Date of Results</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Delamanid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ethambutol</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ethionamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Gatifloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Amikacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bedaquiline</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Capreomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Clofazimine</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cycloserine</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Delamanid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethambutol</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethionamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Gatifloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Isoniazid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Kanamycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Levofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Linezolid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Moxifloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pretomanid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pyrazinamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Rifampicin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Streptomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Isoniazid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Kanamycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Levofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Linezolid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Moxifloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>File Upload Section</td>
        <td>TB DRS SRL: Import .csv</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Ofloxacin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Pretomanid</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Pyrazinamide</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Comments and Remarks</td>
        <td>TB DRS SRL: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Rifampicin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Streptomycin</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
      </tr>
    </table>
    <h2 id="programIndicators">Program Indicators</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Code</th>
        <th>Description</th>
        <th>Analytics Type</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Days between all lab sample collection and arrival, mean</td>
        <td>Collection_arrival_interval_mean</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>hA9Or527BMx</td>
      </tr>
      <tr>
        <td>Days between lab sample 1 collection and arrival, mean</td>
        <td>Collection_arrival_interval_mean_sample1</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>ykjQxt9OYX8</td>
      </tr>
      <tr>
        <td>Days between lab sample 1 collection and liquid culture inoculation, mean</td>
        <td>Collection_liquidculture_interval_mean_s1</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>BDH0DBbNGR0</td>
      </tr>
      <tr>
        <td>Days between lab sample 1 collection and solid culture inoculation, mean</td>
        <td>Collection_solidculture_interval_mean_s1</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>IxuPKi0SKpH</td>
      </tr>
      <tr>
        <td>Days between lab sample 1 collection and testing for LPA, mean</td>
        <td>Collection_LPA_interval_mean_s1</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>OeaU81K99Xf</td>
      </tr>
      <tr>
        <td>Days between lab sample 1 collection and testing for Xpert MTB/RIF, mean</td>
        <td>Collection_xpert_interval_mean_s1</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>o0Ox1RgmDwG</td>
      </tr>
      <tr>
        <td>Days between lab sample 2 collection and arrival, mean</td>
        <td>Collection_arrival_interval_mean_sample2</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>A8oEYKWa0N5</td>
      </tr>
      <tr>
        <td>Days between lab sample 3 collection and arrival, mean</td>
        <td>Collection_arrival_interval_mean_sample3</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>KZtLVKluVZV</td>
      </tr>
      <tr>
        <td>DRS Enrollments, cumulative</td>
        <td>enrollments, cumulative</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>qd9PbhmNYnR</td>
      </tr>
      <tr>
        <td>DRS Enrollments, cumulative, with 1+ test started</td>
        <td>enrollments, cumulative, test started</td>
        <td></td>
        <td>At least one test must be started by the end of the reporting period</td>
        <td>EVENT</td>
        <td>2020-03-18</td>
        <td>AafZDJB4CTv</td>
      </tr>
      <tr>
        <td>DRS Enrollments, total</td>
        <td>enrollments_total</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>gTPmPsKLwdR</td>
      </tr>
      <tr>
        <td>DRS Sample Processing Events, total</td>
        <td>events_processing_total</td>
        <td></td>
        <td> </td>
        <td>EVENT</td>
        <td>2020-03-18</td>
        <td>Z0pHyvWCUNG</td>
      </tr>
      <tr>
        <td>Missing Data: Age</td>
        <td>MD: Age</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>AIhr0Sqq0Nl</td>
      </tr>
      <tr>
        <td>Missing Data: ALL of Age, Gender, HIV Status, TB treatment history</td>
        <td>MD: All key demographics</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>xatw8TkviiQ</td>
      </tr>
      <tr>
        <td>Missing Data: ANY of Age, Gender, HIV Status, TB treatment history</td>
        <td>MD: Any key demographics</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>qGLJdB5Qg2I</td>
      </tr>
      <tr>
        <td>Missing Data: Gender</td>
        <td>MD: Gender</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>vXwdB7fhkW5</td>
      </tr>
      <tr>
        <td>Missing Data: HIV Result</td>
        <td>MD: HIV</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>XOE7Mzfedq4</td>
      </tr>
      <tr>
        <td>Missing Data: TB treatment history</td>
        <td>MD: TB Treatment history</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-03-18</td>
        <td>Ir4RiYE3Nke</td>
      </tr>
      <tr>
        <td>Missing Data: TB treatment history_EVENT_TEST</td>
        <td>MD: TB Treatment history_EVENT</td>
        <td></td>
        <td> </td>
        <td>EVENT</td>
        <td>2020-03-18</td>
        <td>PEggRKndlrO</td>
      </tr>
      <tr>
        <td>Samples rejected on arrival</td>
        <td>Samples rejected on arrival</td>
        <td></td>
        <td> </td>
        <td>EVENT</td>
        <td>2020-03-18</td>
        <td>hZP8QqW2Hgr</td>
      </tr>
    </table>
    <h4 id="programRules">Program Rules</h4>
    <table>
      <tr>
        <th>Program rule</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>01_Generate DRS Sample 1 ID</td>
        <td>Generate DRS Sample 1 ID</td>
        <td>2020-02-03</td>
        <td>cryxj5ORjxk</td>
      </tr>
      <tr>
        <td>01_Generate DRS Sample 2 ID</td>
        <td>Generate DRS Sample 2 ID</td>
        <td>2020-02-03</td>
        <td>bQ9VZww9wNM</td>
      </tr>
      <tr>
        <td>01_Generate DRS Sample 3 ID</td>
        <td>Generate DRS Sample 3 ID</td>
        <td>2020-02-03</td>
        <td>LyXgAkRoTgM</td>
      </tr>
      <tr>
        <td>01_Generate DRS Sample 4 ID</td>
        <td>Generate DRS Sample 4 ID</td>
        <td>2020-02-03</td>
        <td>gzN6Ya5yOFf</td>
      </tr>
      <tr>
        <td>Assign Cluster ID to PrRVar</td>
        <td>Assign Cluster ID to a PRRVar if Cluster ID is used</td>
        <td>2020-01-29</td>
        <td>BTQvSqCiUl1</td>
      </tr>
      <tr>
        <td>CIF: Assign "Yes" to "Previous_TB_Treatment" Variable</td>
        <td>Assign "Yes" to "TB DRS Treatment History - treatment >1 month" if "Treatment history" & "Prior TB Registration" or "Control Question" & "Prior TB Registration" = Yes </td>
        <td>2020-01-15</td>
        <td>fHu5DLVW1Q2</td>
      </tr>
      <tr>
        <td>CIF: Assign "Yes" to "TB DRS Treatment History - treatment >1 month"</td>
        <td>Assign "Yes" to "TB DRS Treatment History - treatment >1 month" if "Treatment history" & "Prior TB Registration" or "Control Question" & "Prior TB Registration" = Yes </td>
        <td>2020-01-15</td>
        <td>mtSkTzHDV1Z</td>
      </tr>
      <tr>
        <td>CIF: Display guidelines for Microscopy samples in the form</td>
        <td>If initial screening is based on microscopy examination of > 2 samples then add only the 2 samples with the highest bacterial load.</td>
        <td>2020-02-03</td>
        <td>BCkatIfqdYk</td>
      </tr>
      <tr>
        <td>CIF: Hide "HIV Test Date"</td>
        <td>Hide "HIV Test Date" if "HIV Test Result" = Unknown</td>
        <td>2020-01-15</td>
        <td>hpkXGVKETRq</td>
      </tr>
      <tr>
        <td>CIF: Hide "TB DRS CIF - Outcome Other"</td>
        <td>Hide "TB DRS TB DRS CIF - Outcome Other" unless Other is selected</td>
        <td>2020-02-03</td>
        <td>vjXTnHT2OtT</td>
      </tr>
      <tr>
        <td>CIF: Hide "TB DRS Treatment History - Names of Drugs"</td>
        <td>Hide "TB DRS Treatment History - Names of Drugs" unless the answer for "TB DRS Treatment History - Tuberculosis Drugs" is "Yes".</td>
        <td>2020-01-15</td>
        <td>sCdmieN4lT7</td>
      </tr>
      <tr>
        <td>CIF: Hide "TB DRS Treatment History - Outcome"</td>
        <td>Hide "TB DRS Treatment History - Outcome" unless the patient was treated for more than a month</td>
        <td>2020-01-15</td>
        <td>XBOo5soKgDT</td>
      </tr>
      <tr>
        <td>CIF: Hide "TB DRS Treatment History - previous treatment registration number"</td>
        <td>Hide "TB DRS Treatment History - previous treatment registration number" unless prior TB registration is "Yes"</td>
        <td>2020-01-15</td>
        <td>OjyDPFPlZ4L</td>
      </tr>
      <tr>
        <td>CIF: Hide Microscopy Test Result Fields</td>
        <td>Hide Microscopy Test Result fields unless Sputum Smear Microscopy is selected</td>
        <td>2020-01-15</td>
        <td>LnaeeZd9aYe</td>
      </tr>
      <tr>
        <td>CIF: Hide Treatment History Provided by Patient</td>
        <td>Hide "Treatment History Provided by Patient" fields if the patient was previously treated for TB</td>
        <td>2020-01-15</td>
        <td>XxpX3sJalg4</td>
      </tr>
      <tr>
        <td>CIF: Hide Xpert MTB/RIF</td>
        <td>Hide Xpert MTB/RIF Test fields unless Xpert MTB/RIF is selected</td>
        <td>2020-01-15</td>
        <td>qZ32JJQDYxp</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide "3 Step DRS ID"</td>
        <td>Hide "3 Step DRS ID" if full DRS Entry is selected.</td>
        <td>2020-02-03</td>
        <td>gk7OBVBqlXe</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide "CIF: Cluster ID"</td>
        <td>Hide "CIF: Cluster ID" if not used</td>
        <td>2020-01-21</td>
        <td>C0HrM84AAIB</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide "CIF: TB Bacteriological Confirmation - Sputum Smear Microscopy"</td>
        <td>Hide "CIF: TB Bacteriological Confirmation - Sputum Smear Microscopy" if not used</td>
        <td>2020-01-20</td>
        <td>pgRQzrtyeoZ</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide "CIF: TB Bacteriological Confirmation - Xpert MTB/RIF"</td>
        <td>Hide "CIF: TB Bacteriological Confirmation - Xpert MTB/RIF" if not used</td>
        <td>2020-01-20</td>
        <td>yPHeTz8frbN</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide "embB" field</td>
        <td> Hide "embB" field if Ethambutol is not being tested</td>
        <td>2020-01-27</td>
        <td>X8QIPW2W05n</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide "Patient TB DRS ID"</td>
        <td>Hide "Patient TB DRS ID" if 3-step entry is used.</td>
        <td>2020-02-03</td>
        <td>KXROKuIZZov</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide "Sample 2", "Sample 3" and "Section 4" Sections</td>
        <td>Hide "Sample 2", "Sample 3" and "Section 4" if not used</td>
        <td>2020-01-28</td>
        <td>ob26R9u3bye</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide "Sample 3" and "Section 4" Sections</td>
        <td>Hide "Sample 3" and "Section 4" if not used</td>
        <td>2020-01-28</td>
        <td>rSPDV6Kfj1x</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide "Sample 4" Section</td>
        <td>Hide "Sample 4" if not used</td>
        <td>2020-01-28</td>
        <td>BIwvQ6ek8Vu</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide "SRL"</td>
        <td>Hide "SRL" if samples are never sent to SRL</td>
        <td>2020-01-24</td>
        <td>SYrJsO8xr6C</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Amikacin</td>
        <td>Hide Amikacin from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>hYQkQaPFuwT</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Bedaquiline</td>
        <td>Hide Bedaquiline from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>c0VHXIVBluv</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Capreomycin</td>
        <td>Hide Capreomycin from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>ksFoI0wvsek</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Clofazimine</td>
        <td>Hide Clofazimine from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>pbOuqeol2Wy</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Delamanid</td>
        <td>Hide Delamanid from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>VMe40J3NnVl</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Ethambutol</td>
        <td>Hide Ethambutol from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>S1mDE2iiUlk</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Ethionamide</td>
        <td>Hide Ethionamide from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>rCAXrzcgzg1</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Gatifloxacin</td>
        <td>Hide Gatifloxacin from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>dUCEjCLUfo9</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Isoniazid CB</td>
        <td>Hide Isoniazid CB from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-03-01</td>
        <td>wCZHu3exKHT</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Isoniazid CC</td>
        <td>Hide Isoniazid CC from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-03-01</td>
        <td>lCPmmg8ANPP</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Kanamycin</td>
        <td>Hide Kanamycin from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>jJ6zNlKJhVP</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Levofloxacin</td>
        <td>Hide Levofloxacin from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>dll60xcQXpr</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Linezolid</td>
        <td>Hide Linezolid from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>onpLkiwFP1Y</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Moxifloxacin CB</td>
        <td>Hide Moxifloxacin CB from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-02-04</td>
        <td>tCbPN4u9DVh</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Moxifloxacin CC</td>
        <td>Hide Moxifloxacin CC from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-02-04</td>
        <td>wE0yhLXQd2Y</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Ofloxacin</td>
        <td>Hide Ofloxacin from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>M4NBSgfIBhT</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Pyrazinamide</td>
        <td>Hide Pyrazinamide from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>OtODxIj253U</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Rifampicin</td>
        <td>Hide Rifampicin from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>MhQJWkudWc9</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Streptomycin</td>
        <td>Hide Streptomycin from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>kKtLPxMW525</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Amikacin</td>
        <td>Hide Amikacin from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>GdkouxMOawY</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Bedaquiline</td>
        <td>Hide Bedaquiline from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>lsbuAFe4LTe</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Capreomycin</td>
        <td>Hide Capreomycin from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>D51Bn31nOCL</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Clofazimine</td>
        <td>Hide Clofazimine from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>UnNaEVfXEF2</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Delamanid</td>
        <td>Hide Delamanid from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>B5K6hdkZCyR</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Ethambutol</td>
        <td>Hide Ethambutol from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>hZ46pxd6j0K</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Ethionamide</td>
        <td>Hide Ethionamide from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>xMKBezlsSfq</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Gatifloxacin</td>
        <td>Hide Gatifloxacin from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>TqGoFnEM21Y</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Isoniazid CB</td>
        <td>Hide Isoniazid CB from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-03-01</td>
        <td>ZcoiBN36Je1</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Isoniazid CC</td>
        <td>Hide Isoniazid CC from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-03-01</td>
        <td>xdTQICXUrRr</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Kanamycin</td>
        <td>Hide Kanamycin from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>tU8LHbakvRU</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Levofloxacin</td>
        <td>Hide Levofloxacin from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>yMO3HkkVQRA</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Linezolid</td>
        <td>Hide Linezolid from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>H9dJ3ebaaFn</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Moxifloxacin CB</td>
        <td>Hide Moxifloxacin CB from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-02-04</td>
        <td>cqYWWBueNqe</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Moxifloxacin CC</td>
        <td>Hide Moxifloxacin CC from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-02-04</td>
        <td>a2EZOnGtShT</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Ofloxacin</td>
        <td>Hide Ofloxacin from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>xGzOjSIu5Fu</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Pyrazinamide</td>
        <td>Hide Pyrazinamide from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>seL9DsDnIO7</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Rifampicin</td>
        <td>Hide Rifampicin from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>ivrzYMSxVnO</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Streptomycin</td>
        <td>Hide Streptomycin from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>UpyzNUM6VBS</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Amikacin</td>
        <td>Hide Amikacin from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>tin0buEUJWh</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Bedaquiline</td>
        <td>Hide Bedaquiline from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>HKS0a7Y4nHT</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Capreomycin</td>
        <td>Hide Capreomycin from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>wuv8LXNG5jB</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Clofazimine</td>
        <td>Hide Clofazimine from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>lHG1nvtrf4F</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Delamanid</td>
        <td>Hide Delamanid from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>bhDFETNiD4W</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Ethambutol</td>
        <td>Hide Ethambutol from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>mKB2hn5PfNO</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Ethionamide</td>
        <td>Hide Ethionamide from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>lwWWXYWeFbd</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Gatifloxacin</td>
        <td>Hide Gatifloxacin from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>EDrUq7i5M8f</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Isoniazid CB</td>
        <td>Hide Isoniazid CB from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-03-01</td>
        <td>saKIwUXzmXv</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Isoniazid CC</td>
        <td>Hide Isoniazid CC from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-03-01</td>
        <td>tWuhWCgEHBD</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Kanamycin</td>
        <td>Hide Kanamycin from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>hAcvtUtEDcL</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Levofloxacin</td>
        <td>Hide Levofloxacin from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>SboB8RbxOjj</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Linezolid</td>
        <td>Hide Linezolid from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>IVZAJ5wLIPq</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Moxifloxacin CB</td>
        <td>Hide Moxifloxacin CB from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-02-04</td>
        <td>wBkYPnKAVOV</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Moxifloxacin CC</td>
        <td>Hide Moxifloxacin CC from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-02-04</td>
        <td>MdNdxhRQ1Ce</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Ofloxacin</td>
        <td>Hide Ofloxacin from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>LbJ79I7NAyP</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Pyrazinamide</td>
        <td>Hide Pyrazinamide from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>D6taGou1EWN</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Rifampicin</td>
        <td>Hide Rifampicin from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>vgqaTQVEM5r</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Streptomycin</td>
        <td>Hide Streptomycin from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-01-27</td>
        <td>bwmUeDI0bcu</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Amikacin</td>
        <td>Hide Amikacin from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>vjUK8GGhx3R</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Bedaquiline</td>
        <td>Hide Bedaquiline from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>DVza0nU07P7</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Capreomycin</td>
        <td>Hide Capreomycin from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>NixNquCt9Zh</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Clofazimine</td>
        <td>Hide Clofazimine from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>bm4p4dc1JPN</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Delamanid</td>
        <td>Hide Delamanid from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>QgUL7zDk98e</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Ethambutol</td>
        <td>Hide Ethambutol from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>J4rPKa1u9Nl</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Ethionamide</td>
        <td>Hide Ethionamide from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>Vg4iRi1kfkd</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Gatifloxacin</td>
        <td>Hide Gatifloxacin from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>gxHnkvEM6GH</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Isoniazid CB</td>
        <td>Hide Isoniazid CB from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-03-01</td>
        <td>uIOtFwtC1gH</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Isoniazid CC</td>
        <td>Hide Isoniazid CC from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-03-01</td>
        <td>x7b5voqD5Hf</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Kanamycin</td>
        <td>Hide Kanamycin from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>X3Pt8HDb6TJ</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Levofloxacin</td>
        <td>Hide Levofloxacin from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>b89lO4YuJ1Q</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Linezolid</td>
        <td>Hide Linezolid from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>yqL2JNGSCHi</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Moxifloxacin CB</td>
        <td>Hide Moxifloxacin CB from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-02-04</td>
        <td>xly48Oj31dZ</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Moxifloxacin CC</td>
        <td>Hide Moxifloxacin CC from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-02-04</td>
        <td>hITJ6mxIPkN</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Ofloxacin</td>
        <td>Hide Ofloxacin from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>b3tIdOUvouH</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Pyrazinamide</td>
        <td>Hide Pyrazinamide from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>bKX5rPBfyfW</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Rifampicin</td>
        <td>Hide Rifampicin from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>L8hrzv44viB</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Streptomycin</td>
        <td>Hide Streptomycin from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-01-27</td>
        <td>jQ6nNST2MWv</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "Culture in Liquid Media (e.g. MGIT)"</td>
        <td>Hide "Culture in Liquid Media (e.g. MGIT)" if not used</td>
        <td>2020-01-21</td>
        <td>O9mMu01lgq9</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "Culture in Solid Media (e.g. LG)"</td>
        <td>Hide "Culture in Solid Media (e.g. LG)" if not used</td>
        <td>2020-01-21</td>
        <td>JD4qaeKxKoW</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "Initial DST in Liquid Media (e.g. MGIT)"</td>
        <td>Hide "Initial DST in Liquid Media (e.g. MGIT)" if not used</td>
        <td>2020-01-24</td>
        <td>TMFKJbuE519</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "Initial DST in Solid Media (e.g. LG)"</td>
        <td>Hide "Initial DST in Solid Media (e.g. LG)" if not used</td>
        <td>2020-01-24</td>
        <td>ykAqcJUSn6T</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "LPA (Fluoroquinolones / Second Line Injectables)"</td>
        <td>Hide "LPA (Fluoroquinolones / Second Line Injectables)" if not used</td>
        <td>2020-01-21</td>
        <td>Q2X5grtVa7h</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "LPA (Rifampicin / Isoniazid)"</td>
        <td>Hide "LPA (Rifampicin / Isoniazid)" if not used</td>
        <td>2020-01-21</td>
        <td>Lfz435z4iQe</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "Sputum Smear Microscopy" </td>
        <td>Hide "Sputum Smear Microscopy" if not used</td>
        <td>2020-01-21</td>
        <td>PcHWmirafV0</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "Subsequent DST in Liquid Media (e.g. MGIT)"</td>
        <td>Hide "Subsequent DST in Liquid Media (e.g. MGIT)" if not used</td>
        <td>2020-01-24</td>
        <td>fVlCUqt0Ps6</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "Subsequent DST in Solid Media (e.g. LG)"</td>
        <td>Hide "Subsequent DST in Solid Media (e.g. LG)" if not used</td>
        <td>2020-01-24</td>
        <td>GwC6uvcUEdn</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "Targeted Gene Sequencing"</td>
        <td>Hide "Targeted Gene Sequencing" if not used</td>
        <td>2020-01-21</td>
        <td>rxnBSLg9bF1</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "WGS"</td>
        <td>Hide "WGS" if not used</td>
        <td>2020-01-21</td>
        <td>reQzgr6rGms</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "Xpert MTB/RIF Ultra"</td>
        <td>Hide "Xpert MTB/RIF Ultra" if not used</td>
        <td>2020-01-21</td>
        <td>rBHpHQHMzzY</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Test "Xpert MTB/RIF"</td>
        <td>Hide "Xpert MTB/RIF" if not used</td>
        <td>2020-01-21</td>
        <td>Zckkhc1uLyH</td>
      </tr>
      <tr>
        <td>CS: Hide "Specify Other" for Sample 1</td>
        <td>Hide "Specify Other" for Sample 1 unless the Answer to "Sample 1 Treatment" is "Other"</td>
        <td>2020-01-15</td>
        <td>g5ttCkqpAas</td>
      </tr>
      <tr>
        <td>CS: Hide "Specify Other" for Sample 2</td>
        <td>Hide "Specify Other" for Sample 2 unless the Answer to "Sample 2 Treatment" is "Other"</td>
        <td>2020-01-15</td>
        <td>VjTyxzlQNO5</td>
      </tr>
      <tr>
        <td>CS: Hide "Specify Other" for Sample 3</td>
        <td>Hide "Specify Other" for Sample 3 unless the Answer to "Sample 3 Treatment" is "Other"</td>
        <td>2020-01-15</td>
        <td>eCsM1NkAMj6</td>
      </tr>
      <tr>
        <td>CS: Hide "Specify Other" for Sample 4</td>
        <td>Hide "Specify Other" for Sample 4 unless the Answer to "Sample 4 Treatment" is "Other"</td>
        <td>2020-01-15</td>
        <td>GN2dzpXZHFq</td>
      </tr>
      <tr>
        <td>DISP Bacteriological Confirmation SSM</td>
        <td>Display Bacteriological Confirmation SSM in the top bar</td>
        <td>2020-02-03</td>
        <td>KD2y7wS5v0U</td>
      </tr>
      <tr>
        <td>DISP Bacteriological Confirmation Xpert</td>
        <td>Display Bacteriological Confirmation Xpert in the top bar</td>
        <td>2020-02-03</td>
        <td>KYFnKMxH7gA</td>
      </tr>
      <tr>
        <td>DISP CULTURE LM: Display Final Result</td>
        <td>Display Final Result for Culture in Liquid Media</td>
        <td>2020-01-31</td>
        <td>Oc6lItv2Glq</td>
      </tr>
      <tr>
        <td>DISP CULTURE SM: Display Final Result</td>
        <td>Display Final Result for Culture in Solid Media</td>
        <td>2020-01-31</td>
        <td>TTXna0GJu9Q</td>
      </tr>
      <tr>
        <td>DISP HIV Test Result</td>
        <td>Display HIV Test Result in the top bar</td>
        <td>2020-02-03</td>
        <td>iYenf9BTI8B</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Am RES to DISP PRVar</td>
        <td>Assign Am RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>h6uFX6K0vHb</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Am SS to DISP PRVar</td>
        <td>Assign Am SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>daNPxnvc4su</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Bdq RES to DISP PRVar</td>
        <td>Assign Bdq RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>jN6A6LqDnJw</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Bdq SS to DISP PRVar</td>
        <td>Assign Bdq SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>b40om9uEkhv</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Cfz RES to DISP PRVar</td>
        <td>Assign Cfz RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>sseZCKBbIWb</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Cfz SS to DISP PRVar</td>
        <td>Assign Cfz SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>w9ajf3TYVXm</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Cm RES to DISP PRVar</td>
        <td>Assign Cm RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>CaFDSZzQEvr</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Cm SS to DISP PRVar</td>
        <td>Assign Cm SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>Je4tvNUvwcs</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Dlm RES to DISP PRVar</td>
        <td>Assign Dlm RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>F3ru6z1aqpr</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Dlm SS to DISP PRVar</td>
        <td>Assign Dlm SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>Vb6Wrofu2Ts</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign E RES to DISP PRVar</td>
        <td>Assign E RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>TkV8jSHNF6k</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign E SS to DISP PRVar</td>
        <td>Assign E SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>njfjeeXT8JF</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Eto RES to DISP PRVar</td>
        <td>Assign Eto RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>iYNTyG07QkX</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Eto SS to DISP PRVar</td>
        <td>Assign Eto SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>sDC7zBlImId</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Gfx RES to DISP PRVar</td>
        <td>Assign Gfx RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>CLRaUiluJY8</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Gfx SS to DISP PRVar</td>
        <td>Assign Gfx SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>YlUhZlfpY54</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign H RES to DISP PRVar</td>
        <td>Assign H RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>HtHgj7918bX</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign H SS to DISP PRVar</td>
        <td>Assign H SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>yD8ccK75KEQ</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign H/HC RES to DISP PRVar</td>
        <td>Assign H/HC RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>pY8wPfs1ygZ</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign H/HC SS to DISP PRVar</td>
        <td>Assign H/HC SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>yLV2K6T2IkL</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Km RES to DISP PRVar</td>
        <td>Assign Km RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>R52335AlWOG</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Km SS to DISP PRVar</td>
        <td>Assign Km SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>VT3TAPRpCBX</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Lfx RES to DISP PRVar</td>
        <td>Assign Lfx RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>CkICqIsJRtD</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Lfx SS to DISP PRVar</td>
        <td>Assign Lfx SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>vc5h2an49ey</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Lzd RES to DISP PRVar</td>
        <td>Assign Lzd RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>kensf66PHha</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Lzd SS to DISP PRVar</td>
        <td>Assign Lzd SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>JxUt9LqjEMo</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Mfx CB RES to DISP PRVar</td>
        <td>Assign Mfx CB RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>z79fdLaO2s0</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Mfx CB SS to DISP PRVar</td>
        <td>Assign Mfx CB SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>I0qXxzANUYm</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Mfx CC RES to DISP PRVar</td>
        <td>Assign Mfx CC RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>dY4UENHbsPa</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Mfx CC SS to DISP PRVar</td>
        <td>Assign Mfx CC SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>WECKMiCQbbN</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Ofx RES to DISP PRVar</td>
        <td>Assign Ofx RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>wAWi0g7ffzB</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Ofx SS to DISP PRVar</td>
        <td>Assign Ofx SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>PtdApQb9rcK</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign R RES to DISP PRVar</td>
        <td>Assign R RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>z7Xfkwq2fqw</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign R SS to DISP PRVar</td>
        <td>Assign R SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>x8WiggIy7VQ</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign S RES to DISP PRVar</td>
        <td>Assign S RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>ojQbOVOhK1K</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign S SS to DISP PRVar</td>
        <td>Assign S SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>gnMVh9Md6M3</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Z RES to DISP PRVar</td>
        <td>Assign Z RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>RHLlYO4dbGO</td>
      </tr>
      <tr>
        <td>DISP INIT DST LM: Assign Z SS to DISP PRVar</td>
        <td>Assign Z SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>mLlevyiC5QW</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Am RES to DISP PRVar</td>
        <td>Assign Am RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>iUIUM8IutcA</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Am SS to DISP PRVar</td>
        <td>Assign Am SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>qvdsK6tB82x</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Bdq RES to DISP PRVar</td>
        <td>Assign Bdq RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>mZKBWrVZu4T</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Bdq SS to DISP PRVar</td>
        <td>Assign Bdq SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>RmwXY6YK52L</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Cfz RES to DISP PRVar</td>
        <td>Assign Cfz RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>oBotvK3ojjx</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Cfz SS to DISP PRVar</td>
        <td>Assign Cfz SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>uL5iySelS4D</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Cm RES to DISP PRVar</td>
        <td>Assign Cm RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>uYGlToaaebu</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Cm SS to DISP PRVar</td>
        <td>Assign Cm SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>f9A5s0Jh8fO</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Dlm RES to DISP PRVar</td>
        <td>Assign Dlm RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>kvu3Pq3Bu4q</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Dlm SS to DISP PRVar</td>
        <td>Assign Dlm SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>abI7z1lhve2</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign E RES to DISP PRVar</td>
        <td>Assign E RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>HeY1mgxsYxw</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign E SS to DISP PRVar</td>
        <td>Assign E SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>hTzI9qQYbMN</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Eto RES to DISP PRVar</td>
        <td>Assign Eto RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>Dx6HSihOCaK</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Eto SS to DISP PRVar</td>
        <td>Assign Eto SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>sMkn4ZpI2t0</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Gfx RES to DISP PRVar</td>
        <td>Assign Gfx RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>rDYmdndQ8Ob</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Gfx SS to DISP PRVar</td>
        <td>Assign Gfx SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>KJBLdTZa08L</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign H RES to DISP PRVar</td>
        <td>Assign H RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>F9o9lJVHxqB</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign H SS to DISP PRVar</td>
        <td>Assign H SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>ZQpDfAT12LO</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign H/HC RES to DISP PRVar</td>
        <td>Assign H/HC RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>C9m4TGpAzWU</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign H/HC SS to DISP PRVar</td>
        <td>Assign H/HC SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>O7ORQgBsGZ1</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Km RES to DISP PRVar</td>
        <td>Assign Km RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>kCGGDbQgEIR</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Km SS to DISP PRVar</td>
        <td>Assign Km SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>sWZ7sKvMjbg</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Lfx RES to DISP PRVar</td>
        <td>Assign Lfx RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>q95LwUcRi05</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Lfx SS to DISP PRVar</td>
        <td>Assign Lfx SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>OjBts9wZYS5</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Lzd RES to DISP PRVar</td>
        <td>Assign Lzd RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>GPwb8nTEQxE</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Lzd SS to DISP PRVar</td>
        <td>Assign Lzd SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>l1y2jnvsRLn</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Mfx CB RES to DISP PRVar</td>
        <td>Assign Mfx CB RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>njcSAc77AEo</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Mfx CB SS to DISP PRVar</td>
        <td>Assign Mfx CB SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>WtkuGbuNZ6M</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Mfx CC RES to DISP PRVar</td>
        <td>Assign Mfx CC RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>KsQCzJeo2sT</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Mfx CC SS to DISP PRVar</td>
        <td>Assign Mfx CC SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>W6QkkbxI2HG</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Ofx RES to DISP PRVar</td>
        <td>Assign Ofx RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>y1bFjz0WhGX</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Ofx SS to DISP PRVar</td>
        <td>Assign Ofx SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>ZgXx9wq9Rx9</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign R RES to DISP PRVar</td>
        <td>Assign R RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>GAzmxUjzQfb</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign R SS to DISP PRVar</td>
        <td>Assign R SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>Y76jaGFdRbn</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign S RES to DISP PRVar</td>
        <td>Assign S RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>V1OmWkrvx9I</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign S SS to DISP PRVar</td>
        <td>Assign S SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>LE9NlQuv2VK</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Z RES to DISP PRVar</td>
        <td>Assign Z RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>k2X9OPM8Exe</td>
      </tr>
      <tr>
        <td>DISP INIT DST SM: Assign Z SS to DISP PRVar</td>
        <td>Assign Z SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>ihwzFgdtoqA</td>
      </tr>
      <tr>
        <td>DISP LPA FQ 2LI: Assign Am/Cm RES to DISP PRVar</td>
        <td>Assign Am/Cm RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>M4jHqmLjE3V</td>
      </tr>
      <tr>
        <td>DISP LPA FQ 2LI: Assign Am/Cm SS to DISP PRVar</td>
        <td>Assign Am/Cm SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>T6d5m5CZsPv</td>
      </tr>
      <tr>
        <td>DISP LPA FQ 2LI: Assign E RES to DISP PRVar</td>
        <td>Assign E RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>OQEtnZQcnUv</td>
      </tr>
      <tr>
        <td>DISP LPA FQ 2LI: Assign E SS to DISP PRVar</td>
        <td>Assign E SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>MDopFBAVj3B</td>
      </tr>
      <tr>
        <td>DISP LPA FQ 2LI: Assign FQ RES to DISP PRVar</td>
        <td>Assign FQ RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>epJXl5GvNSp</td>
      </tr>
      <tr>
        <td>DISP LPA FQ 2LI: Assign FQ SS to DISP PRVar</td>
        <td>Assign FQ SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>AVLaIqL8c3n</td>
      </tr>
      <tr>
        <td>DISP LPA FQ 2LI: Assign Km RES to DISP PRVar</td>
        <td>Assign Km RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>lFEHiGMZJgI</td>
      </tr>
      <tr>
        <td>DISP LPA FQ 2LI: Assign Km SS to DISP PRVar</td>
        <td>Assign Km SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>H0hCIeljqnP</td>
      </tr>
      <tr>
        <td>DISP LPA RIF INH: Assign H RES to DISP PRVar</td>
        <td>Assign H RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>mQteluIFRtw</td>
      </tr>
      <tr>
        <td>DISP LPA RIF INH: Assign H SS to DISP PRVar</td>
        <td>Assign H SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>VnLmuLfx9iY</td>
      </tr>
      <tr>
        <td>DISP LPA RIF INH: Assign R RES to DISP PRVar</td>
        <td>Assign R RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>sCPEtJsoXkX</td>
      </tr>
      <tr>
        <td>DISP LPA RIF INH: Assign R SS to DISP PRVar</td>
        <td>Assign R SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>L5FfdIfwBm2</td>
      </tr>
      <tr>
        <td>DISP Previous TB Registration Number</td>
        <td>Display Previous TB Registration Number</td>
        <td>2020-02-03</td>
        <td>SzhYub67ji4</td>
      </tr>
      <tr>
        <td>DISP Previous Treatment Outcome</td>
        <td>Display Previous Treatment Outcome in the top bar</td>
        <td>2020-02-03</td>
        <td>H1GBsn87Y54</td>
      </tr>
      <tr>
        <td>DISP SSM: Display Final Result</td>
        <td>DISP SSM: Display Final Result</td>
        <td>2020-01-31</td>
        <td>CPocSSh4vIh</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Am RES to DISP PRVar</td>
        <td>Assign Am RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>cVB3OYAcDlM</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Am SS to DISP PRVar</td>
        <td>Assign Am SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>QiQZ1RP2Mtp</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Bdq RES to DISP PRVar</td>
        <td>Assign Bdq RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>Ws9L7l30t7I</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Bdq SS to DISP PRVar</td>
        <td>Assign Bdq SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>q9cEu2fgdaw</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Cfz RES to DISP PRVar</td>
        <td>Assign Cfz RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>B7FfmEqFedD</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Cfz SS to DISP PRVar</td>
        <td>Assign Cfz SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>IMhOMgJhYYf</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Cm RES to DISP PRVar</td>
        <td>Assign Cm RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>jEynEdPnOwu</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Cm SS to DISP PRVar</td>
        <td>Assign Cm SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>G7imri6pF6F</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Dlm RES to DISP PRVar</td>
        <td>Assign Dlm RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>Kgj5zQDsGDn</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Dlm SS to DISP PRVar</td>
        <td>Assign Dlm SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>HGN8ZhtyhPg</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign E RES to DISP PRVar</td>
        <td>Assign E RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>SbFHMf59MpV</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign E SS to DISP PRVar</td>
        <td>Assign E SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>h6G4kli6CzH</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Eto RES to DISP PRVar</td>
        <td>Assign Eto RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>jK8j4hLsqJP</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Eto SS to DISP PRVar</td>
        <td>Assign Eto SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>tCopXq90fOQ</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Gfx RES to DISP PRVar</td>
        <td>Assign Gfx RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>GgsRtFICghB</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Gfx SS to DISP PRVar</td>
        <td>Assign Gfx SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>om3q0C7jbZz</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign H RES to DISP PRVar</td>
        <td>Assign H RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>D7Kuh03qjsG</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign H SS to DISP PRVar</td>
        <td>Assign H SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>MrH8T56G7u4</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign H/HC RES to DISP PRVar</td>
        <td>Assign H/HC RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>bz1nJP7HDxW</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign H/HC SS to DISP PRVar</td>
        <td>Assign H/HC SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>IZKG2jkdV3S</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Km RES to DISP PRVar</td>
        <td>Assign Km RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>qliKxyjbTi6</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Km SS to DISP PRVar</td>
        <td>Assign Km SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>GRX8oEaFDXn</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Lfx RES to DISP PRVar</td>
        <td>Assign Lfx RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>B7nHVVrPNTd</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Lfx SS to DISP PRVar</td>
        <td>Assign Lfx SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>de2EDDNnO3a</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Lzd RES to DISP PRVar</td>
        <td>Assign Lzd RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>o9Tasy5ngK3</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Lzd SS to DISP PRVar</td>
        <td>Assign Lzd SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>j8itjeZWM5Z</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Mfx CB RES to DISP PRVar</td>
        <td>Assign Mfx CB RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>ehizAnHwhHH</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Mfx CB SS to DISP PRVar</td>
        <td>Assign Mfx CB SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>tiwYjAymG9P</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Mfx CC RES to DISP PRVar</td>
        <td>Assign Mfx CC RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>hqrXszvoXgN</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Mfx CC SS to DISP PRVar</td>
        <td>Assign Mfx CC SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>C9nWLB5GTOX</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Ofx RES to DISP PRVar</td>
        <td>Assign Ofx RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>jGGXheV7Iy8</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Ofx SS to DISP PRVar</td>
        <td>Assign Ofx SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>mnK1taFShL5</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign R RES to DISP PRVar</td>
        <td>Assign R RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>CFDeTZepQiU</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign R SS to DISP PRVar</td>
        <td>Assign R SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>CxYQAPnc4I5</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign S RES to DISP PRVar</td>
        <td>Assign S RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>x1Y0JwxZnxU</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign S SS to DISP PRVar</td>
        <td>Assign S SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>s7B5rAleown</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Z RES to DISP PRVar</td>
        <td>Assign Z RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>ByI10OrawGF</td>
      </tr>
      <tr>
        <td>DISP SUB DST LM: Assign Z SS to DISP PRVar</td>
        <td>Assign Z SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>lcJp8WNrBrH</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Am RES to DISP PRVar</td>
        <td>Assign Am RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>WvZEANcSdtR</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Am SS to DISP PRVar</td>
        <td>Assign Am SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>AN6JLtN96Lv</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Bdq RES to DISP PRVar</td>
        <td>Assign Bdq RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>fnVWEOfjBYE</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Bdq SS to DISP PRVar</td>
        <td>Assign Bdq SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>kHye62m7yDL</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Cfz RES to DISP PRVar</td>
        <td>Assign Cfz RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>e2l7Po4istU</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Cfz SS to DISP PRVar</td>
        <td>Assign Cfz SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>zyvdJnlhNyz</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Cm RES to DISP PRVar</td>
        <td>Assign Cm RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>RD9P88FT17X</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Cm SS to DISP PRVar</td>
        <td>Assign Cm SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>py53zrn0HJq</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Dlm RES to DISP PRVar</td>
        <td>Assign Dlm RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>OvVcoUbzIsw</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Dlm SS to DISP PRVar</td>
        <td>Assign Dlm SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>mFJCkogKaaU</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign E RES to DISP PRVar</td>
        <td>Assign E RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>zEsMpmbt0mU</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign E SS to DISP PRVar</td>
        <td>Assign E SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>cBiw7XISFaP</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Eto RES to DISP PRVar</td>
        <td>Assign Eto RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>kUkrzsuU7sB</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Eto SS to DISP PRVar</td>
        <td>Assign Eto SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>fy9gva60jEX</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Gfx RES to DISP PRVar</td>
        <td>Assign Gfx RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>gqSEFqcC6YP</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Gfx SS to DISP PRVar</td>
        <td>Assign Gfx SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>SNRgyFqviNs</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign H RES to DISP PRVar</td>
        <td>Assign H RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>qIVN0jNoqIn</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign H SS to DISP PRVar</td>
        <td>Assign H SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>u8t4ZCLQiOF</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign H/HC RES to DISP PRVar</td>
        <td>Assign H/HC RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>h9UQU5Yc4vC</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign H/HC SS to DISP PRVar</td>
        <td>Assign H/HC SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>B8U7V37kCH1</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Km RES to DISP PRVar</td>
        <td>Assign Km RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>glSEjJuqHlW</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Km SS to DISP PRVar</td>
        <td>Assign Km SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>RgwqPFQ9F9o</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Lfx RES to DISP PRVar</td>
        <td>Assign Lfx RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>Y7PPOsudlr0</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Lfx SS to DISP PRVar</td>
        <td>Assign Lfx SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>Y27EAwjoG4R</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Lzd RES to DISP PRVar</td>
        <td>Assign Lzd RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>K6tNWx4Mo7J</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Lzd SS to DISP PRVar</td>
        <td>Assign Lzd SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>r2p8v1EKRkj</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Mfx CB RES to DISP PRVar</td>
        <td>Assign Mfx CB RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>YiPcdxnXK0U</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Mfx CB SS to DISP PRVar</td>
        <td>Assign Mfx CB SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>jWWebXzk4Fq</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Mfx CC RES to DISP PRVar</td>
        <td>Assign Mfx CC RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>heCubI1DJrm</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Mfx CC SS to DISP PRVar</td>
        <td>Assign Mfx CC SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>UanCFXvxG7T</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Ofx RES to DISP PRVar</td>
        <td>Assign Ofx RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>SW6AYfsA957</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Ofx SS to DISP PRVar</td>
        <td>Assign Ofx SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>jP9DffsjsJI</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign R RES to DISP PRVar</td>
        <td>Assign R RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>yVzVZfNiS2s</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign R SS to DISP PRVar</td>
        <td>Assign R SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>hqwb9sJRpGq</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign S RES to DISP PRVar</td>
        <td>Assign S RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>hjvYawM1RJ1</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign S SS to DISP PRVar</td>
        <td>Assign S SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>IhHtTN5k4LI</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Z RES to DISP PRVar</td>
        <td>Assign Z RES to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>D6VI4SEye9e</td>
      </tr>
      <tr>
        <td>DISP SUB DST SM: Assign Z SS to DISP PRVar</td>
        <td>Assign Z SS to DISP PRVar</td>
        <td>2020-01-31</td>
        <td>RoPXY9odB3W</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Am RES to DISP PRVar</td>
        <td>Assign Am RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>F1iCFHwClry</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Am SS to DISP PRVar</td>
        <td>Assign Am SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>nTCBTpvP1LG</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Bdq RES to DISP PRVar</td>
        <td>Assign Bdq RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>ZjzVK74G9NV</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Bdq SS to DISP PRVar</td>
        <td>Assign Bdq SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>pENfLElG3IY</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Cfz RES to DISP PRVar</td>
        <td>Assign Cfz RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>rllUvomu7Ye</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Cfz SS to DISP PRVar</td>
        <td>Assign Cfz SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>VKGlbj6ON6v</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Cm RES to DISP PRVar</td>
        <td>Assign Cm RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>WSEM7kyFrZZ</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Cm SS to DISP PRVar</td>
        <td>Assign Cm SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>yt0EEmHaLtL</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Cs RES to DISP PRVar</td>
        <td>Assign Cs RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>fBj76Qr1Fe4</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Cs SS to DISP PRVar</td>
        <td>Assign Cs SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>aQDA1gUwCTH</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Dlm RES to DISP PRVar</td>
        <td>Assign Dlm RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>cmSbdSQOHIx</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Dlm SS to DISP PRVar</td>
        <td>Assign Dlm SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>yC38bankdgZ</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign E RES to DISP PRVar</td>
        <td>Assign E RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>jvHEMrkBRRp</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign E SS to DISP PRVar</td>
        <td>Assign E SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>F545xByomx2</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Eto RES to DISP PRVar</td>
        <td>Assign Eto RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>UKjk70nh87e</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Eto SS to DISP PRVar</td>
        <td>Assign Eto SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>GjtSoLwLrQ7</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Gfx RES to DISP PRVar</td>
        <td>Assign Gfx RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>evJQ727tA0e</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Gfx SS to DISP PRVar</td>
        <td>Assign Gfx SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>zqzHYVskSXP</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign H RES to DISP PRVar</td>
        <td>Assign H RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>uERs6gS6qUE</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign H SS to DISP PRVar</td>
        <td>Assign H SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>fdwWn9SQD1W</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Km RES to DISP PRVar</td>
        <td>Assign Km RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>vhabOEf6980</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Km SS to DISP PRVar</td>
        <td>Assign Km SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>dRhTc0YZycE</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Lfx RES to DISP PRVar</td>
        <td>Assign Lfx RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>owxylVUWMUN</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Lfx SS to DISP PRVar</td>
        <td>Assign Lfx SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>AANoVw7OtCO</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Lzd RES to DISP PRVar</td>
        <td>Assign Lzd RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>vfI86Vlr0aE</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Lzd SS to DISP PRVar</td>
        <td>Assign Lzd SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>oxsPvj7tGOF</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Mfx RES to DISP PRVar</td>
        <td>Assign Mfx RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>mXklBJ9bCIl</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Mfx SS to DISP PRVar</td>
        <td>Assign Mfx SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>Lnw3zanfLsr</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Ofx RES to DISP PRVar</td>
        <td>Assign Ofx RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>iwqXrbGTJ7y</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Ofx SS to DISP PRVar</td>
        <td>Assign Ofx SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>K9GlP50AfGZ</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Pa RES to DISP PRVar</td>
        <td>Assign Pa RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>BEFmWTMf8gH</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Pa SS to DISP PRVar</td>
        <td>Assign Pa SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>lugAQWDe5uR</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign PAS RES to DISP PRVar</td>
        <td>Assign PAS RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>diVwHezPtyz</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign PAS SS to DISP PRVar</td>
        <td>Assign PAS SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>QvB7JppFO9P</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign R RES to DISP PRVar</td>
        <td>Assign R RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>rk0qpmExDnM</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign R SS to DISP PRVar</td>
        <td>Assign R SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>BGKMVPBl6yi</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign S RES to DISP PRVar</td>
        <td>Assign S RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>MrkkgIHEgm4</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign S SS to DISP PRVar</td>
        <td>Assign S SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>te4w8s5R4Ng</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Z RES to DISP PRVar</td>
        <td>Assign Z RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>HlmioDkErN7</td>
      </tr>
      <tr>
        <td>DISP TGS: Assign Z SS to DISP PRVar</td>
        <td>Assign Z SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>teTpVtcQsws</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Am RES to DISP PRVar</td>
        <td>Assign Am RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>b7lAma5yRPX</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Am SS to DISP PRVar</td>
        <td>Assign Am SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>wW2SUNZICDX</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Bdq RES to DISP PRVar</td>
        <td>Assign Bdq RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>lnOr4n4gV8N</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Bdq SS to DISP PRVar</td>
        <td>Assign Bdq SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>t4Kuu8e2q8C</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Cfz RES to DISP PRVar</td>
        <td>Assign Cfz RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>i5dzSqT03dS</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Cfz SS to DISP PRVar</td>
        <td>Assign Cfz SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>ROhQlSCKjXh</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Cm RES to DISP PRVar</td>
        <td>Assign Cm RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>KlCkUBZRHbl</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Cm SS to DISP PRVar</td>
        <td>Assign Cm SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>nJwypQBXogp</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Cs RES to DISP PRVar</td>
        <td>Assign Cs RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>iCOeK1BHRYQ</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Cs SS to DISP PRVar</td>
        <td>Assign Cs SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>PCgnkBnwq4g</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Dlm RES to DISP PRVar</td>
        <td>Assign Dlm RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>Yd17wyC5yXO</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Dlm SS to DISP PRVar</td>
        <td>Assign Dlm SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>iRU8QvAsg5g</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign E RES to DISP PRVar</td>
        <td>Assign E RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>gGikCREKRQr</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign E SS to DISP PRVar</td>
        <td>Assign E SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>TWYgonwYhPR</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Eto RES to DISP PRVar</td>
        <td>Assign Eto RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>FEjWYVv2FaR</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Eto SS to DISP PRVar</td>
        <td>Assign Eto SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>aw5jpTZltRj</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Gfx RES to DISP PRVar</td>
        <td>Assign Gfx RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>ZIs2nlSh3R2</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Gfx SS to DISP PRVar</td>
        <td>Assign Gfx SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>wzgpiVXvfpj</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign H RES to DISP PRVar</td>
        <td>Assign H RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>IA0tmLtLrOL</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign H SS to DISP PRVar</td>
        <td>Assign H SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>Fp9z6wagUSF</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Km RES to DISP PRVar</td>
        <td>Assign Km RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>g2hVQbVeetY</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Km SS to DISP PRVar</td>
        <td>Assign Km SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>VUE6FTjXLnW</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Lfx RES to DISP PRVar</td>
        <td>Assign Lfx RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>KPXNjQzFODV</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Lfx SS to DISP PRVar</td>
        <td>Assign Lfx SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>sdpPxGesRpK</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Lzd RES to DISP PRVar</td>
        <td>Assign Lzd RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>XsV6AN6NSBr</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Lzd SS to DISP PRVar</td>
        <td>Assign Lzd SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>lMyk03epb2e</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Mfx RES to DISP PRVar</td>
        <td>Assign Mfx RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>O0Cy1EswerP</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Mfx SS to DISP PRVar</td>
        <td>Assign Mfx SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>Xn71GoZhRtr</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Ofx RES to DISP PRVar</td>
        <td>Assign Ofx RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>EXCzfGlx6EQ</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Ofx SS to DISP PRVar</td>
        <td>Assign Ofx SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>qBKk3xxCIYG</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Pa RES to DISP PRVar</td>
        <td>Assign Pa RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>jYKlqtXlkJT</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Pa SS to DISP PRVar</td>
        <td>Assign Pa SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>p0KhtmRgmjH</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign PAS RES to DISP PRVar</td>
        <td>Assign PAS RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>aNNr6BKIEMw</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign PAS SS to DISP PRVar</td>
        <td>Assign PAS SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>UCGoaEj5R69</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign R RES to DISP PRVar</td>
        <td>Assign R RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>A62tJHEXFRq</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign R SS to DISP PRVar</td>
        <td>Assign R SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>k1NxkeJDDGV</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign S RES to DISP PRVar</td>
        <td>Assign S RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>BA29wmPWgAO</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign S SS to DISP PRVar</td>
        <td>Assign S SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>Zf6Rl5LUnnp</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Z RES to DISP PRVar</td>
        <td>Assign Z RES to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>t5DfClgh7Ca</td>
      </tr>
      <tr>
        <td>DISP WGS: Assign Z SS to DISP PRVar</td>
        <td>Assign Z SS to DISP PRVar</td>
        <td>2020-01-30</td>
        <td>LdkaOrDqe6N</td>
      </tr>
      <tr>
        <td>DISP: Assign Patient DRS ID</td>
        <td>Display Patient DRS ID in the Indicator Widget</td>
        <td>2020-02-03</td>
        <td>OmiDOZC8stY</td>
      </tr>
      <tr>
        <td>DISP: Patient DRS ID</td>
        <td>Display Patient DRS ID</td>
        <td>2020-02-03</td>
        <td>mKaEauPcWxu</td>
      </tr>
      <tr>
        <td>DISP: Summarise Resistance for Initial DST in Liquid Media</td>
        <td>Summarise Resistance for Initial DST in Liquid Media</td>
        <td>2020-01-31</td>
        <td>MOlWfAbLEQQ</td>
      </tr>
      <tr>
        <td>DISP: Summarise Resistance for Initial DST in Solid Media</td>
        <td>Summarise Resistance for Initial DST in Solid Media</td>
        <td>2020-01-31</td>
        <td>OeJr47HXjY1</td>
      </tr>
      <tr>
        <td>DISP: Summarise Resistance for LPA FQ/2LI</td>
        <td>Summarise Resistance for LPA FQ/2LI</td>
        <td>2020-01-31</td>
        <td>hC5rr9su45V</td>
      </tr>
      <tr>
        <td>DISP: Summarise Resistance for LPA RIF/INH</td>
        <td>Summarise Resistance for LPA RIF/INH</td>
        <td>2020-01-31</td>
        <td>XmiB3Efa1Ze</td>
      </tr>
      <tr>
        <td>DISP: Summarise Resistance for Subsequent DST in Liquid Media</td>
        <td>Summarise Resistance for Subsequent DST in Liquid Media</td>
        <td>2020-01-31</td>
        <td>al32yeeWtHh</td>
      </tr>
      <tr>
        <td>DISP: Summarise Resistance for Subsequent DST in Solid Media</td>
        <td>Summarise Resistance for Subsequent DST in Solid Media</td>
        <td>2020-01-31</td>
        <td>dthltL3rv0V</td>
      </tr>
      <tr>
        <td>DISP: Summarise Resistance for TGS</td>
        <td>Summarise Resistance for TGS</td>
        <td>2020-01-30</td>
        <td>kfVWdR8Nyc2</td>
      </tr>
      <tr>
        <td>DISP: Summarise Resistance for WGS</td>
        <td>Summarise Resistance for WGS</td>
        <td>2020-01-30</td>
        <td>y2tWjWW4TtH</td>
      </tr>
      <tr>
        <td>DISP: Summarise Susceptibility for LPA RIF/INH</td>
        <td>Summarise Susceptibility for LPA RIF/INH</td>
        <td>2020-01-31</td>
        <td>Ha6Ob13qKkS</td>
      </tr>
      <tr>
        <td>DISP: Summarise Susceptibility for Initial DST in Liquid Media</td>
        <td>Summarise Susceptibility for Initial DST in Liquid Media</td>
        <td>2020-01-31</td>
        <td>jeFuG2QMwhE</td>
      </tr>
      <tr>
        <td>DISP: Summarise Susceptibility for Initial DST in Solid Media</td>
        <td>Summarise Susceptibility for Initial DST in Solid Media</td>
        <td>2020-01-31</td>
        <td>NpUwXANd7O9</td>
      </tr>
      <tr>
        <td>DISP: Summarise Susceptibility for LPA FQ/2LI</td>
        <td>Summarise Susceptibility for LPA FQ/2LI</td>
        <td>2020-01-31</td>
        <td>LYXGZg3uvhg</td>
      </tr>
      <tr>
        <td>DISP: Summarise Susceptibility for Subsequent DST in Liquid Media</td>
        <td>Summarise Susceptibility for Subsequent DST in Liquid Media</td>
        <td>2020-01-31</td>
        <td>feX8H49s835</td>
      </tr>
      <tr>
        <td>DISP: Summarise Susceptibility for Subsequent DST in Solid Media</td>
        <td>Summarise Susceptibility for Subsequent DST in Solid Media</td>
        <td>2020-01-31</td>
        <td>aqketyBEhhI</td>
      </tr>
      <tr>
        <td>DISP: Summarise Susceptibility for TGS</td>
        <td>Summarise Susceptibility for TGS</td>
        <td>2020-01-30</td>
        <td>Oph1UF23Qzs</td>
      </tr>
      <tr>
        <td>DISP: Summarise Susceptibility for WGS</td>
        <td>Summarise Susceptibility for WGS</td>
        <td>2020-01-30</td>
        <td>czSWVyIbSCr</td>
      </tr>
      <tr>
        <td>DISP: Xpert MTB/RIF Final Result</td>
        <td>Display Final Result for Xpert MTB/RIF</td>
        <td>2020-02-03</td>
        <td>N4yZ77rLtwt</td>
      </tr>
      <tr>
        <td>DISP: Xpert MTB/RIF Ultra Final Result</td>
        <td>Display Final Result for Xpert MTB/RIF Ultra</td>
        <td>2020-02-03</td>
        <td>nvyS3S0cKWS</td>
      </tr>
      <tr>
        <td>Generate DRS Sample 1 ID</td>
        <td>Generate DRS Sample 1 ID</td>
        <td>2020-02-03</td>
        <td>tJq1UCrpx4p</td>
      </tr>
      <tr>
        <td>Generate DRS Sample 2 ID</td>
        <td>Generate DRS Sample 2 ID</td>
        <td>2020-02-03</td>
        <td>WyhrK5pCVIr</td>
      </tr>
      <tr>
        <td>Generate DRS Sample 3 ID</td>
        <td>Generate DRS Sample 3 ID</td>
        <td>2020-02-03</td>
        <td>UOtdRCTgYRU</td>
      </tr>
      <tr>
        <td>Generate DRS Sample 4 ID</td>
        <td>Generate DRS Sample 4 ID</td>
        <td>2020-02-03</td>
        <td>fVXqShjK1Ue</td>
      </tr>
      <tr>
        <td>Generate Patient DRS ID</td>
        <td>Generate Patient DRS ID</td>
        <td>2020-02-03</td>
        <td>OVdbdXxA4pw</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for 4-AMINOSALICYLIC ACID (PARA-AMINOSALICYLIC ACID [PAS])"</td>
        <td>Hide "TGS - Genotypic resistance profiling for 4-AMINOSALICYLIC ACID (PARA-AMINOSALICYLIC ACID [PAS])" unless "4-AMINOSALICYLIC ACID (PARA-AMINOSALICYLIC ACID [PAS])" is selected</td>
        <td>2020-01-15</td>
        <td>WQ3EhRSfWrZ</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for AMIKACIN"</td>
        <td>Hide "TGS - Genotypic resistance profiling for AMIKACIN" unless "AMIKACIN" is selected</td>
        <td>2020-01-15</td>
        <td>iTe1I7B3ecJ</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for BEDAQUILINE"</td>
        <td>Hide "TGS - Genotypic resistance profiling for BEDAQUILINE" unless "BEDAQUILINE" is selected</td>
        <td>2020-01-15</td>
        <td>oWvBmLd9YJW</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for CAPREOMYCIN"</td>
        <td>Hide "TGS - Genotypic resistance profiling for CAPREOMYCIN" unless "CAPREOMYCIN" is selected</td>
        <td>2020-01-15</td>
        <td>bohUwq9oYQ5</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for CLOFAZIMINE"</td>
        <td>Hide "TGS - Genotypic resistance profiling for CLOFAZIMINE" unless "CLOFAZIMINE" is selected</td>
        <td>2020-01-15</td>
        <td>MrOZWRJWBTk</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for CYCLOSERINE"</td>
        <td>Hide "TGS - Genotypic resistance profiling for CYCLOSERINE" unless "CYCLOSERINE" is selected</td>
        <td>2020-01-15</td>
        <td>F4ETZ8Pq0JC</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for DELAMANID"</td>
        <td>Hide "TGS - Genotypic resistance profiling for DELAMANID" unless "DELAMANID" is selected</td>
        <td>2020-01-15</td>
        <td>ZQ99gFr5SyM</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for ETHAMBUTOL"</td>
        <td>Hide "TGS - Genotypic resistance profiling for ETHAMBUTOL" unless "ETHAMBUTOL" is selected</td>
        <td>2020-01-15</td>
        <td>O6eqXewEC0o</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for ETHIONAMIDE"</td>
        <td>Hide "TGS - Genotypic resistance profiling for ETHIONAMIDE" unless "ETHIONAMIDE" is selected</td>
        <td>2020-01-15</td>
        <td>Jc9RxNY8HkT</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for GATIFLOXACIN"</td>
        <td>Hide "TGS - Genotypic resistance profiling for GATIFLOXACIN" unless "GATIFLOXACIN" is selected</td>
        <td>2020-01-15</td>
        <td>ELmLN2TjFaZ</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for ISONIAZID"</td>
        <td>Hide "TGS - Genotypic resistance profiling for Isoniazid" unless "Isoniazid" is selected</td>
        <td>2020-01-15</td>
        <td>Z4r8vdPvT4a</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for KANAMYCIN"</td>
        <td>Hide "TGS - Genotypic resistance profiling for KANAMYCIN" unless "KANAMYCIN" is selected</td>
        <td>2020-01-15</td>
        <td>gDnQCFAMAoA</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for LEVOFLOXACIN"</td>
        <td>Hide "TGS - Genotypic resistance profiling for LEVOFLOXACIN" unless "LEVOFLOXACIN" is selected</td>
        <td>2020-01-15</td>
        <td>zeq2qdQqrqL</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for LINEZOLID"</td>
        <td>Hide "TGS - Genotypic resistance profiling for LINEZOLID" unless "LINEZOLID" is selected</td>
        <td>2020-01-15</td>
        <td>f1bBQUflfX3</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for MOXIFLOXACIN"</td>
        <td>Hide "TGS - Genotypic resistance profiling for MOXIFLOXACIN" unless "MOXIFLOXACIN" is selected</td>
        <td>2020-01-15</td>
        <td>xpp4o0BM7JZ</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for OFLOXACIN"</td>
        <td>Hide "TGS - Genotypic resistance profiling for OFLOXACIN" unless "OFLOXACIN" is selected</td>
        <td>2020-01-15</td>
        <td>ujlT9vXobZP</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for PRETOMANID"</td>
        <td>Hide "TGS - Genotypic resistance profiling for PRETOMANID" unless "PRETOMANID" is selected</td>
        <td>2020-01-15</td>
        <td>gf6jw2X2Tfg</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for PYRAZINAMIDE"</td>
        <td>Hide "TGS - Genotypic resistance profiling for Pyrazinamide" unless "Pyrazinamide" is selected</td>
        <td>2020-01-15</td>
        <td>ieCdLbXtae3</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for RIFAMPICIN"</td>
        <td>Hide "TGS - Genotypic resistance profiling for Rifampicin" unless "Rifampicin" is selected</td>
        <td>2020-01-15</td>
        <td>X4p0tzFwtrU</td>
      </tr>
      <tr>
        <td>Hide "TGS - Genotypic resistance profiling for STREPTOMYCIN"</td>
        <td>Hide "TGS - Genotypic resistance profiling for STREPTOMYCIN" unless "STREPTOMYCIN" is selected</td>
        <td>2020-01-15</td>
        <td>dTpgijc8oW8</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for 4-AMINOSALICYLIC ACID (PARA-AMINOSALICYLIC ACID [PAS])"</td>
        <td>Hide "WGS - Genotypic resistance profiling for 4-AMINOSALICYLIC ACID (PARA-AMINOSALICYLIC ACID [PAS])" unless "4-AMINOSALICYLIC ACID (PARA-AMINOSALICYLIC ACID [PAS])" is selected</td>
        <td>2020-01-16</td>
        <td>fsNiuwiNWFN</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for AMIKACIN"</td>
        <td>Hide "WGS - Genotypic resistance profiling for AMIKACIN" unless "AMIKACIN" is selected</td>
        <td>2020-01-16</td>
        <td>TxjDPfagTrd</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for BEDAQUILINE"</td>
        <td>Hide "WGS - Genotypic resistance profiling for BEDAQUILINE" unless "BEDAQUILINE" is selected</td>
        <td>2020-01-16</td>
        <td>e3aDRhSYvQL</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for CAPREOMYCIN"</td>
        <td>Hide "WGS - Genotypic resistance profiling for CAPREOMYCIN" unless "CAPREOMYCIN" is selected</td>
        <td>2020-01-16</td>
        <td>TvmoZCW1VYz</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for CLOFAZIMINE"</td>
        <td>Hide "WGS - Genotypic resistance profiling for CLOFAZIMINE" unless "CLOFAZIMINE" is selected</td>
        <td>2020-01-16</td>
        <td>qOUaneSgo6r</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for CYCLOSERINE"</td>
        <td>Hide "WGS - Genotypic resistance profiling for CYCLOSERINE" unless "CYCLOSERINE" is selected</td>
        <td>2020-01-16</td>
        <td>WImukwwrmNG</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for DELAMANID"</td>
        <td>Hide "WGS - Genotypic resistance profiling for DELAMANID" unless "DELAMANID" is selected</td>
        <td>2020-01-16</td>
        <td>vbli8kOt40j</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for ETHAMBUTOL"</td>
        <td>Hide "WGS - Genotypic resistance profiling for ETHAMBUTOL" unless "ETHAMBUTOL" is selected</td>
        <td>2020-01-16</td>
        <td>BgOho09nvHl</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for ETHIONAMIDE"</td>
        <td>Hide "WGS - Genotypic resistance profiling for ETHIONAMIDE" unless "ETHIONAMIDE" is selected</td>
        <td>2020-01-16</td>
        <td>U2QjqWVXXan</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for GATIFLOXACIN"</td>
        <td>Hide "WGS - Genotypic resistance profiling for GATIFLOXACIN" unless "GATIFLOXACIN" is selected</td>
        <td>2020-01-16</td>
        <td>O9OQRsOsQ2L</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for ISONIAZID"</td>
        <td>Hide "WGS - Genotypic resistance profiling for Isoniazid" unless "Isoniazid" is selected</td>
        <td>2020-01-16</td>
        <td>pVtxk5aRo1A</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for KANAMYCIN"</td>
        <td>Hide "WGS - Genotypic resistance profiling for KANAMYCIN" unless "KANAMYCIN" is selected</td>
        <td>2020-01-16</td>
        <td>iIVGItnOAgE</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for LEVOFLOXACIN"</td>
        <td>Hide "WGS - Genotypic resistance profiling for LEVOFLOXACIN" unless "LEVOFLOXACIN" is selected</td>
        <td>2020-01-16</td>
        <td>udtDetU45tM</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for LINEZOLID"</td>
        <td>Hide "WGS - Genotypic resistance profiling for LINEZOLID" unless "LINEZOLID" is selected</td>
        <td>2020-01-16</td>
        <td>sg73xxlHIXQ</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for MOXIFLOXACIN"</td>
        <td>Hide "WGS - Genotypic resistance profiling for MOXIFLOXACIN" unless "MOXIFLOXACIN" is selected</td>
        <td>2020-01-16</td>
        <td>ZxFV25UIVeE</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for OFLOXACIN"</td>
        <td>Hide "WGS - Genotypic resistance profiling for OFLOXACIN" unless "OFLOXACIN" is selected</td>
        <td>2020-01-16</td>
        <td>Fq7iJi59sct</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for PRETOMANID"</td>
        <td>Hide "WGS - Genotypic resistance profiling for PRETOMANID" unless "PRETOMANID" is selected</td>
        <td>2020-01-16</td>
        <td>yxXkTN1Fe5m</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for PYRAZINAMIDE"</td>
        <td>Hide "WGS - Genotypic resistance profiling for Pyrazinamide" unless "Pyrazinamide" is selected</td>
        <td>2020-01-16</td>
        <td>OPOqlzeTdgg</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for RIFAMPICIN"</td>
        <td>Hide "WGS - Genotypic resistance profiling for Rifampicin" unless "Rifampicin" is selected</td>
        <td>2020-01-16</td>
        <td>Smh5tAUwrDR</td>
      </tr>
      <tr>
        <td>Hide "WGS - Genotypic resistance profiling for STREPTOMYCIN"</td>
        <td>Hide "WGS - Genotypic resistance profiling for STREPTOMYCIN" unless "STREPTOMYCIN" is selected</td>
        <td>2020-01-16</td>
        <td>gOr8fHRgzKN</td>
      </tr>
      <tr>
        <td>LAB: Hide " Culture in Liquid Media (e.g. MGIT)" fields</td>
        <td>Hide "Culture in Liquid Media (e.g. MGIT)" fields unless "Liquid (e.g. MGIT)" is selected</td>
        <td>2020-02-12</td>
        <td>M7Ohl8yE15X</td>
      </tr>
      <tr>
        <td>LAB: Hide "Culture in Solid Media (e.g. LJ)" fields</td>
        <td>Hide "Culture in Solid Media (e.g. LJ)" fields unless "Culture in Solid Media (e.g. LJ)" is selected</td>
        <td>2020-01-15</td>
        <td>IYXGAFbCSIP</td>
      </tr>
      <tr>
        <td>LAB: Hide "Initial DST in Liquid Media (Mgit)" fields</td>
        <td>Hide "Initial DST in Liquid Media (Mgit)" fields unless "Initial DST in Liquid Media (Mgit)" is selected</td>
        <td>2020-01-16</td>
        <td>oSEcFhWKeQU</td>
      </tr>
      <tr>
        <td>LAB: Hide "Initial DST in Solid Media (LJ)" fields</td>
        <td>Hide "Initial DST in Solid Media (LJ)" fields unless "Initial DST in Solid Media (LJ)" is selected</td>
        <td>2020-01-16</td>
        <td>adZGFjUODor</td>
      </tr>
      <tr>
        <td>LAB: Hide "LAB - Targeted Gene Sequencing Drugs Tested" section</td>
        <td>Hide "LAB - Targeted Gene Sequencing Drugs Tested" section unless "TGS - Interpretable genetic resistance profiling for MTBc" is available</td>
        <td>2020-01-30</td>
        <td>DW8n3TWamam</td>
      </tr>
      <tr>
        <td>LAB: Hide "LAB - Tested Drugs (Initial DST LM)" section</td>
        <td>Hide "LAB - Tested Drugs (Initial DST LM)" section unless "Initial DST LM" is selected</td>
        <td>2020-01-30</td>
        <td>yHzbiWa4qnF</td>
      </tr>
      <tr>
        <td>LAB: Hide "LAB - Tested Drugs (Initial DST SM)" section</td>
        <td>Hide "LAB - Tested Drugs (Initial DST SM)" section unless "Initial DST SM" is selected</td>
        <td>2020-01-30</td>
        <td>rv5bDc0loqv</td>
      </tr>
      <tr>
        <td>LAB: Hide "LAB - Tested Drugs (Subsequent DST LM)" section</td>
        <td>Hide "LAB - Tested Drugs (Subsequent DST LM)" section unless "Subsequent DST LM" is selected</td>
        <td>2020-01-30</td>
        <td>gyEgVmikOZo</td>
      </tr>
      <tr>
        <td>LAB: Hide "LAB - Tested Drugs (Subsequent DST SM)" section</td>
        <td>Hide "LAB - Tested Drugs (Subsequent DST SM)" section unless "Subsequent DST SM" is selected</td>
        <td>2020-01-30</td>
        <td>yhUxqzLVROr</td>
      </tr>
      <tr>
        <td>LAB: Hide "LAB - TGS Reasons for No Resistance Profiling Available" field</td>
        <td>Hide "LAB - TGS Reasons for No Resistance Profiling Available" field if "TGS - Interpretable genetic resistance profiling for MTBc" is available</td>
        <td>2020-01-21</td>
        <td>qTNHmDzV7OB</td>
      </tr>
      <tr>
        <td>LAB: Hide "LAB - WGS Drugs Tested" section</td>
        <td>Hide "LAB - WGS Drugs Tested" section unless "WGS - Interpretable genetic resistance profiling for MTBc" is available</td>
        <td>2020-01-30</td>
        <td>i2OuX4baRcc</td>
      </tr>
      <tr>
        <td>LAB: Hide "LAB - WGS Reasons for No Resistance Profiling Available" field</td>
        <td>Hide "LAB - WGS Reasons for No Resistance Profiling Available" field if "WGS - Interpretable genetic resistance profiling for MTBc" is available</td>
        <td>2020-01-21</td>
        <td>vDfzXrPqVKw</td>
      </tr>
      <tr>
        <td>LAB: Hide "LPA (FQ/2LI)" fields</td>
        <td>Hide "LPA (FQ/2LI)" unless "LPA (FQ/2LI)" is selected</td>
        <td>2020-02-04</td>
        <td>h8E2btTqxKM</td>
      </tr>
      <tr>
        <td>LAB: Hide "LPA (RIF/INH)" Fields</td>
        <td>Hide "LPA (RIF/INH)" unless "LPA (RIF/INH)" is selected</td>
        <td>2020-02-04</td>
        <td>p7T5h5IhfR8</td>
      </tr>
      <tr>
        <td>LAB: Hide "Reasons for sample rejection or loss" fields</td>
        <td>Hide "Reasons for sample rejection or loss" unless "Sample Rejected or Lost" is selected</td>
        <td>2020-01-15</td>
        <td>EydNGX3KeUY</td>
      </tr>
      <tr>
        <td>LAB: Hide "Sputum Smear Microscopy" fields</td>
        <td>Hide "Sputum Smear Microscopy Fields" unless "Sputum Smear Microscopy" is selected</td>
        <td>2020-01-15</td>
        <td>fhJpvDBPZWN</td>
      </tr>
      <tr>
        <td>LAB: Hide "Subsequent DST in Liquid Media (MGIT)" fields</td>
        <td>Hide "Subsequent DST in Liquid Media (MGIT)" fields unless "Subsequent DST in Liquid Media (MGIT)" is selected</td>
        <td>2020-01-17</td>
        <td>Nfkzw58T1On</td>
      </tr>
      <tr>
        <td>LAB: Hide "Subsequent DST in Solid Media (LJ)" fields</td>
        <td>Hide "Subsequent DST in Solid Media (LJ)" fields unless "Subsequent DST in Solid Media (LJ)" is selected</td>
        <td>2020-01-16</td>
        <td>v6MhkRp66X4</td>
      </tr>
      <tr>
        <td>LAB: Hide "TGS - Is Interpretable genetic resistance profiling for MTBc available?" field</td>
        <td>Hide "TGS - Is Interpretable genetic resistance profiling for MTBc available?" field unless "TGS Genotypic Speciation Results" include MTBc</td>
        <td>2020-01-15</td>
        <td>QhFwiQPkez5</td>
      </tr>
      <tr>
        <td>LAB: Hide "TGS - Reasons for Failed Genotypic Speciation Results" field</td>
        <td>Hide "TGS - Reasons for Failed Genotypic Speciation Results" field if Genotypic Speciation results failed</td>
        <td>2020-01-15</td>
        <td>mUWZalW1I2i</td>
      </tr>
      <tr>
        <td>LAB: Hide "TGS Genotypic Speciation Results" fields</td>
        <td>Hide "TGS Genotypic Speciation Results" fields unless "Targeted Gene Sequencing" is selected</td>
        <td>2020-01-15</td>
        <td>AegsTJUK1a2</td>
      </tr>
      <tr>
        <td>LAB: Hide "WGS - Is Interpretable genetic resistance profiling for MTBc available?" field</td>
        <td>Hide "WGS - Is Interpretable genetic resistance profiling for MTBc available?" field unless "WGS Genotypic Speciation Results" include MTBc</td>
        <td>2020-01-16</td>
        <td>NMoHHtNiIow</td>
      </tr>
      <tr>
        <td>LAB: Hide "WGS - Reasons for Failed Genotypic Speciation Results" field</td>
        <td>Hide "WGS - Reasons for Failed Genotypic Speciation Results" field if Genotypic Speciation results failed</td>
        <td>2020-01-16</td>
        <td>i7IJAq6Dexs</td>
      </tr>
      <tr>
        <td>LAB: Hide "WGS Genotypic Speciation Results" fields</td>
        <td>Hide "WGS Genotypic Speciation Results" fields unless "WGS" is selected</td>
        <td>2020-01-16</td>
        <td>VLZOl0DJLS4</td>
      </tr>
      <tr>
        <td>LAB: Hide "WGS" fields</td>
        <td>Hide "WGS" fields unless "WGS" is selected</td>
        <td>2020-01-15</td>
        <td>W8Eq5lh30rL</td>
      </tr>
      <tr>
        <td>LAB: Hide "Xpert MTB/RIF Quantitative Result"</td>
        <td>Hide "Xpert MTB/RIF Quantitative Result" unless MTB is detected</td>
        <td>2020-01-29</td>
        <td>QfW0Fzg0Gj8</td>
      </tr>
      <tr>
        <td>LAB: Hide "Xpert MTB/RIF Ultra Quantitative Result"</td>
        <td>Hide "Xpert MTB/RIF Ultra Quantitative Result" unless MTB is detected</td>
        <td>2020-01-29</td>
        <td>aZMgpoSFbJY</td>
      </tr>
      <tr>
        <td>LAB: Hide "Xpert MTB/RIF Ultra" fields</td>
        <td>Hide "Xpert MTB/RIF Ultra" fields unless "Xpert MTB/RIF Ultra" is selected</td>
        <td>2020-01-15</td>
        <td>nd0bwVElmAJ</td>
      </tr>
      <tr>
        <td>LAB: Hide "Xpert MTB/RIF" fields</td>
        <td>Hide "Xpert MTB/RIF" fields unless "Xpert MTB/RIF" is selected</td>
        <td>2020-01-15</td>
        <td>HwGNeimZpes</td>
      </tr>
      <tr>
        <td>LAB: Hide Final FQ/2LI LPA Results for FQ, 2LI and Ethambutol fields</td>
        <td>Hide Final FQ/2LI LPA Results for FQ, 2LI and Ethambutol fields unless MTBc is detected</td>
        <td>2020-01-24</td>
        <td>UCz4TkFAacz</td>
      </tr>
      <tr>
        <td>LAB: Hide Final RIF/INH LPA Results for Rifampicin and Isoniazid fields</td>
        <td>Hide Hide Final RIF/INH LPA Results for Rifampicin and Isoniazid fields unless MTBc is detected</td>
        <td>2020-01-17</td>
        <td>y6QL5z3fXky</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Amikacin (LM)</td>
        <td>Hide "Initial DST Result for Amikacin (LM)" field unless "Amikacin" is selected</td>
        <td>2020-01-15</td>
        <td>sZ5GV2ezxZW</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Amikacin (SM)</td>
        <td>Hide "Initial DST Result for Amikacin (SM)" field unless "Amikacin" is selected</td>
        <td>2020-01-15</td>
        <td>mA99gTduWqP</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Bedaquiline (LM)</td>
        <td>Hide "Initial DST Result for Bedaquiline (LM)" field unless "Bedaquiline" is selected</td>
        <td>2020-01-15</td>
        <td>nSVVILMKErD</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Bedaquiline (SM)</td>
        <td>Hide "Initial DST Result for Bedaquiline (SM)" field unless "Bedaquiline" is selected</td>
        <td>2020-01-15</td>
        <td>N9lvD6MozuX</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Capreomycin (LM)</td>
        <td>Hide "Initial DST Result for Capreomycin (LM)" field unless "Capreomycin" is selected</td>
        <td>2020-01-15</td>
        <td>EGuydNHuAHB</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Capreomycin (SM)</td>
        <td>Hide "Initial DST Result for Capreomycin (SM)" field unless "Capreomycin" is selected</td>
        <td>2020-01-15</td>
        <td>W2u6ZVGsPQ2</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Clofazimine (LM)</td>
        <td>Hide "Initial DST Result for Clofazimine (LM)" field unless "Clofazimine" is selected</td>
        <td>2020-01-15</td>
        <td>IKRslnjEfym</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Clofazimine (SM)</td>
        <td>Hide "Initial DST Result for Clofazimine (SM)" field unless "Clofazimine" is selected</td>
        <td>2020-01-16</td>
        <td>ODkzGDLpGuB</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Delamanid (LM)</td>
        <td>Hide "Initial DST Result for Delamanid (LM)" field unless "Delamanid" is selected</td>
        <td>2020-01-15</td>
        <td>mu1wjx5TSlx</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Delamanid (SM)</td>
        <td>Hide "Initial DST Result for Delamanid (SM)" field unless "Delamanid" is selected</td>
        <td>2020-01-15</td>
        <td>U6gqetdESGb</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Ethambutol (LM)</td>
        <td>Hide "Initial DST Result for Ethambutol (LM)" field unless "Ethambutol" is selected</td>
        <td>2020-01-15</td>
        <td>Ma43ZbOLKNa</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Ethambutol (SM)</td>
        <td>Hide "Initial DST Result for Ethambutol (SM)" field unless "Ethambutol" is selected</td>
        <td>2020-01-15</td>
        <td>uanMudnFfWx</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Ethionamide (LM)</td>
        <td>Hide "Initial DST Result for Ethionamide (LM)" field unless "Ethionamide" is selected</td>
        <td>2020-01-15</td>
        <td>sFDpvveWVIu</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Ethionamide (SM)</td>
        <td>Hide "Initial DST Result for Ethionamide (SM)" field unless "Ethionamide" is selected</td>
        <td>2020-01-15</td>
        <td>tGnbVg0MTnX</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Gatifloxacin (LM)</td>
        <td>Hide "Initial DST Result for Gatifloxacin (LM)" field unless "Gatifloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>xNkewtMUQgB</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Gatifloxacin (SM)</td>
        <td>Hide "Initial DST Result for Gatifloxacin (SM)" field unless "Gatifloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>RwYFFA8MWAw</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Isoniazid (LM)</td>
        <td>Hide "Initial DST Result for Isoniazid (LM)" field unless "Isoniazid" is selected</td>
        <td>2020-01-15</td>
        <td>F2HL3IGjhrO</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Isoniazid (SM)</td>
        <td>Hide "Initial DST Result for Isoniazid (SM)" field unless "Isoniazid" is selected</td>
        <td>2020-01-15</td>
        <td>EDKB1ovP2cg</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Isoniazid HC (LM)</td>
        <td>Hide "Initial DST Result for Isoniazid HC (LM)" field unless "Isoniazid HC" is selected</td>
        <td>2020-02-04</td>
        <td>Xk73ev8l3OH</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Isoniazid HC (SM)</td>
        <td>Hide "Initial DST Result for Isoniazid HC (SM)" field unless "Isoniazid HC" is selected</td>
        <td>2020-02-04</td>
        <td>RDRSeajQBB9</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Kanamycin (LM)</td>
        <td>Hide "Initial DST Result for Kanamycin (LM)" field unless "Kanamycin" is selected</td>
        <td>2020-01-15</td>
        <td>KyDDzX7t37X</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Kanamycin (SM)</td>
        <td>Hide "Initial DST Result for Kanamycin (SM)" field unless "Kanamycin" is selected</td>
        <td>2020-01-15</td>
        <td>NOycR3cSEbn</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Levofloxacin (LM)</td>
        <td>Hide "Initial DST Result for Levofloxacin (LM)" field unless "Levofloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>O9lA8Sp4jqi</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Levofloxacin (SM)</td>
        <td>Hide "Initial DST Result for Levofloxacin (SM)" field unless "Levofloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>ZxozlEB0Vv9</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Linezolid (LM)</td>
        <td>Hide "Initial DST Result for Linezolid (LM)" field unless "Linezolid" is selected</td>
        <td>2020-01-15</td>
        <td>cScGE7BgAAp</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Linezolid (SM)</td>
        <td>Hide "Initial DST Result for Linezolid (SM)" field unless "Linezolid" is selected</td>
        <td>2020-01-15</td>
        <td>QqK6z2aN0L2</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Moxifloxacin (LM)</td>
        <td>Hide "Initial DST Result for Moxifloxacin (LM)" field unless "Moxifloxacin" is selected</td>
        <td>2020-01-22</td>
        <td>S3TsDcqFsRn</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Moxifloxacin (SM)</td>
        <td>Hide "Initial DST Result for Moxifloxacin (SM)" field unless "Moxifloxacin" is selected</td>
        <td>2020-02-03</td>
        <td>iEErAG38FxY</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Moxifloxacin CB (LM)</td>
        <td>Hide "Initial DST Result for Moxifloxacin CB (LM)" field unless "Moxifloxacin CB" is selected</td>
        <td>2020-02-04</td>
        <td>tvk7SjFegXA</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Moxifloxacin CB (SM)</td>
        <td>Hide "Initial DST Result for Moxifloxacin CB (SM)" field unless "Moxifloxacin CB" is selected</td>
        <td>2020-02-04</td>
        <td>bVJtmwDxCHH</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Ofloxacin (LM)</td>
        <td>Hide "Initial DST Result for Ofloxacin (LM)" field unless "Ofloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>M5Sr2vuDW3q</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Ofloxacin (SM)</td>
        <td>Hide "Initial DST Result for Ofloxacin (SM)" field unless "Ofloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>UdEcdrUTjqG</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Pyrazinamide (LM)</td>
        <td>Hide "Initial DST Result for Pyrazinamide(LM)" field unless "Pyrazinamide" is selected</td>
        <td>2020-01-15</td>
        <td>jJ0NX8RaLhJ</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Pyrazinamide (SM)</td>
        <td>Hide "Initial DST Result for Pyrazinamide(SM)" field unless "Pyrazinamide" is selected</td>
        <td>2020-01-16</td>
        <td>LBFedHYNlZy</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Rifampicin (LM)</td>
        <td>Hide "Initial DST Result for Rifampicin (LM)" field unless "Rifampicin" is selected</td>
        <td>2020-01-15</td>
        <td>PYjhzPpaj7q</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Rifampicin (SM)</td>
        <td>Hide "Initial DST Result for Rifampicin (SM)" field unless "Rifampicin" is selected</td>
        <td>2020-01-15</td>
        <td>NsNTyaUJt02</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Streptomycin (LM)</td>
        <td>Hide "Initial DST Result for Streptomycin (LM)" field unless "Streptomycin" is selected</td>
        <td>2020-01-15</td>
        <td>Lza98pKMMQZ</td>
      </tr>
      <tr>
        <td>LAB: Hide Initial DST Result for Streptomycin (SM)</td>
        <td>Hide "Initial DST Result for Streptomycin (SM)" field unless "Streptomycin" is selected</td>
        <td>2020-01-15</td>
        <td>cmWxJp10ADf</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Amikacin (LM)</td>
        <td>Hide "Subsequent DST Result for Amikacin (LM)" field unless "Amikacin" is selected</td>
        <td>2020-01-15</td>
        <td>cYQQ4Evoxj4</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Amikacin (SM)</td>
        <td>Hide "Subsequent DST Result for Amikacin (SM)" field unless "Amikacin" is selected</td>
        <td>2020-01-15</td>
        <td>aB4Ok3Bwile</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Bedaquiline (LM)</td>
        <td>Hide "Subsequent DST Result for Bedaquiline (LM)" field unless "Bedaquiline" is selected</td>
        <td>2020-01-15</td>
        <td>HUAxIoqsY9Q</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Bedaquiline (SM)</td>
        <td>Hide "Subsequent DST Result for Bedaquiline (SM)" field unless "Bedaquiline" is selected</td>
        <td>2020-01-15</td>
        <td>o3PgOUEIKU2</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Capreomycin (LM)</td>
        <td>Hide "Subsequent DST Result for Capreomycin (LM)" field unless "Capreomycin" is selected</td>
        <td>2020-01-15</td>
        <td>hC7yDlkySnn</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Capreomycin (SM)</td>
        <td>Hide "Subsequent DST Result for Capreomycin (SM)" field unless "Capreomycin" is selected</td>
        <td>2020-01-15</td>
        <td>sJv5htU7sdg</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Clofazimine (LM)</td>
        <td>Hide "Subsequent DST Result for Clofazimine (LM)" field unless "Clofazimine" is selected</td>
        <td>2020-01-15</td>
        <td>TIyH4C2LK6E</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Clofazimine (SM)</td>
        <td>Hide "Subsequent DST Result for Clofazimine (SM)" field unless "Clofazimine" is selected</td>
        <td>2020-01-16</td>
        <td>IS8bb8GUYKe</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Delamanid (LM)</td>
        <td>Hide "Subsequent DST Result for Delamanid (LM)" field unless "Delamanid" is selected</td>
        <td>2020-01-15</td>
        <td>PQ6wf5Sa6dD</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Delamanid (SM)</td>
        <td>Hide "Subsequent DST Result for Delamanid (SM)" field unless "Delamanid" is selected</td>
        <td>2020-01-15</td>
        <td>Aqz309QAleu</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for ETHAMBUTOL (LM)</td>
        <td>Hide "Subsequent DST Result for ETHAMBUTOL (LM)" field unless "ETHAMBUTOL" is selected</td>
        <td>2020-01-17</td>
        <td>FhiFAuNvYKO</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for ETHAMBUTOL (SM)</td>
        <td>Hide "Subsequent DST Result for ETHAMBUTOL (SM)" field unless "ETHAMBUTOL" is selected</td>
        <td>2020-01-17</td>
        <td>ewP0ZetGzWM</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Ethionamide (LM)</td>
        <td>Hide "Subsequent DST Result for Ethionamide (LM)" field unless "Ethionamide" is selected</td>
        <td>2020-01-15</td>
        <td>hn5BL94Ks0i</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Ethionamide (SM)</td>
        <td>Hide "Subsequent DST Result for Ethionamide (SM)" field unless "Ethionamide" is selected</td>
        <td>2020-01-15</td>
        <td>lApJuVfTSwd</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Gatifloxacin (LM)</td>
        <td>Hide "Subsequent DST Result for Gatifloxacin (LM)" field unless "Gatifloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>m1w0TTAqpHt</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Gatifloxacin (SM)</td>
        <td>Hide "Subsequent DST Result for Gatifloxacin (SM)" field unless "Gatifloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>g7T2XLTuffs</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Isoniazid (LM)</td>
        <td>Hide "Subsequent DST Result for Isoniazid (LM)" field unless "Isoniazid" is selected</td>
        <td>2020-01-16</td>
        <td>s86I5xBWF8x</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for ISONIAZID (SM)</td>
        <td>Hide "Subsequent DST Result for ISONIAZID (SM)" field unless "ISONIAZID" is selected</td>
        <td>2020-01-17</td>
        <td>fxiZBSclQEJ</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Isoniazid HC (LM)</td>
        <td>Hide "Subsequent DST Result for Isoniazid HC (LM)" field unless "Isoniazid HC" is selected</td>
        <td>2020-02-04</td>
        <td>pnJ420CUXu0</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Isoniazid HC (SM)</td>
        <td>Hide "Subsequent DST Result for Isoniazid HC (SM)" field unless "Isoniazid HC" is selected</td>
        <td>2020-02-04</td>
        <td>lMJYc4a3IRF</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Kanamycin (LM)</td>
        <td>Hide "Subsequent DST Result for Kanamycin (LM)" field unless "Kanamycin" is selected</td>
        <td>2020-01-15</td>
        <td>RNx6dogXCxb</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Kanamycin (SM)</td>
        <td>Hide "Subsequent DST Result for Kanamycin (SM)" field unless "Kanamycin" is selected</td>
        <td>2020-01-15</td>
        <td>r8sYsnDBv42</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Levofloxacin (LM)</td>
        <td>Hide "Subsequent DST Result for Levofloxacin (LM)" field unless "Levofloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>bWD0T1bxTWa</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Levofloxacin (SM)</td>
        <td>Hide "Subsequent DST Result for Levofloxacin (SM)" field unless "Levofloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>iX75kPqGx5L</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Linezolid (LM)</td>
        <td>Hide "Subsequent DST Result for Linezolid (LM)" field unless "Linezolid" is selected</td>
        <td>2020-01-15</td>
        <td>vtZINrWWLdN</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Linezolid (SM)</td>
        <td>Hide "Subsequent DST Result for Linezolid (SM)" field unless "Linezolid" is selected</td>
        <td>2020-01-15</td>
        <td>WRmVZspYrgs</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Moxifloxacin (LM)</td>
        <td>Hide "Subsequent DST Result for Moxifloxacin (LM)" field unless "Moxifloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>EznA9tFqSZR</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Moxifloxacin (SM)</td>
        <td>Hide "Subsequent DST Result for Moxifloxacin (SM)" field unless "Moxifloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>gIzaLYMToYe</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Moxifloxacin CB (LM)</td>
        <td>Hide "Subsequent DST Result for Moxifloxacin CB (LM)" field unless "Moxifloxacin CB" is selected</td>
        <td>2020-02-04</td>
        <td>ewuZXFKXUOP</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Moxifloxacin CB (SM)</td>
        <td>Hide "Subsequent DST Result for Moxifloxacin CB (SM)" field unless "Moxifloxacin CB" is selected</td>
        <td>2020-02-04</td>
        <td>c9lg3iHqoNt</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Ofloxacin (LM)</td>
        <td>Hide "Subsequent DST Result for Ofloxacin (LM)" field unless "Ofloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>mugdn10OAZI</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Ofloxacin (SM)</td>
        <td>Hide "Subsequent DST Result for Ofloxacin (SM)" field unless "Ofloxacin" is selected</td>
        <td>2020-01-15</td>
        <td>gSbIwtdIyim</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Pyrazinamide (LM)</td>
        <td>Hide "Subsequent DST Result for Pyrazinamide (LM)" field unless "Pyrazinamide" is selected</td>
        <td>2020-01-16</td>
        <td>NG3TuTKr7C6</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Pyrazinamide (SM)</td>
        <td>Hide "Subsequent DST Result for Pyrazinamide (SM)" field unless "Pyrazinamide" is selected</td>
        <td>2020-01-16</td>
        <td>w57JlrR8HXv</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Rifampicin (LM)</td>
        <td>Hide "Subsequent DST Result for Rifampicin (LM)" field unless "Rifampicin" is selected</td>
        <td>2020-01-16</td>
        <td>lmxGUWJIVuA</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for Rifampicin (SM)</td>
        <td>Hide "Subsequent DST Result for Rifampicin (SM)" field unless "Rifampicin" is selected</td>
        <td>2020-01-16</td>
        <td>Us3HUjUBmS1</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for STREPTOMYCIN (LM)</td>
        <td>Hide "Subsequent DST Result for STREPTOMYCIN (LM)" field unless "STREPTOMYCIN" is selected</td>
        <td>2020-01-17</td>
        <td>FTSi5Q7f8Yw</td>
      </tr>
      <tr>
        <td>LAB: Hide Subsequent DST Result for STREPTOMYCIN (SM)</td>
        <td>Hide "Subsequent DST Result for STREPTOMYCIN (SM)" field unless "STREPTOMYCIN" is selected</td>
        <td>2020-01-17</td>
        <td>tSJztHr8HKu</td>
      </tr>
      <tr>
        <td>SRL: Hide "Reasons for not sending results to SRL" field</td>
        <td>Hide "TB DRS SRL - Reasons for not sending results to SRL" field if shipped or not applicable</td>
        <td>2020-01-24</td>
        <td>RIBNrOhnWFm</td>
      </tr>
      <tr>
        <td>SRL: Hide "SRL" fields</td>
        <td>Hide "TB DRS SRL fields unless Samples shipped to SRL </td>
        <td>2020-01-24</td>
        <td>M0i7NMp24EO</td>
      </tr>
    </table>
    <h4>Program Tracked Entity Attributes</h4>
    <table>
      <tr>
        <th>Tracked Entity Attribute Name</th>
        <th>Last updated</th>
        <th>Program Tracked Entity Attribute UID</th>
        <th>Tracked Entity Attribute UID</th>
      </tr>
      <tr>
        <td>Address</td>
        <td>2020-02-06</td>
        <td>ylfC4Fjo2NN</td>
        <td>VCtm2pySeEV</td>
      </tr>
      <tr>
        <td>Administrative Area of Residence</td>
        <td>2020-02-06</td>
        <td>qObTmB2O3iw</td>
        <td>ljHL8NnSEAD</td>
      </tr>
      <tr>
        <td>Cluster ID</td>
        <td>2020-02-06</td>
        <td>iHuT7Jf69il</td>
        <td>aOrGt5JE0gV</td>
      </tr>
      <tr>
        <td>Country of origin</td>
        <td>2020-02-06</td>
        <td>ZSreVJc1YHl</td>
        <td>PBdqXh8Nvuj</td>
      </tr>
      <tr>
        <td>Date of birth (age)</td>
        <td>2020-02-06</td>
        <td>oBXflxK0OPH</td>
        <td>mAWcalQYYyk</td>
      </tr>
      <tr>
        <td>Date of birth is estimated</td>
        <td>2020-02-06</td>
        <td>jjATJmtN4T4</td>
        <td>Z1rLc1rVHK8</td>
      </tr>
      <tr>
        <td>First Name</td>
        <td>2020-02-06</td>
        <td>YVhcTRS789c</td>
        <td>TfdH5KvFmMy</td>
      </tr>
      <tr>
        <td>Health Facility Code</td>
        <td>2020-02-06</td>
        <td>UJlkDqDxNlG</td>
        <td>sWn0CERcUYj</td>
      </tr>
      <tr>
        <td>Last Name</td>
        <td>2020-02-06</td>
        <td>yKAmutvvxlx</td>
        <td>aW66s2QSosT</td>
      </tr>
      <tr>
        <td>Location of Residence</td>
        <td>2020-02-06</td>
        <td>tymxPk5geMN</td>
        <td>f038nOc9uRF</td>
      </tr>
      <tr>
        <td>Patient DRS ID</td>
        <td>2020-02-06</td>
        <td>jf47G3ie95T</td>
        <td>BdvE9shT6GX</td>
      </tr>
      <tr>
        <td>Patient DRS Serial Number</td>
        <td>2020-02-06</td>
        <td>rZKv16lFq9y</td>
        <td>Qj7EXFIXcyc</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>2020-02-06</td>
        <td>mdcwEKRScEb</td>
        <td>CklPZdOd6H1</td>
      </tr>
      <tr>
        <td>TB Registration Number</td>
        <td>2020-02-06</td>
        <td>FNMUKiZ2TXa</td>
        <td>ntelZthDPpR</td>
      </tr>
    </table>
    <h2>Data Elements</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Code</th>
        <th>Description</th>
        <th>Categorycombo</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB DRS CIF: Bacteriological Confirmation - Sputum Smear Microscopy</td>
        <td>Confirmation: Sputum Smear Microscopy</td>
        <td></td>
        <td>Bacteriological confirmation of TB by Sputum smear microscopy</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>KMP0CCj6hEC</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Bacteriological Confirmation - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF</td>
        <td></td>
        <td>Bacteriological confirmation of TB by Xpert MTB/RIF</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>peo25u2dcLt</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Date of Xpert MTB/RIF Initial Screening Test</td>
        <td>Xpert MTB/RIF Initial Screening Date</td>
        <td></td>
        <td>Date of Xpert MTB/RIF Initial Screening Test</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>jIyPHXFmBZ3</td>
      </tr>
      <tr>
        <td>TB DRS CIF: HIV Test Date</td>
        <td>HIV Test Date</td>
        <td></td>
        <td>HIV Test Date</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>C03Ya1vvaam</td>
      </tr>
      <tr>
        <td>TB DRS CIF: HIV Test Result</td>
        <td>HIV Test Result</td>
        <td></td>
        <td>HIV Test Result</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>tlgvzxYlF2S</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Specimen 1 Microscopy Test Result</td>
        <td>Specimen 1 Microscopy Result</td>
        <td></td>
        <td>Specimen 1 Microscopy Test Result. If initial screening is based on microscopy examination of > 2 specimens then add only the 2 specimens with the highest bacterail load.</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>nYThQIcbo27</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Specimen 2 Microscopy Test Result</td>
        <td>Specimen 2 Microscopy Result</td>
        <td></td>
        <td>Specimen 2 Microscopy Test Result. If initial screening is based on microscopy examination of > 2 specimens then add only the 2 specimens with the highest bacterail load.</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>cx2xcrp1e18</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History</td>
        <td>TB DRS Treatment History</td>
        <td></td>
        <td>Has the patient been previously treated for TB?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>PjNDfgjWbFC</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - CIF Officer Name</td>
        <td>CIF Officer Name </td>
        <td></td>
        <td>Print name of officer responsible for completing the clinical information form</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>m7q2YJoRG5o</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Control Question</td>
        <td>Control Question</td>
        <td></td>
        <td>Did the patient remember previous treatment for TB after these questions?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Q3sqPGI5Z55</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Injections for TB</td>
        <td>Injections for TB</td>
        <td></td>
        <td>Has the patient ever had injections for TB for more than one month?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>IkDkBipcHuw</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - length of sickness - weeks</td>
        <td>Length of sickness</td>
        <td></td>
        <td>For how long has the patient been sick? (number of weeks; for periods less than a week, use decimal)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>eKEKDJsda40</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Names of Drugs</td>
        <td>Names of Drugs</td>
        <td></td>
        <td>Specify drug/drugs taken:</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>EsP0jPqdCsi</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Other Symptoms of Lung Disease</td>
        <td>Other Symptoms of Lung Disease</td>
        <td></td>
        <td>Did the patient have other symptoms of lung disease prior to this episode (haemoptysis, chest pain, cough)?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>oSUHvzfAOD7</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Outcome</td>
        <td>Outcome</td>
        <td></td>
        <td>What was the outcome of previous treatment?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>fkzW5PRBVuI</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Outcome Other</td>
        <td>Outcome Other</td>
        <td></td>
        <td>What was the other outcome of previous treatment?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>HCBfE6ryH0o</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Previous TB Registration Number</td>
        <td>Previous TB Registration Number</td>
        <td></td>
        <td>Previous TB Registration Number</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>bOFQuGHR4aW</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Prior Symptoms</td>
        <td>TB Prior symptoms</td>
        <td></td>
        <td>Did the patient have the same symptoms prior to this episode?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>yn0LMROuQwZ</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Prior TB Registration</td>
        <td>Prior TB Registration</td>
        <td></td>
        <td>After extensive checking through the medical files and other documents available in the health centre, have you discovered that the patient has been registered for TB treatment before?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>rzts7X4mOUE</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Sputum Examinations</td>
        <td>Sputum Examinations</td>
        <td></td>
        <td>Did the patient have sputum examinations prior to this episode?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ZyxsK4KWkLQ</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Treatment Over 1 Month</td>
        <td>Treatment over 1 month</td>
        <td></td>
        <td>Has patient been previously treated for TB for more than a month?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>WlAQcyJ0xW6</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Tuberculosis Drugs</td>
        <td>Tuberculosis Drugs</td>
        <td></td>
        <td>Has the patient ever taken tuberculosis drugs for more than one month?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>hkMHdJJMRkD</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Xpert MTB/RIF Initial Screening Result</td>
        <td>Xpert MTB/RIF Initial Screening Result</td>
        <td></td>
        <td>Xpert MTB/RIF Initial Screening Result</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>c6w0Nuei0yG</td>
      </tr>
      <tr>
        <td>TB DRS CS: Additional Comments and Remarks</td>
        <td>Additional Comments and Remarks</td>
        <td></td>
        <td>Additional comments and remarks</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Y66pOFOYt6T</td>
      </tr>
      <tr>
        <td>TB DRS CS: Date of Samples Arrival at NRL</td>
        <td>Date of Samples Arrival at NRL</td>
        <td></td>
        <td>Date of samples arrival at NRL</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>nLJ3f34rpYm</td>
      </tr>
      <tr>
        <td>TB DRS CS: Date Samples Shipped to NRL</td>
        <td>Date Samples Shipped to NRL</td>
        <td></td>
        <td>Date samples shipped to Central Laboratory (NRL)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>vD3nvlSC6A6</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 1 Additive</td>
        <td>Sample 1 Additive</td>
        <td></td>
        <td>Sample 1 Additive</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>mq7gNiLqT24</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 1 Collection Date</td>
        <td>Sample 1 Collection Date</td>
        <td></td>
        <td>Sample 1 Collection Date</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Mwl0M4rvqBl</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 1 DRS ID</td>
        <td>Sample 1 DRS ID</td>
        <td></td>
        <td>Sample 1 DRS ID</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>vY0hDQBLuXA</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 2 Additive</td>
        <td>Sample 2 Additive</td>
        <td></td>
        <td>Sample 2 Additive</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>FSPdiABIisY</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 2 Collection Date</td>
        <td>Sample 2 Collection Date</td>
        <td></td>
        <td>Sample 2 Collection Date</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>zVDnm2Bur06</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 2 DRS ID</td>
        <td>Sample 2 DRS ID</td>
        <td></td>
        <td>Sample 2 DRS ID</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>typK2Vw7WMj</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 3 Additive</td>
        <td>Sample 3 Additive</td>
        <td></td>
        <td>Sample 3 Additive</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>nj5kuSbEnnm</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 3 Collection Date</td>
        <td>Sample 3 Collection Date</td>
        <td></td>
        <td>Sample 3 Collection Date</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>JpAoAL6Dbmc</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 3 DRS ID</td>
        <td>Sample 3 DRS ID</td>
        <td></td>
        <td>Sample 3 DRS ID</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>w2e9rGFLNIa</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 4 Additive</td>
        <td>Sample 4 Treatment</td>
        <td></td>
        <td>Sample 4 Additive</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ucaLoGejB2M</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 4 Collection Date</td>
        <td>Sample 4 Collection Date</td>
        <td></td>
        <td>Sample 4 Collection Date</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>sdiW3OMXBHc</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 4 DRS ID</td>
        <td>Sample 4 DRS ID</td>
        <td></td>
        <td>Sample 4 DRS ID</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>YNDJVRtDxbi</td>
      </tr>
      <tr>
        <td>TB DRS CS: Specify Other (Sample 1)</td>
        <td>Specify Other (Sample 1)</td>
        <td></td>
        <td>Specify other</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>kNR9wGWUqnX</td>
      </tr>
      <tr>
        <td>TB DRS CS: Specify Other (Sample 2)</td>
        <td>Specify Other (Sample 2)</td>
        <td></td>
        <td>Specify other</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>z6hnMc1kBNO</td>
      </tr>
      <tr>
        <td>TB DRS CS: Specify Other (Sample 3)</td>
        <td>Specify Other (Sample 3)</td>
        <td></td>
        <td>Specify other</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>IQ8pRiFktkT</td>
      </tr>
      <tr>
        <td>TB DRS CS: Specify Other (Sample 4)</td>
        <td>Specify Other (Sample 4)</td>
        <td></td>
        <td>Specify other</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>JkPoMJSKHxt</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Additional Comments and Remarks</td>
        <td>LAB Additional Comments and Remarks</td>
        <td></td>
        <td>Additional comments and remarks</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>KkH3pmsTJ3M</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Culture in Liquid Media (e.g. MGIT)</td>
        <td>Culture in Liquid Media (e.g. MGIT)</td>
        <td></td>
        <td>Culture in Liquid Media (e.g. MGIT)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>uI7p5xLE1C8</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Culture in Solid Media (e.g. LJ)</td>
        <td>Culture in Solid Media (e.g. LJ)</td>
        <td></td>
        <td>Culture in solid media (e.g. LJ)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>QQEolquguCi</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
        <td>Date of Culture Inoculation (Liquid Media)</td>
        <td></td>
        <td>Date of Culture Inoculation (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>m7NKGHkiJps</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
        <td>Date of Culture Inoculation (Solid Media)</td>
        <td></td>
        <td>Date of Culture Inoculation (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>FIY3uk4J7fK</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
        <td>Date of Final Culture Result (Liquid Media)</td>
        <td></td>
        <td>Date of Final Culture Result (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>OBibApuY05j</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
        <td>Date of Final Culture Result (Solid Media)</td>
        <td></td>
        <td>Date of Final Culture Result (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>rVKthrApqAq</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Final Initial DST Results (Liquid Media)</td>
        <td>Date of Final Initial DST Results (LM)</td>
        <td></td>
        <td>Date of Final Initial Phenotypic DST Results (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Wg7Df5kgpaF</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Final Initial DST Results (Solid Media)</td>
        <td>Date of final Initial DST Results (SM)</td>
        <td></td>
        <td>Date of final Initial Phenotypic DST Results (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>bXaGYMAnfNH</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Liquid Media)</td>
        <td>Date of final Subsequent DST Results (LM)</td>
        <td></td>
        <td>Date of Final Subsequent DST Results (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>wi4NRarMSuv</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Solid Media)</td>
        <td>Date of final Subsequent DST Results (SM)</td>
        <td></td>
        <td>Date of Final Subsequent DST Results (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>uEV8flIOeYI</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
        <td>Date of Initial DST Inoculation (Liquid Media)</td>
        <td></td>
        <td>Date of InitialDST Inoculation (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ngshCLso7Qs</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
        <td>Date of Initial DST Inoculation (Solid Media)</td>
        <td></td>
        <td>Date of Initial Phenotypic DST Inoculation (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ck7gWJKYi8n</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of LPA (FQ/2LI)</td>
        <td>Date of LPA (FQ/2LI)</td>
        <td></td>
        <td>Date of LPA (FQ/2LI)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>vezbpFOckNI</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of LPA (RIF/INH)</td>
        <td>Date of LPA (RIF/INH)</td>
        <td></td>
        <td>Date of LPA (RIF/INH)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>D4z4o6JR9M0</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Sputum Smear Microscopy Examination</td>
        <td>Date of Sputum Smear Microscopy Examination</td>
        <td></td>
        <td>Date of Sputum Smear Microscopy Examination</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>xyczZvsuaWr</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
        <td>Date of Subsequent DST Inoculation (LM)</td>
        <td></td>
        <td>Date of Subsequent DST Inoculation (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>qJH0R9qtDoA</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
        <td>Date of Subsequent DST Inoculation (Solid Media)</td>
        <td></td>
        <td>Date of Subsequent DST Inoculation (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>BMeVWBNe0Id</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
        <td>Date of Targeted Gene Sequencing Results</td>
        <td></td>
        <td>Date of Targeted Gene Sequencing Results</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>slD6pdIC4a6</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
        <td>Xpert MTB/RIF Test</td>
        <td></td>
        <td>Date of Xpert MTB/RIF Test</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>cxi3Lj20Zrg</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
        <td>Xpert MTB/RIF Ultra Test</td>
        <td></td>
        <td>Date of Xpert MTB/RIF Ultra Test</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>NRUmJNJfvDc</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
        <td>Final Culture Result (Liquid Media)</td>
        <td></td>
        <td>Final Culture Result (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>vTvtuUqdhSg</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
        <td>Final Culture Result (Solid Media)</td>
        <td></td>
        <td>Final Culture Result (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Pdo9LB4lZ6H</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (LM)</td>
        <td>Final Initial DST Result for Amikacin (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Amikacin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Np6OSCnL4Le</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (SM)</td>
        <td>Final Initial DST Result for Amikacin (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Amikacin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>BGGGbbVmdVG</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (LM)</td>
        <td>Final Initial DST Result for Bedaquiline (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Bedaquiline (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>PwdAvz5x0mE</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (SM)</td>
        <td>Final Initial DST Result for Bedaquiline (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Bedaquiline (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>DycmWmzsg2b</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (LM)</td>
        <td>Final Initial DST Result for Capreomycin (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Capreomycin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>BbOx5mowYbn</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (SM)</td>
        <td>Final Initial DST Result for Capreomycin (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Capreomycin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>eT89yHU4fvl</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (LM)</td>
        <td>Final Initial DST Result for Clofazimine (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Clofazimine (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Sbxq4E3XtXf</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (SM)</td>
        <td>Final Initial DST Result for Clofazimine (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Clofazimine (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>K6kBGbuu8bL</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (LM)</td>
        <td>Final Initial DST Result for Delamanid (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Delamanid (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>kOghnPkxYU4</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (SM)</td>
        <td>Final Initial DST Result for Delamanid (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Delamanid (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>zRrmZ5XZEGD</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (LM)</td>
        <td>Final Initial DST Result for Ethambutol (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Ethambutol (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>DagUiDXbwAU</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (SM)</td>
        <td>Final Initial DST Result for Ethambutol (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Ethambutol (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>r3h2Fe5jjrq</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (LM)</td>
        <td>Final Initial DST Result for Ethionamide (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Ethionamide (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>EDevJmEfzgB</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (SM)</td>
        <td>Final Initial DST Result for Ethionamide (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Ethionamide (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>EPDpwUyzlCq</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (LM)</td>
        <td>Final Initial DST Result for Gatifloxacin (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Gatifloxacin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>LzWdJDbwDP1</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (SM)</td>
        <td>Final Initial DST Result for Gatifloxacin (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Gatifloxacin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>KF8HNTF74vs</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (LM)</td>
        <td>Final Initial DST Result for Isoniazid (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Isoniazid (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>kB2aBr6zMrV</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (SM)</td>
        <td>Final Initial DST Result for Isoniazid (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Isoniazid (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>MZP34S0WjMt</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (LM)</td>
        <td>Final Initial DST Result LM for H HC</td>
        <td></td>
        <td>Final Initial DST Result for Isoniazid HC (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>nKC0GmAob7s</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (SM)</td>
        <td>Final Initial DST Result for Isoniazid HC (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Isoniazid HC (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>eMrKOJtNCaK</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (LM)</td>
        <td>Final Initial DST Result for Kanamycin (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Kanamycin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>jDtrcgBrPwj</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (SM)</td>
        <td>Final Initial DST Result for Kanamycin (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Kanamycin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>aNgpmTJ5Pec</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (LM)</td>
        <td>Final Initial DST Result for Levofloxacin (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Levofloxacin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>nAgfYw69HJx</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (SM)</td>
        <td>Final Initial DST Result for Levofloxacin (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Levofloxacin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>SXz7iJ4uYo0</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (LM)</td>
        <td>Final Initial DST Result for Linezolid (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Linezolid (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>OHwdmvMmePC</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (SM)</td>
        <td>Final Initial DST Result for Linezolid (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Linezolid (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>HnDiJGYvZG4</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (LM)</td>
        <td>Final Initial DST Result - Mfx CB (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Moxifloxacin CB (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>PnIKaknmzo9</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (SM)</td>
        <td>Final Initial DST Result - Mfx CB (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Moxifloxacin CB (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>TPJMSziCr1I</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (LM)</td>
        <td>Final Initial DST Result LM - Mfx CC</td>
        <td></td>
        <td>Final Initial DST Result for Moxifloxacin CC (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>yHzQOpEFLuS</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (SM)</td>
        <td>Final Initial DST Result SM - Mfx CC</td>
        <td></td>
        <td>Final Initial DST Result for Moxifloxacin CC (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>JBMYyAslnCh</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (LM)</td>
        <td>Final Initial DST Result for Ofloxacin (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Ofloxacin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ee5Hu65urBX</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (SM)</td>
        <td>Final Initial DST Result for Ofloxacin (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Ofloxacin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Au5ztrDog7o</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (LM)</td>
        <td>Final Initial DST Result for Pyrazinamide (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Pyrazinamide (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>wWsCcOG94IL</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (SM)</td>
        <td>Final Initial DST Result for Pyrazinamide (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Pyrazinamide (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>DZLsixPeLg8</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (LM)</td>
        <td>Final Initial DST Result for Rifampicin (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Rifampicin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>S2iNYj1VhvS</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (SM)</td>
        <td>Final Initial DST Result for Rifampicin (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Rifampicin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>JatDNwZ3iwP</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (LM)</td>
        <td>Final Initial DST Result for Streptomycin (LM)</td>
        <td></td>
        <td>Final Initial DST Result for Streptomycin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>KhmXppJHNuW</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (SM)</td>
        <td>Final Initial DST Result for Streptomycin (SM)</td>
        <td></td>
        <td>Final Initial DST Result for Streptomycin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>JUWECuvUhLr</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Amikacin/Capreomycin</td>
        <td>Final LPA (FQ/2LI) Result for Am, Cm</td>
        <td></td>
        <td>Final LPA (FQ/2LI) Result for Amikacin/Capreomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>C2owWE9gaoe</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Ethambutol</td>
        <td>Final LPA (FQ/2LI) Result for Ethambutol</td>
        <td></td>
        <td>Final LPA (Fluoroquinolones / Second-line Injectables) Result for Ethambutol</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>WLaOsGs9ujA</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Fluoroquinolones</td>
        <td>Final LPA (FQ/2LI) Result for Fluoroquinolones</td>
        <td></td>
        <td>Final LPA (FQ/2LI) Result for Fluoroquinolones</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>E61DoZgoPH2</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Kanamycin</td>
        <td>Final LPA (FQ/2LI) Result for Km</td>
        <td></td>
        <td>Final LPA (Fluoroquinolones / Second-line Injectables) Result for Kanamycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>qt2LpZN8Hb3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Isoniazid</td>
        <td>Final (RIF/INH) LPA Result for Isoniazid</td>
        <td></td>
        <td>Final LPA (RIF/INH) Result for Isoniazid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>UIzR3p4nlMI</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Rifampicin</td>
        <td>Final (RIF/INH) LPA Result for Rifampicin</td>
        <td></td>
        <td>Final LPA (RIF/INH) Result for Rifampicin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Gey1agRf0Kh</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
        <td>Final Sputum Smear Microscopy Result</td>
        <td></td>
        <td>Final Sputum Smear Microscopy Result</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>EJaXeYb8MT3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (LM)</td>
        <td>Final Subsequent DST Result for Amikacin (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Amikacin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>AWufpBYv2az</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (SM)</td>
        <td>Final Subsequent DST Result for Amikacin (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Amikacin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>EPGNUZclfCC</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (LM)</td>
        <td>Final Subsequent DST Result for Bedaquiline (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Bedaquiline (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>zuMM3UHToty</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (SM)</td>
        <td>Final Subsequent DST Result for Bedaquiline (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Bedaquiline (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Ae4KCKLh2rz</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (LM)</td>
        <td>Final Subsequent DST Result for Capreomycin (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Capreomycin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>jevxww8VfQH</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (SM)</td>
        <td>Final Subsequent DST Result for Capreomycin (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Capreomycin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>SP4Sqo3p6k2</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (LM)</td>
        <td>Final Subsequent DST Result for Clofazimine (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Clofazimine (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>SghYFLGezHI</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (SM)</td>
        <td>Final Subsequent DST Result for Clofazimine (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Clofazimine (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>nOI6zf5JyM8</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (LM)</td>
        <td>Final Subsequent DST Result for Delamanid (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Delamanid (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>r5ArUPWZkx3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (SM)</td>
        <td>Final Subsequent DST Result for Delamanid (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Delamanid (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>YdAuAcBbwsN</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (LM)</td>
        <td>Final Subsequent DST Result for Ethambutol (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Ethambutol (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>qjlzhgMPOiI</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (SM)</td>
        <td>Final Subsequent DST Result for Ethambutol (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Ethambutol (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>MKOTy2VQIRV</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (LM)</td>
        <td>Final Subsequent DST Result for Ethionamide (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Ethionamide (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>QSHd2sryiiv</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (SM)</td>
        <td>Final Subsequent DST Result for Ethionamide (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Ethionamide (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>rbcQgItfXBj</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (LM)</td>
        <td>Final Subsequent DSTResult for Gatifloxacin (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Gatifloxacin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>W2dTiQYexVm</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (SM)</td>
        <td>Final Subsequent DSTResult for Gatifloxacin (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Gatifloxacin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>u9k4bQFqZsc</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (LM)</td>
        <td>Final Subsequent DST Result for Isoniazid (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Isoniazid (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>e11fgv41Pml</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (SM)</td>
        <td>Final Subsequent DST Result for Isoniazid (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Isoniazid (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>klDWlbk20m7</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (LM)</td>
        <td>Final Subsequent DST Result - Isoniazid HC (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Isoniazid HC (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Ljcuo6xZwvj</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (SM)</td>
        <td>Final Subsequent DST Result - H HC (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Isoniazid HC (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>vIgL7jxWv0G</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (LM)</td>
        <td>Final Subsequent DST Result for Kanamycin (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Kanamycin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>zn4uMR09RzI</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (SM)</td>
        <td>Final Subsequent DST Result for Kanamycin (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Kanamycin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>CL2d6UnsTLo</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (LM)</td>
        <td>Final Subsequent DSTResult for Levofloxacin (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Levofloxacin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>JzIOFsKQNMu</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (SM)</td>
        <td>Final Subsequent DSTResult for Levofloxacin (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Levofloxacin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>e3w6TJmm1ZK</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (LM)</td>
        <td>Final Subsequent DST Result for Linezolid (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Linezolid (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>bOCQqkE7RH3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (SM)</td>
        <td>Final Subsequent DST Result for Linezolid (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Linezolid (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>nnlvO2mC1tl</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (LM)</td>
        <td>Final Subsequent DST Result LM - Mfx CB</td>
        <td></td>
        <td>Final Subsequent DST Result for Moxifloxacin CB (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>oxGt9TZ6EN8</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (SM)</td>
        <td>Final Subsequent DSTResult SM - Mfx CB</td>
        <td></td>
        <td>Final Subsequent DST Result for Moxifloxacin CB (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>V6Z7DnBec0q</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (LM)</td>
        <td>Final Subsequent DST Result LM - for Mfx CC</td>
        <td></td>
        <td>Final Subsequent DST Result for Moxifloxacin CC (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>D7qcRlWU0wm</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (SM)</td>
        <td>Final Subsequent DST Result SM - Mfx CC</td>
        <td></td>
        <td>Final Subsequent DST Result for Moxifloxacin CC (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ssXSEdXFa5B</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (LM)</td>
        <td>Final Subsequent DST Result for Ofloxacin (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Ofloxacin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>t2fBZWmg9SC</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (SM)</td>
        <td>Final Subsequent DST Result for Ofloxacin (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Ofloxacin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>SHiFDCGmMrS</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (LM)</td>
        <td>Final Subsequent DST Result - Pyrazinamide (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Pyrazinamide (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>q6lgtrn4sqC</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (SM)</td>
        <td>Final Subsequent DST Result - Pyrazinamide (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Pyrazinamide (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>oalw8rxyCvS</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (LM)</td>
        <td>Final Subsequent DST Result for Rifampicin (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Rifampicin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>lkR0u026l3V</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (SM)</td>
        <td>Final Subsequent DST Result for Rifampicin (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Rifampicin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>GW5E2EZIWyD</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (LM)</td>
        <td>Final Subsequent DST Result - Streptomycin (LM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Streptomycin (Liquid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>DykjaiofQNc</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (SM)</td>
        <td>Final Subsequent DST Result - Streptomycin (SM)</td>
        <td></td>
        <td>Final Subsequent DST Result for Streptomycin (Solid Media)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>azPIv1j0mAR</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
        <td>Final Xpert MTB/RIF Test Result</td>
        <td></td>
        <td>Final Xpert MTB/RIF Test Result</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>mdhh8AXcNMe</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
        <td>Final Xpert MTB/RIF Ultra Test Result</td>
        <td></td>
        <td>Final Xpert MTB/RIF Ultra Test Result</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>w8t8k2IPqsB</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Amikacin</td>
        <td>Initial DST (LM) Amikacin</td>
        <td></td>
        <td>Initial DST (LM) Amikacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>IgrukduwHuX</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Bedaquiline</td>
        <td>Initial DST (LM) Bedaquiline</td>
        <td></td>
        <td>Initial DST (LM) Bedaquiline</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>M2FSBPjyUbN</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Capreomycin</td>
        <td>Initial DST (LM) Capreomycin</td>
        <td></td>
        <td>Initial DST (LM) Capreomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>vu0iezygkFX</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Clofazimine</td>
        <td>Initial DST (LM) Clofazimine</td>
        <td></td>
        <td>Initial DST (LM) Clofazimine</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ZOyTcelsiMq</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Delamanid</td>
        <td>Initial DST (LM) Delamanid</td>
        <td></td>
        <td>Initial DST (LM) Delamanid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>H5jAlcjjBYl</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Ethambutol</td>
        <td>Initial DST (LM) Ethambutol</td>
        <td></td>
        <td>Initial DST (LM) Ethambutol</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>HyFzElVhmTt</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Ethionamide</td>
        <td>Initial DST (LM) Ethionamide</td>
        <td></td>
        <td>Initial DST (LM) Ethionamide</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>LUPK7TvY7HD</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Gatifloxacin</td>
        <td>Initial DST (LM) Gatifloxacin</td>
        <td></td>
        <td>Initial DST (LM) Gatifloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>o7C6qsFPGyI</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid</td>
        <td>Initial DST (LM) Isoniazid</td>
        <td></td>
        <td>Initial DST (LM) Isoniazid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>A5escguD7ak</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid HC</td>
        <td>Initial DST (LM) Isoniazid HC</td>
        <td></td>
        <td>Initial DST (LM) Isoniazid HC</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>qtdLjHiJ8IP</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Kanamycin</td>
        <td>Initial DST (LM) Kanamycin</td>
        <td></td>
        <td>Initial DST (LM) Kanamycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>wyFVowLQE0u</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Levofloxacin</td>
        <td>Initial DST (LM) Levofloxacin</td>
        <td></td>
        <td>Initial DST (LM) Levofloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>SJ3melUoaux</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Linezolid</td>
        <td>Initial DST (LM) Linezolid</td>
        <td></td>
        <td>Initial DST (LM) Linezolid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Rt7wfNb7rCT</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CB</td>
        <td>Initial DST (LM) Moxifloxacin CB</td>
        <td></td>
        <td>Initial DST (LM) Moxifloxacin CB</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>c3RX2C1xF26</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CC</td>
        <td>Initial DST LM - Mfx CC</td>
        <td></td>
        <td>Initial DST (LM) Moxifloxacin CC</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>y9w7dJWlCsC</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Ofloxacin</td>
        <td>Initial DST (LM) Ofloxacin</td>
        <td></td>
        <td>Initial DST (LM) Ofloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>erdoJtoB0HO</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Pyrazinamide</td>
        <td>Initial DST (LM) Pyrazinamide</td>
        <td></td>
        <td>Initial DST (LM) Pyrazinamide</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>xVe8YaeZaGp</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Rifampicin</td>
        <td>Initial DST (LM) Rifampicin</td>
        <td></td>
        <td>Initial DST (LM) Rifampicin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>bkm00czMnOI</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (LM) Streptomycin</td>
        <td>Initial DST (LM) Streptomycin</td>
        <td></td>
        <td>Initial DST (LM) Streptomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ZLpGq1CD1Nq</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Amikacin</td>
        <td>Initial DST (SM) Amikacin</td>
        <td></td>
        <td>Initial DST (SM) Amikacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>inkVTZbcFm3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Bedaquiline</td>
        <td>Initial DST (SM) Bedaquiline</td>
        <td></td>
        <td>Initial DST (SM) Bedaquiline</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Fs8wCV83u3Q</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Capreomycin</td>
        <td>Initial DST (SM) Capreomycin</td>
        <td></td>
        <td>Initial DST (SM) Capreomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>OEmj97xTKLP</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Clofazimine</td>
        <td>Initial DST (SM) Clofazimine</td>
        <td></td>
        <td>Initial DST (SM) Clofazimine</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>SpBpLQvL5Qy</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Delamanid</td>
        <td>Initial DST (SM) Delamanid</td>
        <td></td>
        <td>Initial DST (SM) Delamanid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Cj9cZUsnYXr</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Ethambutol</td>
        <td>Initial DST (SM) Ethambutol</td>
        <td></td>
        <td>Initial DST (SM) Ethambutol</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>AlFJCuU3q5K</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Ethionamide</td>
        <td>Initial DST (SM) Ethionamide</td>
        <td></td>
        <td>Initial DST (SM) Ethionamide</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>tcwbtAG7RkV</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Gatifloxacin</td>
        <td>Initial DST (SM) Gatifloxacin</td>
        <td></td>
        <td>Initial DST (SM) Gatifloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>AWinnuvu60a</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid</td>
        <td>Initial DST (SM) Isoniazid</td>
        <td></td>
        <td>Initial DST (SM) Isoniazid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ALXvOyEZfq4</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid HC</td>
        <td>Initial DST (SM) Isoniazid HC</td>
        <td></td>
        <td>Initial DST (SM) Isoniazid HC</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>GRp8AyJyRQn</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Kanamycin</td>
        <td>Initial DST (SM) Kanamycin</td>
        <td></td>
        <td>Initial DST (SM) Kanamycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Zpg9eWtaqw3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Levofloxacin</td>
        <td>Initial DST (SM) Levofloxacin</td>
        <td></td>
        <td>Initial DST (SM) Levofloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>qq6VRXwUDlP</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Linezolid</td>
        <td>Initial DST (SM) Linezolid</td>
        <td></td>
        <td>Initial DST (SM) Linezolid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>S2oobb4DjLr</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CB</td>
        <td>Initial DST (SM) - Mfx CB</td>
        <td></td>
        <td>Initial DST (SM) Moxifloxacin CB</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>k3v85WYCKHg</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CC</td>
        <td>Initial DST SM - Mfx CC</td>
        <td></td>
        <td>Initial DST (SM) Moxifloxacin CC</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>WWrOIQZN3EG</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Ofloxacin</td>
        <td>Initial DST (SM) Ofloxacin</td>
        <td></td>
        <td>Initial DST (SM) Ofloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>LLI55jQaocT</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Pyrazinamide</td>
        <td>Initial DST (SM) Pyrazinamide</td>
        <td></td>
        <td>Initial DST (SM) Pyrazinamide</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>fkmnkZXkCpe</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Rifampicin</td>
        <td>Initial DST (SM) Rifampicin</td>
        <td></td>
        <td>Initial DST (SM) Rifampicin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>btiKYHdYnaO</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST (SM) Streptomycin</td>
        <td>Initial DST (SM) Streptomycin</td>
        <td></td>
        <td>Initial DST (SM) Streptomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>CPkVnuJhZuo</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST in Liquid Media (e.g. MGIT)</td>
        <td>Initial DST in Liquid Media (e.g. MGIT)</td>
        <td></td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>HkZ1hGWBqlZ</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Initial DST in Solid Media (e.g. LJ)</td>
        <td>Initial DST in Solid Media (e.g. LJ)</td>
        <td></td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>OZV3tzf7bux</td>
      </tr>
      <tr>
        <td>TB DRS LAB: LPA (FQ/2LI)</td>
        <td>LPA (FQ/2LI)</td>
        <td></td>
        <td>LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Sd91IsXISjp</td>
      </tr>
      <tr>
        <td>TB DRS LAB: LPA (FQ/2LI) - Was MTBc detected by LPA?</td>
        <td>LPA (FQ/2LI) - Was MTBc detected by LPA?</td>
        <td></td>
        <td>LPA (FQ/2LI) - Was MTBc detected by LPA?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>z0j1fZQHoSB</td>
      </tr>
      <tr>
        <td>TB DRS LAB: LPA (RIF/INH)</td>
        <td>LPA (RIF/INH)</td>
        <td></td>
        <td>LPA (Rifampicin / Isoniazid)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>a2I7mdEL028</td>
      </tr>
      <tr>
        <td>TB DRS LAB: LPA (RIF/INH) - Was MTBc detected by LPA?</td>
        <td>LPA (RIF/INH) - Was MTBc detected by LPA?</td>
        <td></td>
        <td>LPA (RIF/INH) - Was MTBc detected by LPA?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Zd7703kfnOC</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
        <td>Reasons for Sample Rejection or Loss</td>
        <td></td>
        <td>Reasons for Sample Rejection or Loss</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>A58cijzgyCn</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Sample 2 - Reasons for Sample Rejection or Loss</td>
        <td>Reasons for sample 2 rejection or loss</td>
        <td></td>
        <td>Reasons for sample 2 rejection or loss</td>
        <td>default</td>
        <td>2020-01-15</td>
        <td>f9kGs0Uulxe</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Sample 3 - Reasons for Sample Rejection or Loss</td>
        <td>Reasons for sample 3 rejection or loss</td>
        <td></td>
        <td>Reasons for sample 3 rejection or loss</td>
        <td>default</td>
        <td>2020-01-15</td>
        <td>UFJB0MeQHzO</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Sample 4 - Reasons for Sample Rejection or Loss</td>
        <td>Reasons for sample 4 rejection or loss</td>
        <td></td>
        <td>Reasons for sample 4 rejection or loss</td>
        <td>default</td>
        <td>2020-01-20</td>
        <td>K0RIvVgLrN3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
        <td>Sample Rejected or Lost</td>
        <td></td>
        <td>Sample Rejected or Lost</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>CtMCpcRTKkI</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Specimen Type used for LPA (FQ/2LI)</td>
        <td>Specimen Type used for LPA (FQ/2LI)</td>
        <td></td>
        <td>What specimen type was used for LPA?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>FKxBceeFNuR</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Specimen Type used for LPA (RIF/INH)</td>
        <td>Specimen Type used for LPA (RIF/INH)</td>
        <td></td>
        <td>What specimen type was used for LPA?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>p3L4HYkzU4o</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Sputum Smear Microscopy</td>
        <td>Sputum Smear Microscopy</td>
        <td></td>
        <td>Sputum Smear Microscopy</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Dd95Kl4aXZf</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Storage Only</td>
        <td>Storage Only</td>
        <td></td>
        <td>Storage Only</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>gf1mmDm59da</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Amikacin</td>
        <td>Subsequent DST (LM) Amikacin</td>
        <td></td>
        <td>Subsequent DST (LM) Amikacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>c9Xf7On1URp</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Bedaquiline</td>
        <td>Subsequent DST (LM) Bedaquiline</td>
        <td></td>
        <td>Subsequent DST (LM) Bedaquiline</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ZNaklWBGQZ8</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Capreomycin</td>
        <td>Subsequent DST (LM) Capreomycin</td>
        <td></td>
        <td>Subsequent DST (LM) Capreomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>xYGMAvUMCWZ</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Clofazimine</td>
        <td>Subsequent DST (LM) Clofazimine</td>
        <td></td>
        <td>Subsequent DST (LM) Clofazimine</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>fEaYflKmWNV</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Delamanid</td>
        <td>Subsequent DST (LM) Delamanid</td>
        <td></td>
        <td>Subsequent DST (LM) Delamanid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ofbBziFQiiz</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Ethambutol</td>
        <td>Subsequent DST (LM) Ethambutol</td>
        <td></td>
        <td>Subsequent DST (LM) Ethambutol</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>QrEj61cPfFE</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Ethionamide</td>
        <td>Subsequent DST (LM) Ethionamide</td>
        <td></td>
        <td>Subsequent DST (LM) Ethionamide</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>jzf1XGop1vf</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Gatifloxacin</td>
        <td>Subsequent DST (LM) Gatifloxacin</td>
        <td></td>
        <td>Subsequent DST (LM) Gatifloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>GWGXHeNvafj</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid</td>
        <td>Subsequent DST (LM) Isoniazid</td>
        <td></td>
        <td>Subsequent DST (LM) Isoniazid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>LKld1PYYWVq</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid HC</td>
        <td>Subsequent DST (LM) - H HC</td>
        <td></td>
        <td>Subsequent DST (LM) Isoniazid HC</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>HON8n7ympBQ</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Kanamycin</td>
        <td>Subsequent DST (LM) Kanamycin</td>
        <td></td>
        <td>Subsequent DST (LM) Kanamycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>nOtPlyNDakF</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Levofloxacin</td>
        <td>Subsequent DST (LM) Levofloxacin</td>
        <td></td>
        <td>Subsequent DST (LM) Levofloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>oxeeucyvWf8</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Linezolid</td>
        <td>Subsequent DST (LM) Linezolid</td>
        <td></td>
        <td>Subsequent DST (LM) Linezolid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>fAaOFiWHG00</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CB</td>
        <td>Subsequent DST (LM) Mfx CB</td>
        <td></td>
        <td>Subsequent DST (LM) Mfx CB</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>f9btToRmhF0</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CC</td>
        <td>Subsequent DST LM - Mfx CC</td>
        <td></td>
        <td>Subsequent DST (LM) Moxifloxacin CC</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>aGdQGSpE1nH</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Ofloxacin</td>
        <td>Subsequent DST (LM) Ofloxacin</td>
        <td></td>
        <td>Subsequent DST (LM) Ofloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>dbnGbVNSliC</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Pyrazinamide</td>
        <td>Subsequent DST (LM) Pyrazinamide</td>
        <td></td>
        <td>Subsequent DST (LM) Pyrazinamide</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>dn0Zv1sTAyK</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Rifampicin</td>
        <td>Subsequent DST (LM) Rifampicin</td>
        <td></td>
        <td>Subsequent DST (LM) Rifampicin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>kl5WPZXCJe7</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (LM) Streptomycin</td>
        <td>Subsequent DST (LM) Streptomycin</td>
        <td></td>
        <td>Subsequent DST (LM) Streptomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>dPjMTIq7ed6</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Amikacin</td>
        <td>Subsequent DST (SM) Amikacin</td>
        <td></td>
        <td>Subsequent DST (SM) Amikacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>P52ps9ODa6p</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Bedaquiline</td>
        <td>Subsequent DST (SM) Bedaquiline</td>
        <td></td>
        <td>Subsequent DST (SM) Bedaquiline</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>qD9DJDp2anV</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Capreomycin</td>
        <td>Subsequent DST (SM) Capreomycin</td>
        <td></td>
        <td>Subsequent DST (SM) Capreomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>eFjeYiIpqF3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Clofazimine</td>
        <td>Subsequent DST (SM) Clofazimine</td>
        <td></td>
        <td>Subsequent DST (SM) Clofazimine</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Ed5FxENroJE</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Delamanid</td>
        <td>Subsequent DST (SM) Delamanid</td>
        <td></td>
        <td>Subsequent DST (SM) Delamanid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>THQkzg8zPp0</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Ethambutol</td>
        <td>Subsequent DST (SM) Ethambutol</td>
        <td></td>
        <td>Subsequent DST (SM) Ethambutol</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>u4zOjREFDal</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Ethionamide</td>
        <td>Subsequent DST (SM) Ethionamide</td>
        <td></td>
        <td>Subsequent DST (SM) Ethionamide</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ZE0tnyGERon</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Gatifloxacin</td>
        <td>Subsequent DST (SM) Gatifloxacin</td>
        <td></td>
        <td>Subsequent DST (SM) Gatifloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>x2LifvToFMX</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid</td>
        <td>Subsequent DST (SM) Isoniazid</td>
        <td></td>
        <td>Subsequent DST (SM) Isoniazid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>gjBTfw5dWZk</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid HC</td>
        <td>Subsequent DST (SM) - H HC</td>
        <td></td>
        <td>Subsequent DST (SM) Isoniazid HC</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>s9qxU6Ua0u5</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Kanamycin</td>
        <td>Subsequent DST (SM) Kanamycin</td>
        <td></td>
        <td>Subsequent DST (SM) Kanamycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>kEHt8sIydzh</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Levofloxacin</td>
        <td>Subsequent DST (SM) Levofloxacin</td>
        <td></td>
        <td>Subsequent DST (SM) Levofloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ZmZYSsOxU1z</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Linezolid</td>
        <td>Subsequent DST (SM) Linezolid</td>
        <td></td>
        <td>Subsequent DST (SM) Linezolid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>hHYyik5Srsh</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CB</td>
        <td>Subsequent DST SM - Mfx CB</td>
        <td></td>
        <td>Subsequent DST (SM) Moxifloxacin CB</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>wlDBglLM80h</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CC</td>
        <td>Subsequent DST SM - Mfx CC</td>
        <td></td>
        <td>Subsequent DST (SM) Moxifloxacin CC</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>AzknaLRPzJD</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Ofloxacin</td>
        <td>Subsequent DST (SM) Ofloxacin</td>
        <td></td>
        <td>Subsequent DST (SM) Ofloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>lUc46V4xDLq</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Pyrazinamide</td>
        <td>Subsequent DST (SM) Pyrazinamide</td>
        <td></td>
        <td>Subsequent DST (SM) Pyrazinamide</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>mMsbA1faYrS</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Rifampicin</td>
        <td>Subsequent DST (SM) Rifampicin</td>
        <td></td>
        <td>Subsequent DST (SM) Rifampicin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>JtlLE4PiFCP</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST (SM) Streptomycin</td>
        <td>Subsequent DST (SM) Streptomycin</td>
        <td></td>
        <td>Subsequent DST (SM) Streptomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>sINw8slPwCn</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST in Liquid Media (e.g. MGIT)</td>
        <td>Subsequent DST in Liquid Media (e.g. MGIT)</td>
        <td></td>
        <td>Subsequent DST in Liquid Media (e.g. MGIT)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>uaewAATQgBJ</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Subsequent DST in Solid Media (e.g. LJ)</td>
        <td>Subsequent DST in Solid Media (e.g. LJ)</td>
        <td></td>
        <td>Subsequent DST in Solid Media (e.g. LJ)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>BNkkWpCKgLR</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
        <td>Targeted Gene Sequencing</td>
        <td></td>
        <td>Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>zfF3GMpuYAP</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid) </td>
        <td>TGS - 4-Aminosalicylic Acid</td>
        <td></td>
        <td>Targeted Gene Sequencing - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>xkTsrRXno32</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Amikacin</td>
        <td>TGS - Amikacin</td>
        <td></td>
        <td>Targeted Gene Sequencing - Amikacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ZRZuu4yfO8W</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Bedaquiline</td>
        <td>TGS - Bedaquiline</td>
        <td></td>
        <td>Targeted Gene Sequencing - Bedaquiline</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>MRH7YydJDcy</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Capreomycin</td>
        <td>TGS - Capreomycin</td>
        <td></td>
        <td>Targeted Gene Sequencing - Capreomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>vfJ8kKoo0Q4</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Clofazimine</td>
        <td>TGS - Clofazimine</td>
        <td></td>
        <td>Targeted Gene Sequencing - Clofazimine</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>GVKNIHjWjm3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Cycloserine</td>
        <td>TGS - Cycloserine</td>
        <td></td>
        <td>Targeted Gene Sequencing - Cycloserine</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>lqfUzukldaU</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Delamanid</td>
        <td>TGS - Delamanid</td>
        <td></td>
        <td>Targeted Gene Sequencing - Delamanid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>L0vlVRzP9we</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Ethambutol</td>
        <td>TGS - Ethambutol</td>
        <td></td>
        <td>Targeted Gene Sequencing - Ethambutol</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>cX54Ku7ADIP</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Ethionamide</td>
        <td>TGS - Ethionamide</td>
        <td></td>
        <td>Targeted Gene Sequencing - Ethionamide</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>B2U7YXUSeOy</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Gatifloxacin</td>
        <td>TGS - Gatifloxacin</td>
        <td></td>
        <td>Targeted Gene Sequencing - Gatifloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ez6zEp0VFFK</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
        <td>TGS GenotypicResistProfiling - 4AminosalicylicAcid</td>
        <td></td>
        <td>Genotypic resistance profiling for 4-Aminosalicylic acid (para-aminosalicylic acid) by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>OuvOpkEUnPX</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Amikacin</td>
        <td>TGS Genotypic resistance profiling - Amikacin</td>
        <td></td>
        <td>Genotypic resistance profiling for Amikacin by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Drmi6zCWAeX</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bedaquiline</td>
        <td>TGS Genotypic resistance profiling - Bedaquiline</td>
        <td></td>
        <td>Genotypic resistance profiling for Bedaquiline by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>fhqQzSVeTR1</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Capreomycin</td>
        <td>TGS Genotypic resistance profiling - Capreomycin</td>
        <td></td>
        <td>Genotypic resistance profiling for Capreomycin by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>oOmuzSnIwdQ</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Clofazimine</td>
        <td>TGS Genotypic resistance profiling - Clofazimine</td>
        <td></td>
        <td>Genotypic resistance profiling for Clofazimine by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>tSe484MEuFG</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cycloserine</td>
        <td>TGS Genotypic resistance profiling - Cycloserine</td>
        <td></td>
        <td>Genotypic resistance profiling for Cycloserine by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>qLkTtd47k3k</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Delamanid</td>
        <td>TGS Genotypic resistance profiling - Delamanid</td>
        <td></td>
        <td>Genotypic resistance profiling for Delamanid by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>oixCCbTWNYH</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethambutol</td>
        <td>TGS Genotypic Resistance Profiling - Ethambutol</td>
        <td></td>
        <td>Genotypic resistance profiling for Ethambutol by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>rVPpiiHMzTs</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethionamide</td>
        <td>TGS Genotypic resistance profiling - Ethionamide</td>
        <td></td>
        <td>Genotypic resistance profiling for Ethionamide by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>B4PXKvPqTBY</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Gatifloxacin</td>
        <td>TGS Genotypic resistance profiling - Gatifloxacin</td>
        <td></td>
        <td>Genotypic resistance profiling for Gatifloxacin by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>C7sLVfSD0vV</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Isoniazid</td>
        <td>TGS Genotypic resistance profiling - Isoniazid</td>
        <td></td>
        <td>Genotypic resistance profiling for Isoniazid by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>LIZFpcp8VTx</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Kanamycin</td>
        <td>TGS Genotypic resistance profiling - Kanamycin</td>
        <td></td>
        <td>Genotypic resistance profiling for Kanamycin by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>i3gLbCCYqxw</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Levofloxacin</td>
        <td>TGS Genotypic resistance profiling - Levofloxacin</td>
        <td></td>
        <td>Genotypic resistance profiling for Levofloxacin by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>jtR6rU3hlFN</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Linezolid</td>
        <td>TGS Genotypic resistance profiling - Linezolid</td>
        <td></td>
        <td>Genotypic resistance profiling for Linezolid by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>fQifcktAjNe</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Moxifloxacin</td>
        <td>TGS Genotypic resistance profiling - Mfx</td>
        <td></td>
        <td>Genotypic resistance profiling for Moxifloxacin CC by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>kDOCuhy4P9q</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ofloxacin</td>
        <td>TGS Genotypic resistance profiling - Ofloxacin</td>
        <td></td>
        <td>Genotypic resistance profiling for Ofloxacin by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>A8MwWW7rczm</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pretomanid</td>
        <td>TGS Genotypic resistance profiling - Pretomanid</td>
        <td></td>
        <td>Genotypic resistance profiling for Pretomanid by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>uprsSY93zJA</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pyrazinamide</td>
        <td>TGS Genotypic resistance profiling - Pyrazinamide</td>
        <td></td>
        <td>Genotypic resistance profiling for Pyrazinamide by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>G1zw1rVFH97</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Rifampicin</td>
        <td>TGS Genotypic resistance profiling - Rifampicin</td>
        <td></td>
        <td>Genotypic resistance profiling for Rifampicin by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>w3litCy0uoa</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Streptomycin</td>
        <td>TGS Genotypic resistance profiling - Streptomycin</td>
        <td></td>
        <td>Genotypic resistance profiling for Streptomycin by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Hj2KPZfk42M</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
        <td>TGS - Interpretable Profiling for MTBc</td>
        <td></td>
        <td>Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>FYe5AbkFGjL</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Isoniazid</td>
        <td>TGS - Isoniazid</td>
        <td></td>
        <td>Targeted Gene Sequencing - Isoniazid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>z96R7OKrM0V</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Kanamycin</td>
        <td>TGS - Kanamycin</td>
        <td></td>
        <td>Targeted Gene Sequencing - Kanamycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>gfdtvoE1hQB</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Levofloxacin</td>
        <td>TGS - Levofloxacin</td>
        <td></td>
        <td>Targeted Gene Sequencing - Levofloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>v7hvalWSMdD</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Linezolid</td>
        <td>TGS - Linezolid</td>
        <td></td>
        <td>Targeted Gene Sequencing - Linezolid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ayaXIPFuCKi</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Moxifloxacin</td>
        <td>TGS - Mfx</td>
        <td></td>
        <td>Targeted Gene Sequencing - Moxifloxacin CC</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>qtDEs476qfm</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Ofloxacin</td>
        <td>TGS - Ofloxacin</td>
        <td></td>
        <td>Targeted Gene Sequencing - Ofloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>uo7fwGi3T50</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Pretomanid</td>
        <td>TGS - Pretomanid</td>
        <td></td>
        <td>Targeted Gene Sequencing - Pretomanid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>UivvdCjPlfa</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Pyrazinamide</td>
        <td>TGS - Pyrazinamide</td>
        <td></td>
        <td>Targeted Gene Sequencing - Pyrazinamide</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>RavSarQNgCh</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
        <td>TGS: Reasons for Failure</td>
        <td></td>
        <td>Targeted Gene Sequencing: Reasons for Failure</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>wQqfoI8qTMX</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
        <td>TGS: Reasons for No Resistance Profiling Available</td>
        <td></td>
        <td>Reasons for No Resistance Profiling Available</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>P4qS3sJtCv3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Rifampicin</td>
        <td>TGS - Rifampicin</td>
        <td></td>
        <td>Targeted Gene Sequencing - Rifampicin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Qacn0rcuDDJ</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Streptomycin</td>
        <td>TGS - Streptomycin</td>
        <td></td>
        <td>Targeted Gene Sequencing - Streptomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>D19YEOOFDza</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
        <td>TGS Genotypic Speciation Results</td>
        <td></td>
        <td>TGS Genotypic Speciation Results</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>hidY602crX8</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS</td>
        <td>Whole Genome Sequencing</td>
        <td></td>
        <td>Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>GCEHyuCo1fA</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
        <td>WGS - 4-Aminosalicylic Acid</td>
        <td></td>
        <td>WGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>bRCUs5NKDt6</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Amikacin</td>
        <td>WGS - Amikacin</td>
        <td></td>
        <td>WGS - Amikacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>BeiwTqausl2</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Bedaquiline</td>
        <td>WGS - Bedaquiline</td>
        <td></td>
        <td>WGS - Bedaquiline</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>WeyofuKqwfo</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Capreomycin</td>
        <td>WGS - Capreomycin</td>
        <td></td>
        <td>WGS - Capreomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>NmXlqcFbT5v</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Clofazimine</td>
        <td>WGS - Clofazimine</td>
        <td></td>
        <td>WGS - Clofazimine</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>lVcq306NgCE</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Cycloserine</td>
        <td>WGS - Cycloserine</td>
        <td></td>
        <td>WGS - Cycloserine</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>s3N7gNV6B2U</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Date of Results</td>
        <td>Date of WGS Results</td>
        <td></td>
        <td>Date of WGS Results</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>w1r7ah3H7r7</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Delamanid</td>
        <td>WGS - Delamanid</td>
        <td></td>
        <td>WGS - Delamanid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>KtQ4l6MjobQ</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Ethambutol</td>
        <td>WGS - Ethambutol</td>
        <td></td>
        <td>WGS - Ethambutol</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>nFjWTV4ifUn</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Ethionamide</td>
        <td>WGS - Ethionamide</td>
        <td></td>
        <td>WGS - Ethionamide</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>DWjZ6aSnBM9</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Gatifloxacin</td>
        <td>WGS - Gatifloxacin</td>
        <td></td>
        <td>WGS - Gatifloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>d5vnE1DoVwj</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
        <td>WGS GenotypicResistProfiling - 4AminosalicylicAcid</td>
        <td></td>
        <td>Genotypic resistance profiling for 4-Aminosalicylic Acid (Para-aminosalicylic Acid) by WGS</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>i2mqvqIeMcU</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Amikacin</td>
        <td>WGS Genotypic resistance profiling - Amikacin</td>
        <td></td>
        <td>Genotypic resistance profiling for Amikacin by Whole Genome sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>gtApUJCf41j</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bedaquiline</td>
        <td>WGS Genotypic resistance profiling - Bedaquiline</td>
        <td></td>
        <td>Genotypic resistance profiling for Bedaquiline by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>e7e7q0wadBs</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Capreomycin</td>
        <td>WGS Genotypic resistance profiling - Capreomycin</td>
        <td></td>
        <td>Genotypic resistance profiling for Capreomycin by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>kmnGRvqNAua</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Clofazimine</td>
        <td>WGS Genotypic resistance profiling - Clofazimine</td>
        <td></td>
        <td>Genotypic resistance profiling for Clofazimine by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>QFU2ie7seWU</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cycloserine</td>
        <td>WGS Genotypic resistance profiling - Cycloserine</td>
        <td></td>
        <td>Genotypic resistance profiling for Cycloserine by WGS</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>OsLZZYMI7UG</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Delamanid</td>
        <td>WGS Genotypic resistance profiling - Delamanid</td>
        <td></td>
        <td>Genotypic resistance profiling for Delamanid by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>GQX1kVD3PCY</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethambutol</td>
        <td>WGS Genotypic resistance profiling - Ethambutol</td>
        <td></td>
        <td>Genotypic resistance profiling for Ethambutol by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Xmu74LffbOV</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethionamide</td>
        <td>WGS Genotypic resistance profiling - Ethionamide</td>
        <td></td>
        <td>Genotypic resistance profiling for Ethionamide by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>VW74EEB0Ump</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Gatifloxacin</td>
        <td>WGS Genotypic resistance profiling - Gatifloxacin</td>
        <td></td>
        <td>Genotypic resistance profiling for Gatifloxacin by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>h0ESse3Yutp</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Isoniazid</td>
        <td>WGS Genotypic resistance profiling - Isoniazid</td>
        <td></td>
        <td>Genotypic resistance profiling for Isoniazid by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>LEpQiuWLlog</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Kanamycin</td>
        <td>WGS Genotypic resistance profiling - Kanamycin</td>
        <td></td>
        <td>Genotypic resistance profiling for Kanamycin by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>oNVg1jHyHzJ</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Levofloxacin</td>
        <td>WGS Genotypic resistance profiling - Levofloxacin</td>
        <td></td>
        <td>Genotypic resistance profiling for Levofloxacin by WGS</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Y8R8fTtfeuA</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Linezolid</td>
        <td>WGS Genotypic resistance profiling - Linezolid</td>
        <td></td>
        <td>Genotypic resistance profiling for Linezolid by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>RN3lGwZozL9</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Moxifloxacin</td>
        <td>WGS Genotypic resistance profiling - Mfx</td>
        <td></td>
        <td>Genotypic resistance profiling for Moxifloxacin CC by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>MQRHQhmaron</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ofloxacin</td>
        <td>WGS Genotypic resistance profiling - Ofloxacin</td>
        <td></td>
        <td>Genotypic resistance profiling for Ofloxacin by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>Tpwb8CJ8we0</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pretomanid</td>
        <td>WGS Genotypic resistance profiling - Pretomanid</td>
        <td></td>
        <td>Genotypic resistance profiling for Pretomanid by WGS</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>diVqel7EsfP</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pyrazinamide</td>
        <td>WGS Genotypic resistance profiling - Pyrazinamide</td>
        <td></td>
        <td>Genotypic resistance profiling for Pyrazinamide by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>dNgpCxvkfBa</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Rifampicin</td>
        <td>WGS Genotypic resistance profiling - Rifampicin</td>
        <td></td>
        <td>Genotypic resistance profiling for Rifampicin by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>eAAkJdj12lF</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Streptomycin</td>
        <td>WGS Genotypic resistance profiling - Streptomycin</td>
        <td></td>
        <td>Genotypic resistance profiling for Streptomycin by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>gJqrEu6m2Un</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
        <td>WGS - Genotypic Speciation Results</td>
        <td></td>
        <td>WGS - Genotypic Speciation Results</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>MoMwVSDvenr</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
        <td>WGS - Interpretable Profiling for MTBc</td>
        <td></td>
        <td>Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>SRB4upTdK46</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Isoniazid</td>
        <td>WGS - Isoniazid</td>
        <td></td>
        <td>WGS - Isoniazid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>WYa5fWFahwq</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Kanamycin</td>
        <td>WGS - Kanamycin</td>
        <td></td>
        <td>WGS - Kanamycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ylkv0ZApOqK</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Levofloxacin</td>
        <td>WGS - Levofloxacin</td>
        <td></td>
        <td>WGS - Levofloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>vtTQyHUQYbS</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Linezolid</td>
        <td>WGS - Linezolid</td>
        <td></td>
        <td>WGS - Linezolid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>f1og4JlkeKa</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Moxifloxacin</td>
        <td>WGS - Mfx</td>
        <td></td>
        <td>WGS - Moxifloxacin CC</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>xCnfWsAWsSr</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Ofloxacin</td>
        <td>WGS - Ofloxacin</td>
        <td></td>
        <td>WGS - Ofloxacin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>KBYW7kxnfsj</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Pretomanid</td>
        <td>WGS - Pretomanid</td>
        <td></td>
        <td>WGS - Pretomanid</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>BnNjlXkFklt</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Pyrazinamide</td>
        <td>WGS - Pyrazinamide</td>
        <td></td>
        <td>WGS - Pyrazinamide</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>hFlEa5Hpxvs</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
        <td>WGS: Reasons for Failure</td>
        <td></td>
        <td>WGS - Reasons for Failure</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>SCWmNAXBBE7</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
        <td>WGS: Reasons for No Resistance Profiling Available</td>
        <td></td>
        <td>Reasons for No Resistance Profiling Available</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>w7z2AXGEc5o</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Rifampicin</td>
        <td>WGS - Rifampicin</td>
        <td></td>
        <td>WGS - Rifampicin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>L64R49nQOkr</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Streptomycin</td>
        <td>WGS - Streptomycin</td>
        <td></td>
        <td>WGS - Streptomycin</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>e5WYNBhy8gM</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Xpert MTB/RIF</td>
        <td>TB DRS Xpert MTB/RIF</td>
        <td></td>
        <td>Xpert MTB/RIF</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>VSuQ1rwL2nA</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
        <td>Xpert MTB/RIF Quantitative Result</td>
        <td></td>
        <td>Xpert MTB/RIF Quantitative Result</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>pO5nfo8ea4z</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>MAItgXvlO5L</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
        <td>Xpert MTB/RIF Ultra Quantitative Result</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra Quantitative Result</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>e838DsdVAjN</td>
      </tr>
      <tr>
        <td>TB DRS SRL - Reasons for not Shipping Samples to SRL</td>
        <td>Reasons - No results to SRL</td>
        <td></td>
        <td>Why have Samples not been shipped to SRL</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>bOuViG0JtyT</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Additional Comments and Remarks</td>
        <td>SRL Additional Comments and Remarks</td>
        <td></td>
        <td>Additional comments and remarks</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>DSvVcgTucZL</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Date of Samples Arrival at SRL</td>
        <td>Date of Samples Arrival at SRL</td>
        <td></td>
        <td>Date of samples arrival at SRL</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>uhrqXcvXURW</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Date Samples Shipped to Supranational Laboratory (SRL)</td>
        <td>Date Samples Shipped to SRL</td>
        <td></td>
        <td>Date samples shipped to SRL</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>mriIhfYxKhd</td>
      </tr>
      <tr>
        <td>TB DRS SRL: DRS ID</td>
        <td>Patient DRS ID</td>
        <td></td>
        <td>Patient DRS ID</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>xOhEOb1qLwJ</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Import .csv</td>
        <td>Import csv</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-02-04</td>
        <td>VYQY1CSTWHx</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Samples Shipped to SRL</td>
        <td>Samples to SRL</td>
        <td></td>
        <td>Samples shipped to SRL</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ncuUAcK3obu</td>
      </tr>
    </table>
    <h2>Data Element Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS</td>
        <td>2020-01-29</td>
        <td>SfwwoCbB1m3</td>
      </tr>
    </table>
    <h3>Data Element Groups - Data Elements</h3>
    <table>
      <tr>
        <th>Data Element Group</th>
        <th>Data Element</th>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Clofazimine</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Previous TB Registration Number</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bedaquiline</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Bedaquiline</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Capreomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Amikacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Ethambutol</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Streptomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Specimen 2 Microscopy Test Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 1 DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ethionamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Amikacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Linezolid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Rifampicin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Other Symptoms of Lung Disease</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Streptomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Culture in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Ethionamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Injections for TB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: LPA (RIF/INH) - Was MTBc detected by LPA?</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Streptomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 4 DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Linezolid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Levofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Specify Other (Sample 3)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Rifampicin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Cycloserine</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Gatifloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 2 DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Capreomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pyrazinamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 3 Additive</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Date Samples Shipped to Supranational Laboratory (SRL)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Levofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Bedaquiline</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Ethionamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Kanamycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Pretomanid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Sputum Smear Microscopy Examination</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Samples Shipped to SRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Gatifloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Capreomycin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Ofloxacin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Ofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Capreomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 4 Collection Date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Specify Other (Sample 2)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Streptomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Bedaquiline</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pretomanid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Gatifloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Tuberculosis Drugs</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Moxifloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Amikacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Pyrazinamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: HIV Test Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Cycloserine</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Delamanid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethionamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethionamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Kanamycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Isoniazid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Prior TB Registration</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Ethambutol</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Clofazimine</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Levofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Ethionamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Rifampicin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Amikacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 1 Additive</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Streptomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Kanamycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Names of Drugs</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Rifampicin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Kanamycin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Fluoroquinolones</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Storage Only</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Control Question</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Linezolid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cycloserine</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Delamanid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Final Initial DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Amikacin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Gatifloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Pretomanid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Isoniazid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Outcome</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 1 Collection Date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Isoniazid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Bedaquiline</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Date of Results</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Streptomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL - Reasons for not Shipping Samples to SRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Ethambutol</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Kanamycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Gatifloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Rifampicin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethambutol (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Bacteriological Confirmation - Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Delamanid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CC (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Levofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Ofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Specify Other (Sample 4)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Bedaquiline</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Rifampicin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Pyrazinamide (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Ofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Streptomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Kanamycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Linezolid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Delamanid (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Gatifloxacin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pyrazinamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bedaquiline</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Capreomycin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Kanamycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Streptomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Rifampicin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Amikacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cycloserine</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Levofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Amikacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Levofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Clofazimine</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Kanamycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Specify Other (Sample 1)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - CIF Officer Name</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Moxifloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Moxifloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Final Subsequent DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Kanamycin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Linezolid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Xpert MTB/RIF Initial Screening Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Capreomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Amikacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - length of sickness - weeks</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Gatifloxacin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Linezolid (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Amikacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ethionamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Kanamycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Isoniazid HC (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Delamanid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Isoniazid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ofloxacin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Clofazimine (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Clofazimine</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Kanamycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Delamanid (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid) </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 2 Collection Date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Ethambutol</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 3 DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Bedaquiline</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Sputum Examinations</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Ethionamide (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Bacteriological Confirmation - Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Levofloxacin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Ofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Rifampicin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CC (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Date of Samples Arrival at NRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Amikacin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethambutol (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Capreomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Moxifloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Delamanid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Specimen 1 Microscopy Test Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pretomanid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Linezolid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - 4-Aminosalicylic Acid (Para-aminosalicylic Acid)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Linezolid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Delamanid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Ethambutol</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Capreomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Rifampicin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Streptomycin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Date of Samples Arrival at SRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 2 Additive</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Prior Symptoms</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Linezolid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Clofazimine</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Capreomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Bedaquiline (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Isoniazid HC (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final LPA (RIF/INH) Result for Isoniazid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Delamanid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Linezolid (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Moxifloxacin CB (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Clofazimine</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Clofazimine (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Moxifloxacin CB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Pyrazinamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (LM) Rifampicin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Levofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Ethionamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Date Samples Shipped to NRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Streptomycin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Final Initial DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Amikacin/Capreomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Rifampicin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Treatment Over 1 Month</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Ethambutol</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Levofloxacin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Ethambutol</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Pyrazinamide</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Clofazimine</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Specimen Type used for LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Ethambutol</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Subsequent DST (SM) Moxifloxacin CC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (SM) Isoniazid HC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final LPA (FQ/2LI) Result for Ethambutol</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Culture in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: LPA (FQ/2LI) - Was MTBc detected by LPA?</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Pyrazinamide (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Ethionamide (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Subsequent DST Result for Bedaquiline (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Clofazimine</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Initial DST (LM) Delamanid</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Levofloxacin (SM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Specimen Type used for LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: HIV Test Date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Capreomycin</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 4 Additive</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Date of Xpert MTB/RIF Initial Screening Test</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Initial DST Result for Moxifloxacin CB (LM)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 3 Collection Date</td>
      </tr>
    </table>
    <h2 id="categoryCombos">Category Combinations</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
        <th>Categories</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2020-03-18</td>
        <td>bjDvmb4bfuf</td>
        <td>default</td>
      </tr>
    </table>
    <h2 id="categories">Data Element Categories</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
        <th>Category options</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2020-03-18</td>
        <td>GLevLNI9wkl</td>
        <td>default</td>
      </tr>
    </table>
    <h2 id="categoryOptions">Data Element Category Options</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2020-03-18</td>
        <td>xYerKDKCefk</td>
      </tr>
    </table>
    <h2 id="categoryOptionCombos">Category Option Combination</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2020-03-18</td>
        <td>HllvX50cXC0</td>
      </tr>
    </table>
    <h2 id="optionSets">Option Sets</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
        <th>Options</th>
      </tr>
      <tr>
        <td>Countries</td>
        <td>2020-03-18</td>
        <td>ynHtyLDVeJO</td>
        <td>Afghanistan; Aland Islands; Albania; Algeria; American Samoa; Andorra; Angola; Anguilla; Antarctica; Antigua and Barbuda; Argentina; Armenia; Aruba; Australia; Austria; Azerbaijan; Bahamas; Bahrain; Bangladesh; Barbados; another 229 options not shown.</td>
      </tr>
      <tr>
        <td>Positive/Negative/Unknown</td>
        <td>2020-03-18</td>
        <td>EAesHOyydJi</td>
        <td>Positive; Negative; Unknown</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>2020-03-18</td>
        <td>hiQ3QFheQ3O</td>
        <td>Male; Female</td>
      </tr>
      <tr>
        <td>TB DRS Final Culture Result</td>
        <td>2020-03-18</td>
        <td>rB88xT5ggFg</td>
        <td>MTB; NTM; No growth; Contaminated</td>
      </tr>
      <tr>
        <td>TB DRS Final Sputum Smear Microscopy Result</td>
        <td>2020-03-18</td>
        <td>qu5LpxbpHUa</td>
        <td>Negative; Scanty; +; ++; +++</td>
      </tr>
      <tr>
        <td>TB DRS Final Xpert MTB/RIF Test Result</td>
        <td>2020-03-18</td>
        <td>otxN1DQ61fV</td>
        <td>MTB-Detected (Rifampicin Susceptible); MTB-Detected (Rifampicin Resistant); MTB-Detected (Rifampicin Indeterminate); MTB-Not Detected; No result; Error; Invalid</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>2020-03-18</td>
        <td>acANJTHfW9R</td>
        <td>Susceptible; Resistant; No Interpretable Result (i.e. insufficient quality); Indeterminate (i.e. mutation unknown / not graded)</td>
      </tr>
      <tr>
        <td>TB DRS Initial Microscopy Test Result</td>
        <td>2020-03-18</td>
        <td>ft1PsITQXZ9</td>
        <td>Negative; Scanty; +; ++; +++; Not Done</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Genotypic Speciation Results</td>
        <td>2020-03-18</td>
        <td>KFLJiv8X5Uf</td>
        <td>MTBc; Mixed MTBc and Other; NTM; Contamination; Failed</td>
      </tr>
      <tr>
        <td>TB DRS LPA Specimen</td>
        <td>2020-03-18</td>
        <td>oKESbY0JpLt</td>
        <td>Sputum samples or sediments; MTB culture isolates</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>2020-03-18</td>
        <td>cNBWQaZZQ8g</td>
        <td>Cured/treatment completed; Failed new patient regimen of first-line drugs only; Failed retreatment regimen of first-line drugs only; Failed regimen which included second-line drugs; Lost to follow-up; Other; Unknown</td>
      </tr>
      <tr>
        <td>TB DRS Result</td>
        <td>2020-03-18</td>
        <td>A88N1wapLGS</td>
        <td>Resistant; Susceptible; No Interpretable Result</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>2020-03-18</td>
        <td>pDOu7HaMvKJ</td>
        <td>None; OMNIGene; CPC; Ethanol; PrimeStore; Other</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Initial Screening Result</td>
        <td>2020-03-18</td>
        <td>tL974YWB9tY</td>
        <td>MTB-Detected (Rifampicin Susceptible); MTB-Detected (Rifampicin Resistant); MTB-Detected (Rif Indeterminate); MTB-Not Detected; No Result; Error; Invalid; Not Done</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Quantitative Result</td>
        <td>2020-03-18</td>
        <td>Vh9kmO4yiKE</td>
        <td>Very Low; Low; Average; High; Unknown</td>
      </tr>
      <tr>
        <td>Yes/No</td>
        <td>2020-03-18</td>
        <td>qtswn9lMSXN</td>
        <td>Yes; No</td>
      </tr>
      <tr>
        <td>Yes/No/Not Applicable</td>
        <td>2020-03-18</td>
        <td>qIXXdwltkqk</td>
        <td>Yes; No; Not Applicable</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>2020-03-18</td>
        <td>bLA3AqDKdwx</td>
        <td>Yes; No; Unknown</td>
      </tr>
    </table>
    <h2 id="options">Options</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Code</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB DRS Initial Microscopy Test Result</td>
        <td>+</td>
        <td>+</td>
        <td>2020-03-18</td>
        <td>cxJ3Yp9uSgd</td>
      </tr>
      <tr>
        <td>TB DRS Final Sputum Smear Microscopy Result</td>
        <td>+</td>
        <td>+</td>
        <td>2020-03-18</td>
        <td>z6UTT4AESR8</td>
      </tr>
      <tr>
        <td>TB DRS Initial Microscopy Test Result</td>
        <td>++</td>
        <td>++</td>
        <td>2020-03-18</td>
        <td>fLCbX2L5LH4</td>
      </tr>
      <tr>
        <td>TB DRS Final Sputum Smear Microscopy Result</td>
        <td>++</td>
        <td>++</td>
        <td>2020-03-18</td>
        <td>K9PoNq9YiJw</td>
      </tr>
      <tr>
        <td>TB DRS Initial Microscopy Test Result</td>
        <td>+++</td>
        <td>+++</td>
        <td>2020-03-18</td>
        <td>e34IzQ0SpeU</td>
      </tr>
      <tr>
        <td>TB DRS Final Sputum Smear Microscopy Result</td>
        <td>+++</td>
        <td>+++</td>
        <td>2020-03-18</td>
        <td>f0QayRDQJAw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Afghanistan</td>
        <td>AF</td>
        <td>2020-03-18</td>
        <td>yyeQNBfmO7g</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Aland Islands</td>
        <td>AX</td>
        <td>2020-03-18</td>
        <td>CNnT7FC710W</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Albania</td>
        <td>AL</td>
        <td>2020-03-18</td>
        <td>wuS7cVSEiYA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Algeria</td>
        <td>DZ</td>
        <td>2020-03-18</td>
        <td>ALoq1vKJCDr</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>American Samoa</td>
        <td>AS</td>
        <td>2020-03-18</td>
        <td>OvCy05DV6kt</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Andorra</td>
        <td>AD</td>
        <td>2018-01-18</td>
        <td>aslBaQPVe9V</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Angola</td>
        <td>AO</td>
        <td>2018-01-18</td>
        <td>rpzJ5jGkUAn</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Anguilla</td>
        <td>AI</td>
        <td>2020-03-18</td>
        <td>LMzYJEbDEN6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Antarctica</td>
        <td>AQ</td>
        <td>2020-03-18</td>
        <td>mQ5FOz8JXKs</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Antigua and Barbuda</td>
        <td>AG</td>
        <td>2020-03-18</td>
        <td>TRETd1l7n1N</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Argentina</td>
        <td>AR</td>
        <td>2018-01-18</td>
        <td>xvYNdt7dLiM</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Armenia</td>
        <td>AM</td>
        <td>2018-01-18</td>
        <td>CzdkfAxkAqe</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Aruba</td>
        <td>AW</td>
        <td>2018-01-18</td>
        <td>LoTxSO186BO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Australia</td>
        <td>AU</td>
        <td>2018-01-18</td>
        <td>omWzNDmT2t7</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Austria</td>
        <td>AT</td>
        <td>2018-01-18</td>
        <td>zTtjy8I0bcu</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Quantitative Result</td>
        <td>Average</td>
        <td>AVERAGE</td>
        <td>2020-03-18</td>
        <td>Er3cOin8vnZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Azerbaijan</td>
        <td>AZ</td>
        <td>2020-03-18</td>
        <td>FXk1MDI7CEJ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bahamas</td>
        <td>BS</td>
        <td>2018-01-18</td>
        <td>GGWWOucyQ5L</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bahrain</td>
        <td>BH</td>
        <td>2020-03-18</td>
        <td>cc1JEMv0suu</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bangladesh</td>
        <td>BD</td>
        <td>2018-01-18</td>
        <td>t0fFxYw3Cg4</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Barbados</td>
        <td>BB</td>
        <td>2018-01-18</td>
        <td>uM1WgdIueNA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Belarus</td>
        <td>BY</td>
        <td>2020-03-18</td>
        <td>dUEKKaPFcVU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Belgium</td>
        <td>BE</td>
        <td>2020-03-18</td>
        <td>zsS0Xx2iUV6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Belize</td>
        <td>BZ</td>
        <td>2020-03-18</td>
        <td>MdSOAa4C4gW</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Benin</td>
        <td>BJ</td>
        <td>2018-01-18</td>
        <td>fEV7BkjJi8V</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bermuda</td>
        <td>BM</td>
        <td>2020-03-18</td>
        <td>zITeQ1j7Jmz</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bhutan</td>
        <td>BT</td>
        <td>2020-03-18</td>
        <td>RNUEujTD4AN</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bolivia (Plurinational State of)</td>
        <td>BO</td>
        <td>2020-03-18</td>
        <td>WIleZf4Cua4</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bonaire, Sint Eustatius and Saba</td>
        <td>BQ</td>
        <td>2020-03-18</td>
        <td>vuiZtzbuwWx</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bosnia and Herzegovina</td>
        <td>BA</td>
        <td>2020-03-18</td>
        <td>Yf0Gb9nZiQ1</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Botswana</td>
        <td>BW</td>
        <td>2020-03-18</td>
        <td>ga22tvzYHEZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bouvet Island</td>
        <td>BV</td>
        <td>2020-03-18</td>
        <td>k9qiH4Z3K6m</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Brazil</td>
        <td>BR</td>
        <td>2020-03-18</td>
        <td>ZqOOqkOV8Zm</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>British Indian Ocean Territory</td>
        <td>IO</td>
        <td>2020-03-18</td>
        <td>JUY113J4COL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Brunei Darussalam</td>
        <td>BN</td>
        <td>2018-01-18</td>
        <td>AlKNJVD0Bqv</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bulgaria</td>
        <td>BG</td>
        <td>2018-01-18</td>
        <td>cGLoDkT864j</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Burkina Faso</td>
        <td>BF</td>
        <td>2018-01-18</td>
        <td>OIXRi2caf6J</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Burundi</td>
        <td>BI</td>
        <td>2018-01-18</td>
        <td>CIYwznedTto</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cabo Verde</td>
        <td>CV</td>
        <td>2018-01-18</td>
        <td>phN4setkIfq</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cambodia</td>
        <td>KH</td>
        <td>2020-03-18</td>
        <td>l8WR0m3GGuB</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cameroon</td>
        <td>CM</td>
        <td>2020-03-18</td>
        <td>JqPKssESKSC</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Canada</td>
        <td>CA</td>
        <td>2018-01-18</td>
        <td>zonuQ6g4FFh</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cayman Islands</td>
        <td>KY</td>
        <td>2020-03-18</td>
        <td>pQhtDfYHXlQ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Central African Republic</td>
        <td>CF</td>
        <td>2020-03-18</td>
        <td>bANs6w1wFgV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Chad</td>
        <td>TD</td>
        <td>2018-01-18</td>
        <td>rBktLnj3vUY</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Chile</td>
        <td>CL</td>
        <td>2018-01-18</td>
        <td>bQX37dUQTAr</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>China</td>
        <td>CN</td>
        <td>2018-01-18</td>
        <td>CQR9IijKrgo</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Christmas Island</td>
        <td>CX</td>
        <td>2020-03-18</td>
        <td>m9vCfHK0sLC</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cocos (Keeling) Islands</td>
        <td>CC</td>
        <td>2020-03-18</td>
        <td>Rb9W87URnVe</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Colombia</td>
        <td>CO</td>
        <td>2020-03-18</td>
        <td>e4CswJZAFBR</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Comoros</td>
        <td>KM</td>
        <td>2020-03-18</td>
        <td>LRjLr9oMe1M</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Congo</td>
        <td>CG</td>
        <td>2018-01-18</td>
        <td>Cy4TaW1hskg</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Congo (Democratic Republic of the)</td>
        <td>CD</td>
        <td>2020-03-18</td>
        <td>VnmVMbf4mwL</td>
      </tr>
      <tr>
        <td>TB DRS Final Culture Result</td>
        <td>Contaminated</td>
        <td>CONTAMINATED</td>
        <td>2020-03-18</td>
        <td>Ix8MPUuGZXD</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Genotypic Speciation Results</td>
        <td>Contamination</td>
        <td>CONTAMINATION</td>
        <td>2020-03-18</td>
        <td>EzNcSEhsU1n</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cook Islands</td>
        <td>CK</td>
        <td>2020-03-18</td>
        <td>Rx05JdBEHIW</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Costa Rica</td>
        <td>CR</td>
        <td>2018-01-18</td>
        <td>WBvTizbhaXP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cote d'Ivoire</td>
        <td>CI</td>
        <td>2020-03-18</td>
        <td>iwk6djvOBNV</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>CPC</td>
        <td>CPC</td>
        <td>2020-03-18</td>
        <td>Y85Yik3kfq6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Croatia</td>
        <td>HR</td>
        <td>2020-03-18</td>
        <td>tLn4hW3TbNZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cuba</td>
        <td>CU</td>
        <td>2018-01-18</td>
        <td>DEO4vDvhNEv</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Curacao</td>
        <td>CW</td>
        <td>2020-03-18</td>
        <td>C5DXQidiMMc</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Cured/treatment completed</td>
        <td>CURED_TREATMENT_COMPLETED</td>
        <td>2020-03-18</td>
        <td>onqAZ9bio2t</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cyprus</td>
        <td>CY</td>
        <td>2020-03-18</td>
        <td>ccs1kikyZS3</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Czech Republic</td>
        <td>CZ</td>
        <td>2020-03-18</td>
        <td>Scdk35fgY12</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Denmark</td>
        <td>DK</td>
        <td>2020-03-18</td>
        <td>t0mq3u8SNgz</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Djibouti</td>
        <td>DJ</td>
        <td>2020-03-18</td>
        <td>PMSl473rekw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Dominica</td>
        <td>DM</td>
        <td>2018-01-18</td>
        <td>MpwuGzXBpAk</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Dominican Republic</td>
        <td>DO</td>
        <td>2020-03-18</td>
        <td>CedH1TzSPgO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ecuador</td>
        <td>EC</td>
        <td>2018-01-18</td>
        <td>mJexWvdoaXE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Egypt</td>
        <td>EG</td>
        <td>2020-03-18</td>
        <td>RkxuXQTQjxk</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>El Salvador</td>
        <td>SV</td>
        <td>2018-01-18</td>
        <td>CDBeT1lT7n2</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Equatorial Guinea</td>
        <td>GQ</td>
        <td>2020-03-18</td>
        <td>KNU7Tm8S245</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Eritrea</td>
        <td>ER</td>
        <td>2018-01-18</td>
        <td>v16FQ3xwnGN</td>
      </tr>
      <tr>
        <td>TB DRS Final Xpert MTB/RIF Test Result</td>
        <td>Error</td>
        <td>ERROR</td>
        <td>2020-03-18</td>
        <td>sSxqp8mUH3o</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Initial Screening Result</td>
        <td>Error</td>
        <td>ERROR</td>
        <td>2020-03-18</td>
        <td>TNuxhjBcMfC</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Estonia</td>
        <td>EE</td>
        <td>2018-01-18</td>
        <td>aOX23O03bBw</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>Ethanol</td>
        <td>ETHANOL</td>
        <td>2020-03-18</td>
        <td>BZCqdbW974l</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ethiopia</td>
        <td>ET</td>
        <td>2020-03-18</td>
        <td>W4KroB1nw6P</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Genotypic Speciation Results</td>
        <td>Failed</td>
        <td>FAILED</td>
        <td>2020-03-18</td>
        <td>HAHhOpw9qIc</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Failed new patient regimen of first-line drugs only</td>
        <td>FAILED_NEW_PATIENT_REGIMEN_OF_FIRST_LINE_DRUGS_ONLY</td>
        <td>2020-03-18</td>
        <td>mhlm2fG6bMA</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Failed regimen which included second-line drugs</td>
        <td>FAILED_REGIMEN_WHICH_INCLUDED_SECOND_LINE_DRUGS</td>
        <td>2020-03-18</td>
        <td>f6a0BmjhXDL</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Failed retreatment regimen of first-line drugs only</td>
        <td>FAILED_RETREATMENT_REGIMEN_OF_FIRST_LINE_DRUGS_ONLY</td>
        <td>2020-03-18</td>
        <td>CgXmdquvoVv</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Falkland Islands (Malvinas)</td>
        <td>FK</td>
        <td>2020-03-18</td>
        <td>CWhuePZuC9y</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Faroe Islands</td>
        <td>FO</td>
        <td>2020-03-18</td>
        <td>upfjuKBGHq9</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>Female</td>
        <td>FEMALE</td>
        <td>2020-03-18</td>
        <td>AZK4rjJCss5</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Fiji</td>
        <td>FJ</td>
        <td>2020-03-18</td>
        <td>wVl5DoJmza2</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Finland</td>
        <td>FI</td>
        <td>2020-03-18</td>
        <td>fQzvkEY9chs</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>France</td>
        <td>FR</td>
        <td>2020-03-18</td>
        <td>pBNkmU3hDoT</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>French Guiana</td>
        <td>GF</td>
        <td>2020-03-18</td>
        <td>otDBqUSWuzE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>French Polynesia</td>
        <td>PF</td>
        <td>2020-03-18</td>
        <td>THPEMRSnC4G</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>French Southern Territories</td>
        <td>TF</td>
        <td>2020-03-18</td>
        <td>MKmqLvOYWos</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Gabon</td>
        <td>GA</td>
        <td>2018-01-18</td>
        <td>hF9y363enrH</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Gambia</td>
        <td>GM</td>
        <td>2020-03-18</td>
        <td>EQULu0IwQNE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Georgia</td>
        <td>GE</td>
        <td>2018-01-18</td>
        <td>I9v1TBhT3OV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Germany</td>
        <td>DE</td>
        <td>2020-03-18</td>
        <td>CxKFBwhGuJr</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ghana</td>
        <td>GH</td>
        <td>2018-01-18</td>
        <td>N9bYrawJaqR</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Gibraltar</td>
        <td>GI</td>
        <td>2018-01-18</td>
        <td>riIXFPTUnZX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Greece</td>
        <td>GR</td>
        <td>2020-03-18</td>
        <td>QyJHXS44Xj9</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Greenland</td>
        <td>GL</td>
        <td>2020-03-18</td>
        <td>dMRNgoCtogj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Grenada</td>
        <td>GD</td>
        <td>2020-03-18</td>
        <td>gDARdk8cZ3H</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guadeloupe</td>
        <td>GP</td>
        <td>2020-03-18</td>
        <td>AneyNa28ceQ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guam</td>
        <td>GU</td>
        <td>2018-01-18</td>
        <td>ELm3SnuBHJZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guatemala</td>
        <td>GT</td>
        <td>2018-01-18</td>
        <td>Oh3CJhGeaoi</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guernsey</td>
        <td>GG</td>
        <td>2018-01-18</td>
        <td>l69MO3y6LuS</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guinea</td>
        <td>GN</td>
        <td>2018-01-18</td>
        <td>T0gujEdp3Z6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guinea-Bissau</td>
        <td>GW</td>
        <td>2018-01-18</td>
        <td>I8A7Q4zi1YI</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guyana</td>
        <td>GY</td>
        <td>2018-01-18</td>
        <td>TfyHeFLDOKu</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Haiti</td>
        <td>HT</td>
        <td>2018-01-18</td>
        <td>ZyGPejjzvGD</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Heard Island and McDonald Islands</td>
        <td>HM</td>
        <td>2020-03-18</td>
        <td>OC0K30ETDLD</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Quantitative Result</td>
        <td>High</td>
        <td>HIGH</td>
        <td>2020-03-18</td>
        <td>j2cnORcpi4l</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Holy See</td>
        <td>VA</td>
        <td>2018-01-18</td>
        <td>FmIGl5AnbxN</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Honduras</td>
        <td>HN</td>
        <td>2018-01-18</td>
        <td>ALX1BnV0GrW</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Hong Kong</td>
        <td>HK</td>
        <td>2018-01-18</td>
        <td>S3Dt4ozhM8X</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Hungary</td>
        <td>HU</td>
        <td>2020-03-18</td>
        <td>eGQJGkiLamm</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Iceland</td>
        <td>IS</td>
        <td>2020-03-18</td>
        <td>vzzPNV6Wu0J</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>Indeterminate (i.e. mutation unknown / not graded)</td>
        <td>INDETERMINATE</td>
        <td>2020-03-18</td>
        <td>cdwZvx6AcLV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>India</td>
        <td>IN</td>
        <td>2018-01-18</td>
        <td>AObPqV4cHPb</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Indonesia</td>
        <td>ID</td>
        <td>2018-01-18</td>
        <td>kPQes5oG21J</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Initial Screening Result</td>
        <td>Invalid</td>
        <td>INVALID</td>
        <td>2020-03-18</td>
        <td>dbOg3402TdW</td>
      </tr>
      <tr>
        <td>TB DRS Final Xpert MTB/RIF Test Result</td>
        <td>Invalid</td>
        <td>INVALID</td>
        <td>2020-03-18</td>
        <td>U9s3LZ1Rp6E</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Iran (Islamic Republic of)</td>
        <td>IR</td>
        <td>2020-03-18</td>
        <td>bEj6P1jqHje</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Iraq</td>
        <td>IQ</td>
        <td>2018-01-18</td>
        <td>UXyOlL9FJ5o</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ireland</td>
        <td>IE</td>
        <td>2020-03-18</td>
        <td>tiwJrxfBoHT</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Isle of Man</td>
        <td>IM</td>
        <td>2020-03-18</td>
        <td>ecANXpkkcPT</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Israel</td>
        <td>IL</td>
        <td>2018-01-18</td>
        <td>VQkdjFxCLNH</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Italy</td>
        <td>IT</td>
        <td>2020-03-18</td>
        <td>QIjTIxTedos</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Jamaica</td>
        <td>JM</td>
        <td>2018-01-18</td>
        <td>etZCdyFxz4w</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Japan</td>
        <td>JP</td>
        <td>2020-03-18</td>
        <td>H65niFKFuSs</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Jersey</td>
        <td>JE</td>
        <td>2018-01-18</td>
        <td>JwslMKjECF2</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Jordan</td>
        <td>JO</td>
        <td>2020-03-18</td>
        <td>IqyWsh1pbYf</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kazakhstan</td>
        <td>KZ</td>
        <td>2020-03-18</td>
        <td>JWIEjkUmsWH</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kenya</td>
        <td>KE</td>
        <td>2020-03-18</td>
        <td>UJppzPKIQRv</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kiribati</td>
        <td>KI</td>
        <td>2020-03-18</td>
        <td>BFMEIXmaqFE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Korea (Democratic People's Republic of)</td>
        <td>KP</td>
        <td>2020-03-18</td>
        <td>i0Dl3gB8WuY</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Korea (Republic of)</td>
        <td>KR</td>
        <td>2020-03-18</td>
        <td>G9rNnfnVNcB</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kuwait</td>
        <td>KW</td>
        <td>2018-01-18</td>
        <td>mCnaSMEODSz</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kyrgyzstan</td>
        <td>KG</td>
        <td>2020-03-18</td>
        <td>LjRX17TMcTX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Lao People's Democratic Republic</td>
        <td>LA</td>
        <td>2020-03-18</td>
        <td>SN9NeGsvfmM</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Latvia</td>
        <td>LV</td>
        <td>2020-03-18</td>
        <td>CkE4sCvC7zj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Lebanon</td>
        <td>LB</td>
        <td>2020-03-18</td>
        <td>THKtWeVTuBk</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Lesotho</td>
        <td>LS</td>
        <td>2020-03-18</td>
        <td>PFq4nWHt0fM</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Liberia</td>
        <td>LR</td>
        <td>2018-01-18</td>
        <td>LfjyJpiu8dL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Libya</td>
        <td>LY</td>
        <td>2020-03-18</td>
        <td>p0vsNlHuo7N</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Liechtenstein</td>
        <td>LI</td>
        <td>2018-01-18</td>
        <td>XQZko5dUFGU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Lithuania</td>
        <td>LT</td>
        <td>2020-03-18</td>
        <td>SXD2EhrNaQu</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Lost to follow-up</td>
        <td>LOST_TO_FOLLOW_UP</td>
        <td>2020-03-18</td>
        <td>x49MjXdjPNr</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Quantitative Result</td>
        <td>Low</td>
        <td>LOW</td>
        <td>2020-03-18</td>
        <td>vq8qUW3pu22</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Luxembourg</td>
        <td>LU</td>
        <td>2020-03-18</td>
        <td>M2XM0PR40oH</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Macao</td>
        <td>MO</td>
        <td>2018-01-18</td>
        <td>IyBPcxO7hfB</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Macedonia (the former Yugoslav Republic of)</td>
        <td>MK</td>
        <td>2020-03-18</td>
        <td>cxvpqSjkTjP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Madagascar</td>
        <td>MG</td>
        <td>2018-01-18</td>
        <td>kaf9448wuv0</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Malawi</td>
        <td>MW</td>
        <td>2018-01-18</td>
        <td>ApCSe2JdIUw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Malaysia</td>
        <td>MY</td>
        <td>2020-03-18</td>
        <td>KtR12m8FoT0</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Maldives</td>
        <td>MV</td>
        <td>2020-03-18</td>
        <td>Qtp6HW63yqV</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>Male</td>
        <td>MALE</td>
        <td>2020-03-18</td>
        <td>UrUdMteQzlT</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mali</td>
        <td>ML</td>
        <td>2018-01-18</td>
        <td>nOMNxq2fHGq</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Malta</td>
        <td>MT</td>
        <td>2018-01-18</td>
        <td>C2Ws5NctBqi</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Marshall Islands</td>
        <td>MH</td>
        <td>2020-03-18</td>
        <td>BpqJwhPqI9O</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Martinique</td>
        <td>MQ</td>
        <td>2020-03-18</td>
        <td>V1nDCD6QvPs</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mauritania</td>
        <td>MR</td>
        <td>2018-01-18</td>
        <td>HScqQPe1X9u</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mauritius</td>
        <td>MU</td>
        <td>2020-03-18</td>
        <td>RmjKEjs388f</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mayotte</td>
        <td>YT</td>
        <td>2020-03-18</td>
        <td>jQ3mYwytyZn</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mexico</td>
        <td>MX</td>
        <td>2020-03-18</td>
        <td>sK6lzdZiwIg</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Micronesia (Federated States of)</td>
        <td>FM</td>
        <td>2020-03-18</td>
        <td>nDTKZYmGEvT</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Genotypic Speciation Results</td>
        <td>Mixed MTBc and Other</td>
        <td>MIXED_MTBC_AND_OTHER</td>
        <td>2020-03-18</td>
        <td>tI2yNUx4RML</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Moldova (Republic of)</td>
        <td>MD</td>
        <td>2020-03-18</td>
        <td>EABP62Ce29b</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Monaco</td>
        <td>MC</td>
        <td>2018-01-18</td>
        <td>QT9Erxe7UaX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mongolia</td>
        <td>MN</td>
        <td>2018-01-18</td>
        <td>UmW7wmw0AX9</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Montenegro</td>
        <td>ME</td>
        <td>2018-01-18</td>
        <td>lCww3l79Wem</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Montserrat</td>
        <td>MS</td>
        <td>2020-03-18</td>
        <td>q36uKrRjq1P</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Morocco</td>
        <td>MA</td>
        <td>2020-03-18</td>
        <td>MBVq67Tm1wK</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mozambique</td>
        <td>MZ</td>
        <td>2018-01-18</td>
        <td>OvzdfV1qrvP</td>
      </tr>
      <tr>
        <td>TB DRS Final Culture Result</td>
        <td>MTB</td>
        <td>MTB</td>
        <td>2020-03-18</td>
        <td>UsugTEaeBhi</td>
      </tr>
      <tr>
        <td>TB DRS LPA Specimen</td>
        <td>MTB culture isolates</td>
        <td>MTB_CULTURE_ISOLATES</td>
        <td>2020-03-18</td>
        <td>zAH62QSxRYh</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Initial Screening Result</td>
        <td>MTB-Detected (Rif Indeterminate)</td>
        <td>MTB_DETECTED_RIF_INDETERMINATE</td>
        <td>2020-03-18</td>
        <td>B3B5gY6qCiS</td>
      </tr>
      <tr>
        <td>TB DRS Final Xpert MTB/RIF Test Result</td>
        <td>MTB-Detected (Rifampicin Indeterminate)</td>
        <td>MTB_DETECTED_RIF_INDETERMINATE</td>
        <td>2020-03-18</td>
        <td>nIKou981NQB</td>
      </tr>
      <tr>
        <td>TB DRS Final Xpert MTB/RIF Test Result</td>
        <td>MTB-Detected (Rifampicin Resistant)</td>
        <td>MTB_DETECTED_RIFAMPICIN_RESISTANT</td>
        <td>2020-03-18</td>
        <td>Jbx4393qLtO</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Initial Screening Result</td>
        <td>MTB-Detected (Rifampicin Resistant)</td>
        <td>MTB_DETECTED_RIFAMPICIN_RESISTANT</td>
        <td>2020-03-18</td>
        <td>rsMARKUbUVN</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Initial Screening Result</td>
        <td>MTB-Detected (Rifampicin Susceptible)</td>
        <td>MTB_DETECTED_RIFAMPICIN_SUSCEPTIBLE</td>
        <td>2020-03-18</td>
        <td>TrUeUqOLKrx</td>
      </tr>
      <tr>
        <td>TB DRS Final Xpert MTB/RIF Test Result</td>
        <td>MTB-Detected (Rifampicin Susceptible)</td>
        <td>MTB_DETECTED_RIFAMPICIN_SUSCEPTIBLE</td>
        <td>2020-03-18</td>
        <td>xq1DHmnRamj</td>
      </tr>
      <tr>
        <td>TB DRS Final Xpert MTB/RIF Test Result</td>
        <td>MTB-Not Detected</td>
        <td>MTB_NOT_DETECTED</td>
        <td>2020-03-18</td>
        <td>wxaK4PQwtar</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Initial Screening Result</td>
        <td>MTB-Not Detected</td>
        <td>MTB_NOT_DETECTED</td>
        <td>2020-03-18</td>
        <td>yMpqtxLJKZj</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Genotypic Speciation Results</td>
        <td>MTBc</td>
        <td>MTBC</td>
        <td>2020-03-18</td>
        <td>cXeTwncrs81</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Myanmar</td>
        <td>MM</td>
        <td>2018-01-18</td>
        <td>ElBqHdoLnsc</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Namibia</td>
        <td>NA</td>
        <td>2018-01-18</td>
        <td>e4HCJJlYOQP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Nauru</td>
        <td>NR</td>
        <td>2020-03-18</td>
        <td>rbvEOlaNkUU</td>
      </tr>
      <tr>
        <td>Positive/Negative/Unknown</td>
        <td>Negative</td>
        <td>NEGATIVE</td>
        <td>2020-03-18</td>
        <td>IYKMiif5Uno</td>
      </tr>
      <tr>
        <td>TB DRS Initial Microscopy Test Result</td>
        <td>Negative</td>
        <td>NEGATIVE</td>
        <td>2020-03-18</td>
        <td>pFfaAwmxLUa</td>
      </tr>
      <tr>
        <td>TB DRS Final Sputum Smear Microscopy Result</td>
        <td>Negative</td>
        <td>NEGATIVE</td>
        <td>2020-03-18</td>
        <td>WhaoVoBAFxG</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Nepal</td>
        <td>NP</td>
        <td>2018-01-18</td>
        <td>LRsQdDERp1f</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Netherlands</td>
        <td>NL</td>
        <td>2020-03-18</td>
        <td>ztgG5fQPur9</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>New Caledonia</td>
        <td>NC</td>
        <td>2020-03-18</td>
        <td>fg3tUp5fFH1</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>New Zealand</td>
        <td>NZ</td>
        <td>2020-03-18</td>
        <td>lBZHFe8qxEL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Nicaragua</td>
        <td>NI</td>
        <td>2018-01-18</td>
        <td>Y2ze1UBngud</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Niger</td>
        <td>NE</td>
        <td>2018-01-18</td>
        <td>UzC7hScynz0</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Nigeria</td>
        <td>NG</td>
        <td>2018-01-18</td>
        <td>xsNVICc3jPD</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Niue</td>
        <td>NU</td>
        <td>2020-03-18</td>
        <td>ibFgvQscr1i</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>No</td>
        <td>NO</td>
        <td>2020-03-18</td>
        <td>PLlPgcfbL1D</td>
      </tr>
      <tr>
        <td>Yes/No/Not Applicable</td>
        <td>No</td>
        <td>NO</td>
        <td>2020-03-18</td>
        <td>sEqMay8BGdJ</td>
      </tr>
      <tr>
        <td>Yes/No</td>
        <td>No</td>
        <td>NO</td>
        <td>2020-03-18</td>
        <td>vak9GKjzzAP</td>
      </tr>
      <tr>
        <td>TB DRS Final Culture Result</td>
        <td>No growth</td>
        <td>NO_GROWTH</td>
        <td>2020-03-18</td>
        <td>iRIdWqmsuhn</td>
      </tr>
      <tr>
        <td>TB DRS Result</td>
        <td>No Interpretable Result</td>
        <td>NO_INTERPRETABLE_RESULT</td>
        <td>2020-03-18</td>
        <td>cV8z3qmRY1w</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>No Interpretable Result (i.e. insufficient quality)</td>
        <td>NO_INTERPRETABLE_RESULT</td>
        <td>2020-03-18</td>
        <td>vaxQgTZQXpM</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Initial Screening Result</td>
        <td>No Result</td>
        <td>NO_RESULT</td>
        <td>2019-12-23</td>
        <td>bsgjIfffUJP</td>
      </tr>
      <tr>
        <td>TB DRS Final Xpert MTB/RIF Test Result</td>
        <td>No result</td>
        <td>NO_RESULT</td>
        <td>2020-03-18</td>
        <td>ozqzmmfyvu8</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>None</td>
        <td>NONE</td>
        <td>2020-03-18</td>
        <td>vEL863qZ6HA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Norfolk Island</td>
        <td>NF</td>
        <td>2020-03-18</td>
        <td>jmZqHjwAKxJ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Northern Mariana Islands</td>
        <td>MP</td>
        <td>2020-03-18</td>
        <td>KGoEICL7PmU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Norway</td>
        <td>NO</td>
        <td>2020-03-18</td>
        <td>JpY27WXUqOI</td>
      </tr>
      <tr>
        <td>Yes/No/Not Applicable</td>
        <td>Not Applicable</td>
        <td>NOT_APPLICABLE</td>
        <td>2020-03-18</td>
        <td>pv1WdxdAZl8</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Initial Screening Result</td>
        <td>Not Done</td>
        <td>NOT_DONE</td>
        <td>2020-03-18</td>
        <td>t3nvofGzmjF</td>
      </tr>
      <tr>
        <td>TB DRS Initial Microscopy Test Result</td>
        <td>Not Done</td>
        <td>NOT_DONE</td>
        <td>2020-03-18</td>
        <td>yHsbq4UIlbU</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Genotypic Speciation Results</td>
        <td>NTM</td>
        <td>NTM</td>
        <td>2020-03-18</td>
        <td>AADFw8OdflX</td>
      </tr>
      <tr>
        <td>TB DRS Final Culture Result</td>
        <td>NTM</td>
        <td>NTM</td>
        <td>2020-03-18</td>
        <td>YoZDgCMUpJy</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Oman</td>
        <td>OM</td>
        <td>2018-01-18</td>
        <td>yxbHuzqF6VS</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>OMNIGene</td>
        <td>OMNIGENE</td>
        <td>2020-03-18</td>
        <td>TQVYllQ10BK</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>Other</td>
        <td>OTHER</td>
        <td>2020-03-18</td>
        <td>bxKZffLCvEp</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Other</td>
        <td>OTHER</td>
        <td>2020-03-18</td>
        <td>IBK5YnfOcim</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Pakistan</td>
        <td>PK</td>
        <td>2018-01-18</td>
        <td>eHKdzDVgEuj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Palau</td>
        <td>PW</td>
        <td>2020-03-18</td>
        <td>xuUrPK5b7MP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Palestine, State of</td>
        <td>PS</td>
        <td>2020-03-18</td>
        <td>Publ7A7E6r3</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Panama</td>
        <td>PA</td>
        <td>2018-01-18</td>
        <td>Lyu0GDGZLU3</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Papua New Guinea</td>
        <td>PG</td>
        <td>2020-03-18</td>
        <td>ovWqm6wr1dP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Paraguay</td>
        <td>PY</td>
        <td>2018-01-18</td>
        <td>UvnjescFIbU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Peru</td>
        <td>PE</td>
        <td>2018-01-18</td>
        <td>hUQDnRc6BKw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Philippines</td>
        <td>PH</td>
        <td>2020-03-18</td>
        <td>nTQRDVcTHr0</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Pitcairn</td>
        <td>PN</td>
        <td>2020-03-18</td>
        <td>oMLQaRXOs1B</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Poland</td>
        <td>PL</td>
        <td>2020-03-18</td>
        <td>mTmjaDWUfDG</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Portugal</td>
        <td>PT</td>
        <td>2018-01-18</td>
        <td>NlVuvr5WbKy</td>
      </tr>
      <tr>
        <td>Positive/Negative/Unknown</td>
        <td>Positive</td>
        <td>POSITIVE</td>
        <td>2020-03-18</td>
        <td>Mn39beDtXNS</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>PrimeStore</td>
        <td>PRIMESTORE</td>
        <td>2020-03-18</td>
        <td>eefJopL3w3t</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Puerto Rico</td>
        <td>PR</td>
        <td>2018-01-18</td>
        <td>ThLyMbT1IvD</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Qatar</td>
        <td>QA</td>
        <td>2018-01-18</td>
        <td>zooDgQrnVkm</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>Resistant</td>
        <td>RESISTANT</td>
        <td>2020-03-18</td>
        <td>MhctAiVMO5v</td>
      </tr>
      <tr>
        <td>TB DRS Result</td>
        <td>Resistant</td>
        <td>RESISTANT</td>
        <td>2020-03-18</td>
        <td>QnQ1Iy7cbYT</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Reunion</td>
        <td>RE</td>
        <td>2018-01-18</td>
        <td>D9h2axpYFx9</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Romania</td>
        <td>RO</td>
        <td>2020-03-18</td>
        <td>a5ayhZAtUe4</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Russian Federation</td>
        <td>RU</td>
        <td>2020-03-18</td>
        <td>xF48L1VlFrZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Rwanda</td>
        <td>RW</td>
        <td>2020-03-18</td>
        <td>gSPpYw9P7YO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Barthalemy</td>
        <td>BL</td>
        <td>2020-03-18</td>
        <td>lufRQXPgcJ8</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Helena, Ascension and Tristan da Cunha</td>
        <td>SH</td>
        <td>2020-03-18</td>
        <td>CCzBKhjSPFo</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Kitts and Nevis</td>
        <td>KN</td>
        <td>2020-03-18</td>
        <td>uJH3wMNmMNO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Lucia</td>
        <td>LC</td>
        <td>2020-03-18</td>
        <td>x4Ohep6Q85T</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Martin (French part)</td>
        <td>MF</td>
        <td>2020-03-18</td>
        <td>rJTXccXhtTG</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Pierre and Miquelon</td>
        <td>PM</td>
        <td>2020-03-18</td>
        <td>hIGURTVsclf</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Vincent and the Grenadines</td>
        <td>VC</td>
        <td>2020-03-18</td>
        <td>L1FmwJC0u3z</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Samoa</td>
        <td>WS</td>
        <td>2018-01-18</td>
        <td>w0S8ngASwmq</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>San Marino</td>
        <td>SM</td>
        <td>2018-01-18</td>
        <td>CysWbM6JFgj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sao Tome and Principe</td>
        <td>ST</td>
        <td>2020-03-18</td>
        <td>AMFu6DFAqll</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saudi Arabia</td>
        <td>SA</td>
        <td>2020-03-18</td>
        <td>p8Tgra7YJ7h</td>
      </tr>
      <tr>
        <td>TB DRS Initial Microscopy Test Result</td>
        <td>Scanty</td>
        <td>SCANTY</td>
        <td>2020-03-18</td>
        <td>FmDk1hsXVe0</td>
      </tr>
      <tr>
        <td>TB DRS Final Sputum Smear Microscopy Result</td>
        <td>Scanty</td>
        <td>SCANTY</td>
        <td>2020-03-18</td>
        <td>ZS5tTttku2i</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Senegal</td>
        <td>SN</td>
        <td>2018-01-18</td>
        <td>sPFJiL1BLTy</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Serbia</td>
        <td>RS</td>
        <td>2018-01-18</td>
        <td>QtjohlzA8cl</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Seychelles</td>
        <td>SC</td>
        <td>2018-01-18</td>
        <td>Oprr3by24Zt</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sierra Leone</td>
        <td>SL</td>
        <td>2020-03-18</td>
        <td>rXsByduwzcw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Singapore</td>
        <td>SG</td>
        <td>2020-03-18</td>
        <td>loTOnrxGmCv</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sint Maarten (Dutch part)</td>
        <td>SX</td>
        <td>2020-03-18</td>
        <td>Kjon60bpcC4</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Slovakia</td>
        <td>SK</td>
        <td>2020-03-18</td>
        <td>kdX0FFam8Vz</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Slovenia</td>
        <td>SI</td>
        <td>2020-03-18</td>
        <td>Jl2tnw6dutF</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Solomon Islands</td>
        <td>SB</td>
        <td>2020-03-18</td>
        <td>sQNVDVNINvY</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Somalia</td>
        <td>SO</td>
        <td>2018-01-18</td>
        <td>JYfvnvIzM84</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>South Africa</td>
        <td>ZA</td>
        <td>2020-03-18</td>
        <td>OozIOFXlUQB</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>South Georgia and the South Sandwich Islands</td>
        <td>GS</td>
        <td>2020-03-18</td>
        <td>vMAK8GtCXzE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>South Sudan</td>
        <td>SS</td>
        <td>2020-03-18</td>
        <td>bhfjgX8aEJQ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Spain</td>
        <td>ES</td>
        <td>2020-03-18</td>
        <td>SXeG3KaIkU8</td>
      </tr>
      <tr>
        <td>TB DRS LPA Specimen</td>
        <td>Sputum samples or sediments</td>
        <td>SPUTUM_SAMPLES_OR_SEDIMENTS</td>
        <td>2020-03-18</td>
        <td>io6qvQDAP8r</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sri Lanka</td>
        <td>LK</td>
        <td>2018-01-18</td>
        <td>qpv7jbqwNTN</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sudan</td>
        <td>SD</td>
        <td>2018-01-18</td>
        <td>ELZXJ7i1DKL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Suriname</td>
        <td>SR</td>
        <td>2020-03-18</td>
        <td>IfwaYvRaIhp</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>Susceptible</td>
        <td>SUSCEPTIBLE</td>
        <td>2020-03-18</td>
        <td>R3xLm0LElMI</td>
      </tr>
      <tr>
        <td>TB DRS Result</td>
        <td>Susceptible</td>
        <td>SUSCEPTIBLE</td>
        <td>2020-03-18</td>
        <td>Y1rzV51irfU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Svalbard and Jan Mayen</td>
        <td>SJ</td>
        <td>2020-03-18</td>
        <td>kNow7wcQT6z</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Swaziland</td>
        <td>SZ</td>
        <td>2020-03-18</td>
        <td>HafX2zWjutb</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sweden</td>
        <td>SE</td>
        <td>2020-03-18</td>
        <td>ban72xOWClE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Switzerland</td>
        <td>CH</td>
        <td>2020-03-18</td>
        <td>ZcaE9JG9xrr</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Syrian Arab Republic</td>
        <td>SY</td>
        <td>2020-03-18</td>
        <td>LuMJaVKadYM</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Taiwan, Province of China</td>
        <td>TW</td>
        <td>2020-03-18</td>
        <td>jLIOTZIi0Ou</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tajikistan</td>
        <td>TJ</td>
        <td>2020-03-18</td>
        <td>yxvBpzHn9VN</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tanzania, United Republic of</td>
        <td>TZ</td>
        <td>2020-03-18</td>
        <td>hB9kKEo5Jav</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Thailand</td>
        <td>TH</td>
        <td>2020-03-18</td>
        <td>lGIM5L1ldVZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Timor-Leste</td>
        <td>TL</td>
        <td>2020-03-18</td>
        <td>txfMqMjfmGK</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Togo</td>
        <td>TG</td>
        <td>2020-03-18</td>
        <td>HOiHQKzyA2h</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tokelau</td>
        <td>TK</td>
        <td>2020-03-18</td>
        <td>roEWVrnX17w</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tonga</td>
        <td>TO</td>
        <td>2020-03-18</td>
        <td>vjJWFh1j9U5</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Trinidad and Tobago</td>
        <td>TT</td>
        <td>2020-03-18</td>
        <td>zJCV30f9Pix</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tunisia</td>
        <td>TN</td>
        <td>2020-03-18</td>
        <td>uNt8kKM8azp</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Turkey</td>
        <td>TR</td>
        <td>2020-03-18</td>
        <td>fmGjlRnf0AW</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Turkmenistan</td>
        <td>TM</td>
        <td>2018-01-18</td>
        <td>vPk3xrZvimA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Turks and Caicos Islands</td>
        <td>TC</td>
        <td>2020-03-18</td>
        <td>xIvocxUNJvn</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tuvalu</td>
        <td>TV</td>
        <td>2018-01-18</td>
        <td>aGozKfvhGv6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Uganda</td>
        <td>UG</td>
        <td>2018-01-18</td>
        <td>NV1MNzAfPWE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ukraine</td>
        <td>UA</td>
        <td>2020-03-18</td>
        <td>E68TvHpnyp5</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>United Arab Emirates</td>
        <td>AE</td>
        <td>2020-03-18</td>
        <td>qCmj8zWn2RQ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>United Kingdom of Great Britain and Northern Ireland</td>
        <td>GB</td>
        <td>2020-03-18</td>
        <td>ZOGqtsOOfdP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>United States Minor Outlying Islands</td>
        <td>UM</td>
        <td>2020-03-18</td>
        <td>JwhF38ZDa7Y</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>United States of America</td>
        <td>US</td>
        <td>2020-03-18</td>
        <td>RvhGvhkGceD</td>
      </tr>
      <tr>
        <td>Positive/Negative/Unknown</td>
        <td>Unknown</td>
        <td>UNKNOWN</td>
        <td>2020-03-18</td>
        <td>QYtc2i3L8Jd</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Quantitative Result</td>
        <td>Unknown</td>
        <td>UNKNOWN</td>
        <td>2020-03-18</td>
        <td>RgKYvq8eYjq</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Unknown</td>
        <td>UNKNOWN</td>
        <td>2020-03-18</td>
        <td>S0V66nR6sFD</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>Unknown</td>
        <td>UNKNOWN</td>
        <td>2020-03-18</td>
        <td>TKD1XJ4ZhMO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Uruguay</td>
        <td>UY</td>
        <td>2018-01-18</td>
        <td>CzJoxdewhsm</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Uzbekistan</td>
        <td>UZ</td>
        <td>2018-01-18</td>
        <td>WrnwBUl0Vzt</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Vanuatu</td>
        <td>VU</td>
        <td>2018-01-18</td>
        <td>yqQ0IiG9maE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Venezuela (Bolivarian Republic of)</td>
        <td>VE</td>
        <td>2020-03-18</td>
        <td>C3Mf3a5OJa3</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Quantitative Result</td>
        <td>Very Low</td>
        <td>VERY_LOW</td>
        <td>2020-03-18</td>
        <td>R58K1QZRG4y</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Viet Nam</td>
        <td>VN</td>
        <td>2020-03-18</td>
        <td>CndbUcexjyJ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Virgin Islands (British)</td>
        <td>VG</td>
        <td>2020-03-18</td>
        <td>VEulszgYUL2</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Virgin Islands (U.S.)</td>
        <td>VI</td>
        <td>2020-03-18</td>
        <td>sgvVI1jilCg</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Wallis and Futuna</td>
        <td>WF</td>
        <td>2020-03-18</td>
        <td>oZPItrH57Zf</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Western Sahara</td>
        <td>EH</td>
        <td>2020-03-18</td>
        <td>hbiFi85xO2g</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Yemen</td>
        <td>YE</td>
        <td>2018-01-18</td>
        <td>lJBsaRbZLZP</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>Yes</td>
        <td>YES</td>
        <td>2020-03-18</td>
        <td>CvivP1rh4ii</td>
      </tr>
      <tr>
        <td>Yes/No/Not Applicable</td>
        <td>Yes</td>
        <td>YES</td>
        <td>2020-03-18</td>
        <td>qEd2VMWfhan</td>
      </tr>
      <tr>
        <td>Yes/No</td>
        <td>Yes</td>
        <td>YES</td>
        <td>2020-03-18</td>
        <td>zPVS0EAEwia</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Zambia</td>
        <td>ZM</td>
        <td>2018-01-18</td>
        <td>WPR1XicphAd</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Zimbabwe</td>
        <td>ZW</td>
        <td>2020-03-18</td>
        <td>r15gweUYYrk</td>
      </tr>
    </table>
    <h2 id="userGroups">User Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB DRS access</td>
        <td>2020-02-16</td>
        <td>LHhbGJKXmzz</td>
      </tr>
      <tr>
        <td>TB DRS admin</td>
        <td>2020-01-23</td>
        <td>vN3X85Hxzno</td>
      </tr>
      <tr>
        <td>TB DRS data capture</td>
        <td>2020-02-16</td>
        <td>byS9SDFsd9p</td>
      </tr>
    </table>
    <h2>Users</h2>
    <table>
      <tr>
        <th>Username</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>who</td>
        <td>2018-08-28</td>
        <td>vUeLeQMSwhN</td>
      </tr>
    </table>
  </body>

</html>